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Resistance is an inevitable consequence of antimicrobial usage. In 2006，a 
multidisciplinary Antimicrobial Stewardship Program (ASP) was implemented in a 
1350-bed teaching hospital in Hong Kong, targeting eight broad-spectrum 
antimicrobials, namely vancomycin, teicoplanin, linezolid, carbapenems 
(imipenem/meropenem), cefepime, ceftazidime, cefoperazone/sulbactam and 
piperacillin/tazobactam. The impact of an interventional ASP on the appropriateness 
of antimicrobial prescription, antibiotic consumption, antimicrobial resistance and 
clinical outcomes in patients of the medical department was examined. Six hundred 
and thirty-five patients who were prescribed one of these agents during February -
•i I 
I August 2006 were reviewed prospectively. Six hundred and five case notes from 
j 
j patients prescribed these agents during March-May 2005 at preintervention were 
reviewed retrospectively. During the intervention period, recommendations were 
made for 19% of cases by the Antimicrobial Management Team. After ASP 
implementation there was a reduction in the rate of antibiotic prescription (83 vs. 63 
prescription/ 1000 admissions). A significant increase in appropriate prescriptions I 
was obtained during the intervention period (OR, 3.15; P<0.001). There was no 
I 
statistical significant difference in the length of hospital stay noted in the two groups. 
A reduction in all-cause mortality was observed in the intervention group. The 
consumption of targeted broad spectrum antimicrobials in defined daily doses per 
1000 bed day occupied (DDDs /lOOOBDO) was reduced by 4.5% overall for 2006. 
The use of cefepime (34.33 vs. 28.79 DDD/IOOOBDO;尸二 0.04) and 
sulbactam/cefoperazone (23.02 vs. 18.92 DDD/IOOOBDO; P=0.002) were 
significantly reduced, but an increase in the use of piperacillin/tazobactam (14.57 vs. 
18.25 DDD/IOOOBDO; 7^=0.02) was observed. A significant increase in 
fluoroquinolone, which was not a targeted antibiotic, was noted (63.8 vs. 73.7 
DDD/IOOOBDO; P=0.03). There was a significant reduction in the resistance rates of 
Escherichia coli to amoxicillin/clavulanate, 35.28 vs. 30.84;户=0.02 for all 
specimens, 47.87 vs. 29.56; P=0.006 for blood culture specimens, but a reduction in 
susceptibility of Pseudomonas aeruginosa to sulbactam/cefoperazone (94.73 vs. 
90.43； P=0.01) was noted. There was no significant change in methicillin-resistant 
Staphylococcus aureus rates. The implementation of ASP in the hospital resulted in 
more rational use of antimicrobials, an overall reduced consumption of antibiotics 
and improved clinical outcomes. 
A retrospective observational study was performed to evaluate the treatment 
outcome and the factors affecting the treatment outcome of patients with bacteremia 
i； 
due to ESBL-producing organisms and who were receiving carbapenem 
'I 
j (imipenem/meropenem) or (3-lactam/p-lactamase inhibitor combinations 
(cefoperazone/sulbactam, piperacillin/tazobactam or amoxicillin/clavulanate). One 
, hundred and eleven episodes in 109 patients with bacteremia due to ESBL-producing 
Escherichia coli, Klebsiella pneumoniae or Klebsiella species, (53 episodes in the 
carbapenem group and 58 episodes in the [3-lactam/[3-lactamase inhibitor group) were 
II 
examined. Treatment with carbapenem during the five-day period after the onset of 
bacteremia due to ESBL-producing organisms was independently associated with 
lower treatment failure (OR, 0.093; 95% CI, 0.028-0.316; PcO.OOl) and lower 
mortality (OR, 0.096; 95% CI, 0.016-0.589;尸=0.011). In conclusion p-lactam/(3-
lactamase inhibitor combinations which were active in vitro were associated with an 
inferior treatment outcome. The presence of multiple comorbidities and prior 
intubation at intensive care unit were identified factors influencing the outcome of 
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CHAPTER 1 - INTRODUCTION 
1.1 Antimicrobial resistance 
1.1.1 Global emergence of drug-resistant organisms 
Throughout the world, healthcare professionals are concerned at the growing 
problem of a global emergence of multi-drug-resistant organisms in the healthcare 
setting and in the community. Penicillin was discovered by Alexander Fleming in 
1929, The widespread use of penicillin in the 1940s and other newly-introduced 
antimicrobials were soon followed by the emergence of resistant microbes [1], The 
prevalence of multidrug-resistant organisms (MDROs) has increased dramatically 
worldwide during the last decades. Some of these resistant microorganisms and their 
emergence relating to the introduction of antimicrobial agents are shown in Table 1.1. 
In the United States, the prevalence of M D R O s has increased steadily [2]. In 
2006, a national survey at U S healthcare facilities showed a prevalence rate of 46.3 
per 1000 inpatients for methicillin-resistant Staphylococcus aureus (MRSA) [3]. The 
prevalence of M R S A is increasing in most European and Asian countries [4，5, 6]. In 
England and Wales, the proportion of S. aureus isolates resistance to methicillin, 
from blood and cerebrospinal fluid remained at about 1.5% during 1989-91, has 
increased to 31.7% in 1997 [7] and in U K , the proportion of M R S A in blood isolates 
has increased from 30.5% in 1999 to 44.5% in 2002 [4]. Vancomycin intermediate S. 
aureus (VISA) was first isolated in Japan in 1997; V R S A (Vancomycin resistant S. 
aureus) was subsequently reported in U S A in 2002, France, Korea, South Africa and 
Brazil [8, 9, 10]. An increasing incidence of heterointermediate resistance to 
vancomycin in S. aureus (hVISA) has been reported in Asian countries [8:. 
1 
Community-acquired methicillin-resistant S. aureus (CA-MRSA) is now endemic in 
some countries, including U S A and parts of Europe [11, 12, 13 . 
An alarming increase in the incidence of Vancomycin-resistant enterococci 
(VRE) has occurred [2, 14, 15, 16]. In U S A , the prevalence of V R E in enterococcal 
isolates from hospitalized patients has increased from < 1 % in 1990 to 15% in 1997 
Penicillin and erythromycin resistance in Streptococcus pneumoniae is also 
of great concern. The A N S O R P study performed in 2000-2001, documented 
increases in the prevalence rates of antimicrobial resistance among S. pneumoniae 
isolates in many Asian countries [17], with documentation of 38.6% -71.4% of 
penicillin resistance and 73.9% - 92.1% of erythromycin resistance. pneumoniae 
isolates resistant to fluroquinolone have increased in prevalence in recent years [18 • 
In Canada, ciprofloxacin resistance has increased from <1 in 1997 to 4.2% in 2005 
with 1.1% resistance rate to levofloxacin [18] among S. pneumoniae and in the U S A 
ciprofloxacin susceptibility has decreased from 86% to 76% during 1994-2000, in 
isolates from intensive care unit (ICU) patients [2:. 
Although linezolid has been used in clinical practice for a relatively short 
period of time, isolates of enterococci, staphylococci and sreptococci resistant to 
linezolid have been reported [19:. 
Within a few years after introduction of third-generation cephalosporins to 
overcome P-lactamase-mediated antimicrobial resistance, the first report of 
extended-spectrum beta lactamase (ESBL) was noted in Klebsiella pneumoniae and 
Serratia marcescens isolates in 1983 in Germany [20]. Since then there has been an 
increasing trend in the prevalence of ESBL-producing Enterohacteriace in the 
healthcare settings, as well as it being increasingly isolated from the community 
2 
worldwide, causing unique challenges to healthcare professionals [21] (Refer to 
section 1.5.4). 
The emergence of imipenem resistance and multidrug resistance in 
Pseudomonas aeruginosa and in Acinetobacter spp. is of concern [2, 22, 23]. In U S A , 
the prevalence of multidrug-resistant Pseudomonas aeruginosa (MRPA) isolates 
from ICU has increased from 9.1% in 2001 to 14% in 2002, in Europe 4.7% and in 
Asia/Pacific region 1.6% of M R P A has been reported from isolates of nosocomial 
infections between 1997 and 1999 [23]. In North America, the proportion of 
carbapenem resistance in Acinetobacter spp. in non-duplicate clinical isolates has 
been reported as 6.5% for meropenem and 8.3% for imipenem during 2002-2004, 
whilst 33% resistance for meropenem and 53% resistance for imipenem have been 
reported for all isolates of Acinetobacter spp. in 2006. In Europe, the prevalence of 
carbapenem resistance in Acinetobacter spp. in non-duplicate clinical isolates has 
almost doubled in recent years, with an average rate of resistance of 27% during 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.1.2 Resistance problem in Hong Kong 
1.1.2.1 Antimicrobial resistance of bacterial isolates in hospital 
Table 1.2 shows the antimicrobial resistance of clinical isolates in hospitals 
between the periods of 1987-1993 [29, 30]. 
Penicillin-nonsusceptible S. pneumoniae has increased from 0 % in 1987/88 to 
10% in 1993 and has increased dramatically up to 26% in 1994 and 52% in 1995 [31；. 
Data� from� the�multinational�study�documented� high� prevalence�rates (43.2%) of 
penicillin resistant pneumoniae isolates in Hong Kong in 2000/01 [17]. A high rate of 
fluoroquinolone resistance in S. pneumoniae was also reported in Hong Kong. In the 
year 2000/01, a high prevalence of ciprofloxacin resistance (11.8%_17.8%) and 
levofloxacin resistance (13.3%) were reported for S. pneumoniae in Hong Kong [17, 32, 
33]. 
M R S A has been endemic in Hong Kong since 1980s.The prevalence of M R S A 
among aureus remained at 30% during the 1990s in Hong Kong [31]. Currently the 
proportions of M R S A in local hospitals are around 30-50% [34]. Sporadic cases of V R E 
have been identified in Hong Kong [34；.�
Among�gram-negative�microorganisms,�even�in�the�1980s�coliforms�resistant�to�
ampicillin�and�gentamicin�were�high�but�resistance�to�cefuroxime�was�relatively�low�for�
Escherichia coli and Klebsiella�spp. [30]. Among clinical isolates collected from four 
regional hospitals in Hong Kong from June 1997 to May 1998, 13% of Klebsiella 
isolates and 11% of E. coli isolates were ESBL producers [35]. The SENTRY 
surveillance in 1998-2002 reported that 14.3% of E. coli isolates from Hong Kong were 
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ESBL producers [28]. According to the local antibiogram at Prince of Wales Hospital, 
Hong Kong in 2006, 21% of E.coli and 14% of Klebsiella spp. were positive in the 
detection of extended-spectrum p- lactamases (unpublished data). 
During 1987-1993, 19% of Pseudomonas spp., 11% Proteus spp., 6 % of P. 
aeruginosa and 3 % of Acinetohacter spp. in clinical isolates from a general hospital in 
Hong Kong were resistant to imipenem [29]. According to the local antibiogram at P W H 
in 2006, 7 % of P. aeruginosa isolates and 5 % of Acinetohacter spp. isolates from the 
ICU were resistant to imipenem. M R P A have emerged and has been confined to a few 
local hospitals in Hong Kong [32:. 
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Table 1.2 Antimicrobial resistance rates in common microorganisms isolated in 
Hong Kong hospitals between 1987-1993. 
Microorganisms^ & % Resistance (No. tested) 
Antimic- Gram-positive cocci Gram-negative bacilli 
robials SPNE 厂 SAUR “ ECOL KLEB PAER ACIN PROS 
S I S 2 ~ S I I S 2 - S I 「 S 2 S I S 2 S I | S 2 — S I S I 
Penicillin� 〇� 0� 95� -
/ o ( 6 0 0 ) • ( 4 9 2 2 ) “ “ 
Ampicillin 58 57 97 79 65 
- - - - (19123) (5955) (8712) (2630) ‘ “ • (6186) 
Methicillin 26 ^^ - - -
0 (4922) ： 
Piperacillin* ” 25- 65 
Carbenicillin- ‘ _ _ ： ： ： ： ； ： “ ( 腿 ） （ 3 0 0 0 )� (3280)� •�
Amoxycillin/� 27� 20� 36�
clavulanate _ _ ‘ ‘ ‘ (洲） ‘ 剛 ‘ ‘ ： (糊 
C e f u r o x i m e� 7� 1 “� 8 34 
- - - - ( 1 8 4 5 5 ) ( 3 5 5 7 ) 、 體 、 ( 2 2 3 7 ) “ ‘ ‘ ( 6 0 6 2 ) 
— P e 酬� -� -� -� -� m。4m ‘ (43^23) • (5044) ‘ (36^52) (2861) 
Gentamicin 20 22 11 22 10 二 44 14 
- - - - ( 1 5 6 1 7 ) ( 5 9 2 3 ) ( 7 7 3 1 ) ( 2 6 3 0 ) ( 6 9 0 3 ) 、 • “ u u u j ( 5 7 6 1 ) ( 5 2 6 8 ) 
—� 1� 5� C� 20� 1�
C — • a c i n _ _ - J i n _� (1833)� •� (85)� _� (317)� (1593)�
O f l o x a c i n 2 4 35 20 2 
训。 X 議 -� I - - (8785) - (2548) ‘ (304) _ (594) (2386) 
Sl:-LingJM, et al H K M J 1995 [29] S2:-Lim W , et al J H K Med Assoc 1991 
Study period- 1987-1993 1988 [30] 
Study setting- Teaching hospital Hong Kong Three general hospitals Hong Kong 
^SPNE, Streptococcus pneumoniae’, SAUR, Staphylococcus aureus] ECOL, Escherichia coli; KLEB 
Klebsiella spp.； PAER, Pseudomonas aeruginosa; ACIN, Acinetobacter spp.; PROS, Proteus spp. 
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1.1.2.2 Antimicrobial resistance of bacterial isolates from community 
In a study performed by Ling et al.2003, her group examined 4741 specimens 
taken from 3977 patients who attended 89 general practitioners during a fifteen month 
period in July 2000-0ctober 2001 [36] • Of these, 28% has yielded positive cultures and 
E. coli (18%), (3-heamolytic streptococci (15%) and S. aureus (12%) were the most 
common identified. The percentages of antimicrobial resistance of the commonly 
isolated bacteria are listed in Table 1.3. 
An alarming increase in penicillin-intermediate susceptible S. pneumoniae to 
81% was noted, together with high prevalence of resistance to macrolides 
(clarithromycin, erythromycin 90%) and tetracycline (87%). All isolates remained 
susceptible to third-generation cephalosporins (cefotaxime, ceftriaxone). 10% of p-
heamolytic streptococcus isolates were noted to have reduced susceptibility to penicillin 
and these belonged to group C and G streptococci. 
Gram-negative bacilli showed a high prevalence of resistance to ampicillin (39% 
in Haemophilus influenzae, 60% in E. coli and Proteus!Morganella spp. and 97% in 
Klebsiella spp.) but are susceptible to ampicillin/clavulanate. H. influenzae showed a 
high prevalence of resistance to macrolides (100% to erythromycin and 69% to 
clarithromycin) but showed 97-98% susceptibility to ampicillin/clavulanate, 
generation cephaloaporins and fluroquinolones. 
In 1999, the Department of Health in Hong Kong started an antibiotic resistance 
surveillance program targeting testing of community pathogens from the public 
outpatient settings. In April 2008 (latest data available at the time of writing), 12 isolates 
of S. pneumoniae had been identified from respiratory�specimens，42% and 58% were 
8 
found to be resistant to penicillin and erythromycin respectively. None were resistant to 
levofloxacin. Among 60 isolates of H. influenzae, 28% of were resistant to ampicillin 
and 5 % were resistant to amoxycillin/clavulanate. 
Among 374 E. coli isolates identified from urine specimens, 10% were ESBL 
producers, 5 % were resistant to amoxycillin/clavulanate, whilst the resistance rate was 
57% to ampicillin and 23% to ofloxacin. Fifty six Klebsiella pneumoniae isolated from 
the urine specimens and all resistant to ampicillin, 2 % were resistant to 
amoxycillin/clavulanate and 4 % were ESBL producers. Proteus isolates (total 42) also 
showed higher prevalence of resistance to ampicillin (36%). Ten percent were resistant 
to ofloxacin and amoxicillin/clavulanate. 
(http:"www.clip.gov.hk/epidemiolog:y.asp?lang=en&id:321 &pid="l 19&ppid^97 
&pppidKZ9). 
An increasing incidence of cases of C A - M R S A infections have been reported in 





























































































































































































































































































































































































































































































































































































































































1.1.3 Dynamics of resistance 
Emergence,�persistence�and�spreading�of�antimicrobial�resistance�is�a�result�of�
the�interaction�of�several�factors�including�the�patient,�the�environment，pathogenicity�of�
the�organism�and�the�use�of�antimicrobials [40]. The key driver of resistance is the 
environmental pressure caused by antimicrobial use in humans, animals and plants, 
which promotes the selection. It is believed that low doses, inappropriate route of 
administration resulting in low concentration at the site of infection, and prolonged 
duration of treatment promote resistance. A consequence of exposure to antimicrobials 
includes also the development of resistance among normal flora. 
Immunocompromised status, increased severity of illness of the patient, the 
presence of foreign body and large bacterial inoculum enhance the development of 
resistance. Factors related to the environment such as frequent or longer hospital 
admissions, residing in long term care facilities [41], cross-contamination via 
contaminated hands of health care workers and contaminated equipments and surfaces, 
frequent patient transfer between wards or institutions are important ways of spreading 
resistant organisms [16, 40, 42]. With advanced medical technologies and an 
increasingly aging population, the results in people with multiple comorbidities who 
need frequent hospitalizations and are susceptible to infections cause by resistant 
organisms are a major concern in the modern world. 
Within the community, inappropriate use of antimicrobials such as antimicrobial 
treatment for viral or self-limiting infections, poor compliance, over-the-counter 
availability and the antimicrobial use in animal husbandry encourage the emergence of 
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resistance. Globalization also plays a role in the spread of these resistant organisms 
worldwide. 
1.1.4 Mechanisms of antimicrobial resistance 
Antimicrobial resistance of microorganisms may arise as an intrinsic resistance 
or as an acquired resistance via mutations or gene transfer [7]. Knowing the mechanisms 
of resistance is important for implementation of strategies for control of spread of 
resistance such as antimicrobial restriction policies and infection control measures. 
Implementation of rigorous restriction of the use of oxyimino p-lactams had led to the 
successful control of a large nosocomial outbreak due to ESBL-producing K. 
pneumoniae [43]. Some microorganisms and antimicrobials pairs and monotherapy with 
particular antimicrobial will cause the development of resistance; for example, treating 
active tuberculosis with isoniazid monotherapy resulted in higher rates of isoniazid 
resistance [44:. 
Several mechanisms by which microorganisms confer resistance to the 
antimicrobials have been described [7, 42]. 
1.1.4.1 Enzymatic inactivation or modification 
Resistance may arise if the antimicrobial is inactivated before it reaches its target 
in the microorganisms. An example is the resistance to P-lactam antimicrobials via the 
production of inactivating enzymes- P-lactamases. These enzymes bind to P-lactam 
antimicrobials and cause hydrolysis of cyclic amide bonds of the P-lactam rings, p-
Lctamases are present in gram-positive (eg. staphylococcal p-lactamases) and gram-
12 
negative microorganisms (P-lactamases in Enterobacteriaceae). p-lactamases are 
increasing in prevalence among gram-negative microorganisms in many countries (Refer 
to section 1.5). 
Aerobic bacteria develop resistance to aminoglycosides by producing 
aminoglycoside-modifying enzymes such as acetyltranferases, phosphotranferases and 
nucleotidyl tranferases that modify the amino or hydroxyl groups of the aminoglycoside 
molecule [45". 
1.1.4.2 Alteration of target site 
Alteration in the target site so that it is no longer recognized by the antimicrobial 
agent, for example P-lactam resistance due to alterations of penicillin-binding proteins 
(PBPs) is another important mechanism of resistance in gram-positive bacteria. M R S A 
produce PBP2a which has low affinity for methicillin and other P-lactams. This PBP2a 
is encoded by the mecA gene. Altered PBPs cause penicillin-resistance in Sreptococcus 
pneumoniae. 
1.1.4.3 Impaired permeability 
Decreasing drug concentrations by reducing drug uptake (decreased 
membrane permeability) is another mechanism by which antimicrobial resistance can 
occur. Some gram-negative bacteria develop resistance to antimicrobial agents due to 
mutations which cause loss of specific porins. Porins facilitate drug entry in to the cell. 
Examples are those deficient in porins such as oprD2 porin leading to imipenem 
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resistance in P. aeruginosa [46] and O m p F causing fluoroquinolones resistance in E. 
coli. 
1.1.4.4 Efflux pumps 
Resistance may arise if the organism pumps back the antimicrobial out of the cell. 
Active efflux pumps which may be single or multiple have been described as another 
way of resistance mechanism [42]. Some enteric gram-negative microorganisms develop 
membrane transporter systems facilitating drug efflux [45:, 
1.1.4.5. Alteration of metabolic pathway 
Microorganisms may develop resistance by altering the metabolic pathway 
which bypasses the target. Resistant to sulfonamide may arise due to production of an 
altered enzyme that has reduced affinity for sulfonamide, and trimethoprim resistance 
may arise as a result of synthesis of dihydrofolate reductases with a decrease in the 
susceptibility to trimethoprim [42:. 
Two or more resistance mechanisms may be involved together to confer a 
resistance to a particular antimicrobial agent. For example in P. aeruginosa active efflux 
pumps, production of (3-lactamases and reduced membrane permeability interplay 
together to cause resistant to (3-lactam antimicrobials and specifically p-lactamase 
activity and reduced membrane permeability due to loss of oprD2 porin causes 
imipenem resistance [44:. 
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Impaired permeability 
Enzymatic inactivation d 
or modification “ 
• "s y 
赞 I) f 動 
Altered metabolic •• •• • � 
pathway Altered target site 丨 
Mechanisms of antimicrobial resistance (modified from the path of feast 
stance; main report; Standing Medical Advisory Committee, (SMAC), Sub-groiip on 
Antimicrobial resistance, Department of Health, England, 1997) [T 
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1.1.5 Association between antimicrobial use and resistance 
Although the emergence of antimicrobial resistance in microorganisms is 
complex, evidence of antimicrobial exposure as the main driver of resistance is 
overwhelming. The overuse or misuse of antimicrobials facilitates the emergence of 
resistance organisms due to selective pressure. 
Penicillin-resistant S. aureus isolates have been recognized soon after its 
introduction in 1940s. Since then the widespread use of penicillin and other newly-
introduced antimicrobials were soon followed by the emergence of resistance microbes 
1]. Antimicrobial resistance is predominant in countries and in hospital units (eg. ICUs) 
which have intensive antimicrobial use [7:. 
The widespread use of broad-spectrum cephalosporins had been associated 
with outbreaks of ESBL-producing K. pneumoniae [43] and likewise ceftazidime usage 
and the prevalence of ceftazidime-resistant P. aeruginosa and Enterobacteriaceae [47:. 
A recent study also demonstrated a significant correlation between antimicrobial use and 
resistance in S. pneumoniae among 15 European countries [48]. Other studies 
demonstrated the exposure to linezolid and isolation of linezolid resistant-coagulase-
negative staphylococci [13], an association between exposures to 
piperaci 11 in/tazobactam and piperci 11 in/tazobactam resistant-P, aeruginosa [49] and the 
isolation of endogenously acquired carbapenem-resistant strains of P. aeruginosa 
colonized in the digestive tract of critically ill patients after exposure to carbapenem [50:. 
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1.1.6 Clinical and economic impact of resistance 





hospital�costs [2, 23'. 
A surveillance study done in U K demonstrated clearly the socio-economic 
burden of hospital acquired infections [52]. Hospital costs were 2.9 times greater, length 
of hospital stay was 2.5 times longer; equivalent to an extra 11 days, and in-patient 
mortality was 7.1% times greater in patients who suffered from hospital-acquired 
infections than those for uninfected patients. Also, this group of patients had frequent 
visits to outpatient appointments and general practitioners. They received more visits 
from district nurses compared with uninfected patients, causing additional economic 
burden. 
Table 1.4 summarizes the findings of some case control studies that evaluated the 
clinical and economic impact of some MDROs. 
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Table 1.4 Impact of antimicrobial resistance on mortality, length of hospital stay 
(LOHS) and hospital costs. 
~ ” ~ T y p e of~“Outcome""“ , , . ^ Referen 
Microorganism • y M a m findings 
^ infection measures ce 
Staphylococcus Bacteremia Mortality RR,1.7 [95% CI, 1.3-2.4] 
aureus risk P <.01 5 
M R S A vs. M S S A 
Acinetobacter Bacteremia Mortality 34.8% vs. 13%; ？==0.036�
bauinannii� LO H S� 54.2�vs.�34.1�days;�
M D R vs. non M D R Hospitalizat ？-.006�
ion�cost US$ 9,349 vs. US$ 4,865 53 
Antibiotic P=001 
therapy cost US$ 2,257 vs. USS 1,610 
户=.014 
Pseudomonas� Nosocomial� Mortality� 31.1%�vs.�16.7%�
aeruginosa� infections RR,1.86; 95% CI,1.38-
imipenem-resistant 2.51; P<.001 




Enterohacteriaceae� Bacteremia� Mortality� 35%�vs.�18%�
ESBL�vs.�non-ESBL OR, 2.5; 95% CI,1.3-4.7; 
P=0.01 




MRSA, Methici 11 in-resistant Staphylococcus aureus; MSSA, Methicillin-sensitive Staphylococcus aureus 
MDR, multidrug-resistant; ESBL, Extended-spectrum ^-lactamases 
*ILS (Israeli shekels); 1 USD=3.40 ILS (at the time of writing) 
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1.1.7 Measures to minimize resistance in healthcare setting 
Previously published studies have shown that most of the time antimicrobial use 
is inappropriate, resulting in the emergence of resistance and an increased cost to the 
health care system [1, 55]. More appropriate prescribing together with prompt infection 
control measures will prevent the situation deteriorating further, will slow the emergence 
of new resistance and may reduce present resistance [7'. 
To combat the emerging resistance problem various infectious diseases societies 
and organizations have published recommendations and guidelines for management of 
antimicrobial resistance [2, 16, 44]. In 2001,WHO published the global strategy for 
containment of antimicrobial resistance and suggested six key interventions, including 
reducing the disease burden and prevention of spread, access to appropriate 
antimicrobials and appropriate use, improvement of surveillance systems, application of 
relevant regulations and legislation, and development of appropriate new antimicrobials 
and vaccines [51". 
The increase in the prevalence of antimicrobial resistance is partly due to the 
transmission of these organisms via contaminated healthcare workers and via a 
contaminated environment. SHEA guideline clearly indicated the spread of M R S A and 
V R E by these methods [44]. It is believed that more than 30% of hospital-acquired 
infections can be prevented by proper infection control measures [47]. Implementation 
of active surveillance system to identify resistant organisms including colonized patients 
is one of the first steps. It was reported that identification of M R S A colonizers by active 
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surveillance cultures and the application of prompt infection control measures for 
patients infected or colonized with M R S A resulted in successful control of M R S A [44；.�
Although�reductions�in�the�consumption�of�antimicrobials�do�not�always�result�in�
decreased�level�of�resistance, [56] evidence from published studies clearly indicates the 
positive impact of Antimicrobial control programs. Restricted use of oxyimino p_ 
lactams had led to the successful control of a large nosocomial outbreak due to ESBL-
producing K. pneumoniae [43]. Specific prescriber practice at ICUs at 20 U S A hospitals 
resulted in reduced consumption of vancomycin and decreased V R E prevalence [57 . 
Implementation of another management program resulted in a significant decrease in 
nosocomial infections caused by Clostridium difficile and resistant Enterobacteriaceae 
along with the reduced consumption of parenteral broad-spectrum antimicrobials [58 . 
The implementation of an antimicrobial control program at a university hospital U S A 
achieved reduction in the use of selected antimicrobial agents by 15%-80%, reversal of 
antimicrobial resistance rate of M R S A by 3 % and a subsequent cost saving [59；. 
Another�antibiotic�control�program�in�a�tertiary�care�hospital�in�Thailand�had�led�to�
significant�reduction� in� inappropriate� antibiotic�use� and� significant�reduction�in�
infections�due�to�methicillin vQS\s\m\\-Staphylococcus aureus�and�extended�spectrum [3-
lactamases producing organisms [55；.�
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1.2 Antimicrobial classes 
1.2.1 P-Lactams 
3-lactaiTis are the most important and commonly-used groups of antimicrobials. 
This class includes penicillins, cephalosporins, carbapenems and monobactams. They 
share a common structure, P-lactam ring and a mechanism of action that is the inhibition 
of bacterial cell wall synthesis [60]. To overcome the resistance to P-lactam 
antimicrobials due to P-lactamases these agents have been modified or combined with P-
lactamase inhibitors resulting in semi-synthetic agents with broader activity. 
The penicillin family consists of natural penicillins-penicillin�G，the�first�
penicillin�introduced�for�therapeutic�use,�penicillin�V� and�numerous�semi-synthetic�
penicillins�with�broader�and�different�antimicrobial�activities.�They�can�be�classified�into�
five�classes�based�on�their�antimicrobial�activity [45]. Class 1 are natural penicillins (G 
and V), highly active against sensitive strains of gram-positive cocci like Group A (3-
heamolytic streptococci, S. pneumoniae and are readily hydrolyzed by penicillinase. The 
semi-synthetic penicillinase-resistant penicillins such as methicillin, flucloxacillin 
belong to class 2 and drugs of choice for penicillin-resistant S. aureus and S. epidermidis 
which are not M R S A . Class 3 are aminopenicillins (ampicillin, amoxicillin) with an 
improved gram-negative spectrum and also active against non p-lactamase producing 
gram-negatives such as Enterobacteriaceae and H. influenzae. Class 4 and Class 5 
consist of antipseudomonal penicillins-carboxypenicillins (carbenicillin, ticarcillin) and 
ureidopenicillins (piperacillin) respectively. Combinations of this group of 
21 
antimicrobials and p-lactamase inhibitors such as clavulanate, sulbactam and tazobactam 
have been produced to widen the activity against p-lactamase producing organisms. 
Much resistance has developed to penicillins mainly due to (3-lactamases. Other 
mechanisms such as impaired permeability; efflux and low-affinity binding to target 
PBPs are described as causative factors responsible for resistance [45；.�
The�increasing�prevalence�of�penicillin�resistance�in S. pneumoniae,� the�most�
important�organism�responsible�for�community�acquired�pneumonia,�is�a�global�problem�
1,7] and the prevalence of M R S A is increasing in the healthcare setting and in the 
community globally (Refer to Table 1.1). 
Cephalosporin is a large family and has been classified into four generations 
based on the antimicrobial activity [60]. The first-generation cephalosporins 
(eg.cephalothin, cephradine) are most active against gram-positive microorganisms, 
second-generation cephalosporins (eg. cefuroxime) have better activity against gram-
negative microorganisms and varying degree of activity against gram-positive cocci .The 
cephamycins (cefmetazole, cefotetan, cefoxitin) are active against anaerobic bacteria 






against Enterohacter, Citrobacter�and Serratia species [45]. Third and fourth-generation 
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cephalosporins are collectively known as extended-spectrum cephaloaporins and 
resistance is accumulating to these agents as well (refer to section 1.5). 
Carbapenems (i mi pen em, meropenem, ertapenem) are derivatives of thienamycin, 
have the broadest antimicrobial spectrum and are the most powerful P-lactams, mainly 
due to increased p-lactamases stability conferred by the trans configuration of its 
hydroxyethyl-side chain at position C-6 [45]. They are stable against penicillinases, 
cephaloporinases and have good antimicrobial activity against aerobic and anaerobic 
microrganisms but are not active against Ambler class B p-lactamases found in 
organisms like Strenotrophomonas maltophilia, B.cereus, and B.anthracis. 
Carbapenems are not active against M R S A and V R E and ertapenem against 
P. aeruginosa and Acinetobacter. Resistance to carbapenems is emerging in 
P.aeruginosa and Acinetobacter spp. and is of great concern worldwide [2, 22, 23:. 
A monobactam-aztreonam is a monocyclic P-lactam and active against gram-
negative bacteria especially for Enterobacteriaceae and P. aeruginosa but not for gram-
positive or anaerobic organisms [45:. 
1.2.2 Glycopeptides 
Vancomycin and teicoplanin are the two glycopeptides available for clinical use 
and the primary mechanism of action is the inhibition of bacterial cell-wall synthesis. 
Vancomycin is a high molecular weight complex tricyclic glycopeptide with 
excellent activity against gram-positive microorganisms such as staphylococci including 
M R S A , streptococci, enterococci, Bacillus spp., Coiynebacterium spp. and gram-
positive anaerobes including most of Clostridium spp., but with no activity against 
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gram-negative bacilli [45]. Resistance has emerged and is spreading in enterococci and S. 
aureus. An alarming increase in the incidence of vancomycin-resistant enterococci 
(VRE) has occurred [2, 14, 15, 16] and incidences of VISA, V R S A and hVISA have 
been reported (refer to Table 1.1). In 1995 to prevent the spread of vancomycin 
resistance, recommendations were made by HICPAC including guidelines for prudent 
vancomycin use [16:. 
Teicoplanin is a mixture of six closely-related compounds and has a somewhat 
similar activity to vancomycin. Although this agent is active against strains of 
streptococci, for optimal bactericidal activity, the addition of an aminoglycoside has 
been suggested to treat infections caused by enterococci and S .aureus [60]. High MICs 
of teicoplanin has been found in VISA [45". 
1.2.3 Quinolones 
The first quinolone, nalidixic acid was discovered in early 1960s during the 
synthesis of chloroquine. In 1980s fluorine-and piperazinyl added quinolones (eg. 
ciprofloxacin, norfloxacin, levofloxacin) which have broad-spectrum antimicrobial 
activity and good oral bioavailability were introduced for clinical use. Quinolones 
inhibit bacterial D N A synthesis via inhibition of essential bacterial enzymes, D N A 
gyrase and topoisomerase IV [45:. 
Fluoroquinolones are active against gram-positive and gram-negative organisms 
including Enterobacteriaceae, H. influenzae, Neisseria and staphylococci but not for 
M R S A . Ciprofloxacin and levofloxacin have good activity against susceptible strains of 
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p. aeruginosa and S. pneumoniae [60]. The newer derivatives, such as gatifloxacin and 
moxifloxacin have more potent activity against gram-positive cocci compared with older 
agents such as ciprofloxacin, ofloxacin and levofloxacin [33:. 
Mutations in the bacterial genes encoding D N A gyrase or topoisomerase IV can 
cause resistance to fluoroquinolones [32]. Increasing fluroquinolone resistance in a 
number of microorganisms including Pseudomonas, Salmonella, andN. gonorrhoeae 
has been reported [60]. S. pneumoniae resistant to fluroquinolone also has increased in 
prevalence in recent years [ 18, 33:. 
1.2.4 Oxazolidinones-Linezolid 
Oxazolidinones are synthetic antimicrobial agents that inhibit the bacterial 
protein synthesis by binding to the 50S ribosomal subunit and are usually bacteriostatic, 
with a few exceptions (bactericidal against streptococci) [45]. Linezolid is the first 
commercially-available oxazolidinone which has a 100% oral bioavailability and is thus 
also available in the oral formula. 
Linezolid has excellent potency against most of the gram-positive organisms, 
including the strains that are resistant to other antimicrobial agents such as M R S A , 
VISA, VRSA, V R E and penicillin-resistant strains of S. pneumoniae; but it has poor 
activity against most of the gram-negative organisms [60'. 
Although linezolid has been used in clinical practice for a relatively short period 
of time, there are already reports of linezolid-resistant strains of V R E and M R S A . 
S E N T R Y antimicrobial surveillance identified linezolid resistance in eight gram-
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positive isolates (0.08%) including Enterococcus faecalis, Enterococcus faecium, 
Staphylococcus epidermidis and Sreptococcus oralis during 2001-2002 in U S A [19:. 
1.3 Antimicrobial Stewardship Program (ASP) 
1.3.1 Definition 
Antimicrobial stewardship is defined as a rational systematic approach to the use 
of antimicrobial agents that includes the optimal selection, dosage and duration of 
treatment in order to achieve optimal therapeutic outcome for the cure or prevention of 
infection, while minimizing toxicity to patient and subsequent emergence of resistance 
[82, 88]. 
This means antimicrobials should only be prescribed when it is beneficial to a 
patient, selecting the appropriate antimicrobial, dosage and duration and targeting 
therapy to the desired pathogens. In general ASPs within healthcare institutions are 
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Various strategies have been described for the implementation of good 
antimicrobial stewardship programs in healthcare settings. They are summarized in 
Figure 1.2 [1, 63, 64]. Strategies for improving antimicrobial prescribing practices of 
prescribers include the development of guidelines for rational antimicrobial use and 
educational programs, restriction of targeted antimicrobials to approved indications, 
introduction of standardized antimicrobial order forms, automatic stop orders (for 
example surgical prophylaxis), prior approval by the expertise personnel or team, and 
selective susceptibility reporting. 
Antimicrobial cycling is also described as a good way to reduce resistance. 
Review of antimicrobials for appropriateness and feedback with recommendations for 
alternative therapy is an important strategy, although the outcome depends on the 
compliance with recommendations. 
Timely conversion of intravenous to oral form, especially for antimicrobials like 
fluoroquinolones which has a good oral bioavailability, is an approach if the other 
criteria are satisfied; e.g. haemodynamic status and functioning status of the 
gastrointestinal tract of the patient. 
The use of information technology such as computer-based order entry and 
computer-assisted decision support programs will help not only to make decisions based 
on patient specific data but also will facilitate the whole process. 
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1.3.3 Multidisciplinary Antimicrobial Management Team 
It has been demonstrated that coordinating and combining these individual 
strategies via a multidisciplinary Antimicrobial Management Team (AMT) is effective 
in doing ASP [1]. The core members of the multidisciplinary A M T include infectious 
disease (ID) physicians, clinical microbiologists and clinical pharmacists [63". 
The role of ID physicians as a member of A M T is important in the formation of 
therapeutic guidelines, antimicrobial restriction policies, review and feedback and other 
measures, as they are well trained and they have more experience regarding infectious 
diseases. 
The clinical microbiologist as well as the microbiology laboratory is a key 
component in the ASP. Their collaboration is needed to identify the extent and important 
resistance issues of the healthcare institute which facilitates interventions like restriction 
of targeted antimicrobials and selective reporting of susceptibilities, and also to ensure 
the timely identification of pathogens. 
The pharmacists are an important member of the ASP because they can provide 
expert advice on the hospital formulary, drug interactions, toxicity and dosing as well as 
the active participation in the interventions like intravenous-to-oral conversion and 
evaluation of the effectiveness of interventions. 
Medical physicians, surgeons, pediatricians, hospital epidemiologists and 
infection control staff can also provide their expert assistance in the implementation of 
ASP together with support from the hospital administration. 
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1.3.4 Limitations 
Every program has limitations. The previously published studies and articles 
have described some limitations relating to the implementation of strategies of ASP [1, 
61]. 
Educational programs influence only those committed to behavioral change. 
Passive educational programs and guidelines have limited impact unless combined with 
active interventional strategies. The perception of threatened autonomy can be a 
significant barrier unless measures are taken to minimize this, such as consistent 
communication and immediate concurrent feedback [62'. 
Streamlining of antimicrobials, frequently according to the microbiology reports, 
will cause some degree of inappropriate exposure [1]. Also, sometimes prior approval 
may delay in initiating therapy with potent antibiotics especially for critically ill patients. 
The perception that the ASP goal is saving money that jeopardizes patient's safety 
is another limitation. Also program funding, lack of manpower and other resources can 
be limitations in some healthcare institutions. 
1.3.5 Experience in ASP 
Multifaceted, multidisciplinary Antimicrobial stewardship programs are being 
increasingly recognized worldwide for their effectiveness [1]. ASP has been established 
in many hospitals in the United States, Europe and recently in South-east Asian 
countries. 
Table 1.5 lists some of the strategies and outcomes of multidisciplinary ASPs at 
various institutions worldwide. Each program was implemented via an Antimicrobial 
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management team/committee with core members of ID physician and clinical 
pharmacist. Most of the A M I included a microbiologist and some of the programs have 
had assistance from epidemiologists, infection control specialists, medical specialists and 
computer system analysts [55, 65]. 
A variety of prospective and passive strategies have been taken, with prior 
authorization and concurrent reviews with feedback being the main strategies. Other 
strategies included the introduction of antibiotic order forms, formulary interventions, 
antibiotic guidelines and educational programs. 
Although each program and study used slightly different�approaches，the�
resulting�data�showed�variable�degrees�of�beneficial�outcomes.�Studies�demonstrated�
that�the�inultidisciplinary� ASP� has�had� significant�impact�on� appropriateness�of�
antimicrobial�prescription [55, 66, 67], antimicrobial consumption and costs [55, 56, 59, 
68]. Some of the programs indicate that the mortality rates, length of hospital stay [65, 
56] and readmission rates were not compromised by the implementation of ASPs and 
even reduction in antibiotic use correlated with the duration of both hospital and ICU 
stay and trends for reduction in crude mortality [68:. 
Regarding the antimicrobial resistance, some ASPs were more targeted [55，59'. 
Most of the ASPs listed in Table 1.5 showed a reduction in antimicrobial use and 
resulted in improvement in antibiotic susceptibilities, although a few had not [56:. 
Hong Kong has very limited experience in ASPs. In 2004, a multidisciplinary 
ASP involving guideline formations, educational programs, and concurrent feedbacks 
for commonly used broad-spectrum antimicrobials, monthly antimicrobial consumptions 
and cost monitoring was implemented in an 1800-bed acute service hospital in Hong 
Kong. The program resulted in a reduction in antimicrobial consumption and overall 
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cost saving without compromising the clinical outcomes of the patients. For restricted 
antimicrobials, the median monthly DDD/1000 patient days was reduced by 43.6% and 
monthly cost reduced by 46.4% (US$ 7,293 vs. 3,906; P <0.001) [69]. 
A pilot study performed to evaluate the impact of ASP on the use of 
carbapenems in the Prince of Wales Hospital, Hong Kong showed that the ASP 
implementation was associated with improvement in the appropriate prescribing of 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.4 ASP in Hong Kong 
To combat the emerging problem of multidrug-resistant organisms, the Hospital 
Authority (HA), with the collaboration of The Center for Health Protection launched the 
health protection program on antimicrobial resistance in Hong Kong. A consensus 
statement was made in 2005 [88]. An implementation Committee of Antibiotic 
Stewardship program was established and, an H A wide multidisciplinary Antimicrobial 
stewardship program was introduced to public hospitals to optimize the antimicrobial 
use. Strategies included the introduction of education programs, audit use of targeted 
antimicrobials, formation of multidisciplinary Antimicrobial Stewardship Teams in 
hospital clusters, construction and monitoring of antibiotic usage database and antibiotic 
resistance database of selected organisms. 
1.4.1 Implementation at Prince of Wales Hospital 
In line with the HA-Antibiotic Stewardship Program, the Prince of Wales Hospital, 
a 1350-bed teaching hospital, launched the ASP in September 2005 targeting eight 
broad-spectrum antimicrobials. The program has implemented several strategies to 
optimize antimicrobial use: 
I) Clinical Practice Guideline. A set of clinical practice guidelines concerning 
antibiotic prescriptions has been updated by IMPACT (Interhospital 
Multidisciplinary Program on Antimicrobial ChemoTherapy) and disseminated to 
medical staff in December 2005. 
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II) Educational seminars. A series of monthly educational seminars on the use of 
antimicrobial agents in hospital have been introduced, providing the latest 
information on local surveillance data and strategies to prevent antibiotic resistance. 
III) Antibiotic Order Form. An antibiotic order form went into effect in January 2006. 
Physicians were required to use the form (Appendix 1), which contains the specific 
indications and guidelines for antibiotics use, for new prescriptions to target eight 
broad-spectrum antibiotics. 
IV) Antimicrobial Management Team. An Antimicrobial Management Team (AMT), 
consisting of clinical microbiologists, infectious disease/medical physicians, 
clinical pharmacists, was formed to evaluate new orders of the target antibiotic 
agents, and make recommendations for drug alteration to doctors if the treatment 
was considered inappropriate. The A M T evaluates the medical records the 
following day after the initial order from Monday to Friday, visits patients when 
needed and makes recommendations. The A M T uses a feedback form documenting 
the recommendations and reasons for change. The recommendations are reviewed 
after 48hrs to check the adherence. Also half-yearly summary feedback to the 
primary care teams would be done by the A M T . 
V) Website. A website in the hospital intranet on Antibiotic Stewardship was 
formed, which contains information on the stewardship program, the educational 
materials from the talks and the antibiotic order form. 
The ASP was endorsed by the Hospital Drug and Therapeutics Committee. The 












1.4.2 Targeted antimicrobials 
ASP� focus�on�the�eight�commonly� used,�broad-spectrum�antimicrobials�for�
monitoring.�The� targeted� antimicrobials� included� glycopeptides� (vancomycin� and�
teicoplanin),�carbapenems�(imipenem�and�meropenem),�oxazolidinones�(linezolid),�3力 
4^ '^ -generation cephalosporins (ceftazidime and cefepime) and p-lactam/p lactamase 
inhibitors (piperaci 11 in/tazobactam and cefoperazone/sulbactam). 
Targeted antimicrobials with average daily dose and cost as at the P W H formulary 
2006 are shown in Table 1.6. Although vancomycin is quite cheap as compared to other 
antimicrobials it is included in ASP because of recommendations for its restricted use in 
the prevention of resistance development of V R E and other gram-positive 
microorganisms (HICPAC guidelines 1995 [16]). 
38 
The indications of appropriate use of these antimicrobials were discussed with 
relevant subspecialties of the clinical departments and finalized as listed in Appendix 11. 
Tablel.6 Targeted antimicrobials included in the ASP and their daily cost 
Drug Name Dose (parenteral) Cost (HKD per Day) 
Vancomycin 500 mg q8h 49.68 
"Linezolid “ 600 mgql2h — 808.00 — 
Imipenem (Tienam) 500 mg q8h 346.95 
"Meropenem — 500ing q8h 382.20 
"Ceftazidime "igqSh 242.10 
Cefepime "igqSh “ 287.43 
Cefoperazone/Sulbactam Ig q8h 271.08 
Piperaci 11 in/Tazobactam 4.5g q8h 327.24 
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1.5 Extended-Spectrum P-Lactamases (ESBLs) 
1.5.1 Classification of P-lactamases 
Several classification schemes have been proposed since the late 1960s, based 
on their hydrolytic spectrum, susceptibility to inhibitors, amino-acid sequence and 
whether they are chromosome or plasmid encoded. 
Currently, the two most widely used p-lactamases classification schemes are, 
first, functional classification based on their substrate spectrum and inhibitor profile. The 
second is molecular classification on the basis of their nucleotide and amino acid 
sequences [71, 72:. 
The molecular classification of p-lactamases was first introduced by Ambler in 
1980 and later revised [73]. This classification system consists of four molecular classes 
designated from A to D. Classes A, C and D are serine dependent where as class B is 
zinc dependent and also known as metallo-P-lactamases. 
The functional classification scheme of p-lactamases was proposed by Bush in 
1989 and was revised by Bush, Jacoby and Medeiros in 1995 [74]. It defines four groups 
from group 1 to 4 and eight subgroups from a to f. 
Group 1 is cephalosporinases not inhibited by clavulanic acid and belonging to 
the molecular class C. This includes the A m p C p-lactamases from gram-negative 
bacteria. Penicillinases and cephalosporinases which are inhibited by clavulanic acid are 
designated to Group 2. These represent the original T E M and S H Y genes belong to the 
molecular classes A and D. They are classified as subgroups a to f. Subgroup 2a 
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consists�of�penicillinases�and�corresponds�to�the�molecular�class�A,�and�the�subgroup�2b�












A� and� are� inhibited� by� clavulanic� acid.�The� last�subgroup� 2f�is�serine-based�






are� inhibited� by� EDTA.� These� enzymes� are� produced� by� organisms� like�
Stenotrophomonas maltophilia. 
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Group 4 (3-lactamases are penicillinases which are not inhibited by clavulanic 
acid. Corresponding molecular class is still undetermined. An example is the 
penicillinase from the Burkholderia cepacia. 
1.5.2 Definition ofESBLs 
Extended-spectrum p-lactamases are (3-lactamases capable of hydrolysing 
penicillins, broad and extended-spectrum cephalosporins (oxyimino-cephalosporins), as 
well as the oxyimino-monobactam, aztreonam. These are not active against cephamycins 
or carbapenems and can generally be inhibited in vitro by p-lactamases inhibitors such 
as clavulanate, sulbactam or tazobactam [21, 25, 75". 
ESBLs are plasmid mediated p-lactamases. 
1.53 Types ofESBLs 
At the time of writing this thesis, over 300 different ESBLs and inhibitor 
resistant P-lactamases have been described on the website hosted by George Jacoby and 
Karen Bush (http://www.lahey.org/studies/). TEM-type and SHV-type ofESBLs are the 
most common. Also CTX-M type ESBLs are being found frequently worldwide. OXA-
type ESBLs are less common. 
The TEM-type ESBLs belong to molecular enzymes class A. they originated 
from TEM-1 and TEM-2 enzymes and differ by as few as a single amino acid 
substitution resulting in altered configuration of the active site of the enzyme. This 
opens and enlarges the active site of the enzyme deflecting the oxyimino component 
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which covers the P-lactam ring of the oxyimino-(3-lactams. This process increases the 
susceptibility of the enzyme to p-lactamase inhibitors [75, 76]. The first TEM-type 
ESBLs, TEM-3, originally known as CTX-1 was first discovered in K. pneumoniae 
isolates in France in 1987 and TEM-12 detected in isolates of Klebsiella oxytoca in 
England [25]. Currently over 150 TEM-type extended-spectrum and inhibitor resistant 
3-lactamases have been recognized and are found worldwide and detected frequently in 
E. coli, K. pneumoniae and other Enter oh acteriacae such as Morganella morgani, 
Proteus mirabilis, Salmonella species, Enterobacter aero genes and some non-
Enterobacteriacae gram-negative bacteria [77:. 
The SHV-type ESBLs also belong to the class A molecular enzymes. In�1983， 
SHV-2�type�was�first�discovered�in�isolates�of Klebsiella ozaenae�in�Germany�and�in�




SHV-type�ESBLs�are�found�in�strains�of K. pneumoniae, E. coli, P. aeruginosa and 
Acinetohacter species [25, 77, 16'. 
CTX-M-type ESBLs are rapidly growing worldwide. They are more active 
against the cefotaxime hence the name given (but some are more active against 
ceftazidime than cefotaxime and hydrolyze cefepime efficiently). They are not very 
closely related to T E M or SHV-type p-lactamases, but to P-lactamases of Kluyvera spp. 
and believed to have acquired chromosomal (3-lactamases genes from Kluyvera spp. [75]. 
Currently 69 CTX-M-type p-lactamases have been reported and CTX-M-2, CTX-M-3 
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and CTX-M-14 are the most frequent C T X - M ESBL types [76]. CTX-M-15 producing E. 
coli emerged in the hospital setting as well as in the community setting in the United 
Kingdom in 2003 [78]. 
Amino acid substitution in O X A (3-lactamases leads to OXA-type ESBLs. These 
OXA-type ESBLs belong to the molecular class D and are poorly inhibited by clavulanic 
acid (OXA-18 p-lactamase are inhibited by clavulanic acid). Several OXA-type ESBLs 
derived have been derived from OXA-10 such as OXA-11, OXA-14, OXA-16 and 
OXA-17 or from OXA-2 such as OXA-15. The OXA-type ESBLs were first discovered 
in isolates of P. aeruginosa in Turkey. Also OXA-type ESBLs such as OXA-28, OXA-
18 and OXA-19 have been discovered in P. aeruginosa isolates in France [25, 77, 76]. 
Currently 9 OXA-type ESBLs have been reported. 




1.5.4 Epidemiology of ESBLs 
Within a few years after introduction of third-generation cephalosporins to 
overcome |3-lactamase-mediated antimicrobial resistance, the first report of ESBL was 
noted in K. pneumoniae and Serratia marcescens isolates in 1983 in Germany [20]. In 
1989, plasmid-mediated (3-lactamase (TEM-10) capable of hydrolyzing the ceftazidime 
and aztreonam in K. pneumoniae and E. coli clinical isolates was reported in the United 
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States [79]. Since then there has been an increasing trend in the prevalence of ESBL-
producing Enterohacteriaceae in healthcare settings, as well as an increasingly isolation 
from the community worldwide, causing unique challenges to healthcare professionals 
[21]. 
The prevalence of ESBL-producing organisms vary from country to country, but are 
more common in countries of�Europe，Asia�and�Central�and�South�America [80:. 
Outbreaks of infections caused by ESBL-producing organisms have been reported from 
almost every European country. In 1997-1998 a survey, which included 24 intensive 
care units in western and southern Europe, 25% of Klebsiella isolates possessed ESBLs 
[25]. In 2003 CTX-M-15 producing E. coli arose as an emerging problem in the United 
Kingdom [78]. A study from January 2003 to November 2005 done to find out the 
prevalence of ESBL producing Enterohacteriaceae in a university hospital in Turkey 
revealed 33% of E. coli, 31.4% of K, pneumoniae isolates positive for ESBLs [81]. 
According to the S E N T R Y antimicrobial surveillance program 1998-1999 
highest prevalence of ESBL-producing K. pneumoniae was reported in Latin America 
(45%) followed by Western Pacific region (25%), Europe (23%), United States (8%) 
and Canada (5%) [26]. High prevalence (45%) of ESBL-producing K. pneumoniae 
isolates are found in Brazilian hospitals [82:. 
ESBL type SHV-2 was reported in K. pneumoniae isolates in 1988 in China. In 
China a high prevalence of ESBL-producing K. pneumoniae and E. coli were reported in 
hospital settings as well as in community settings. High prevalence rates of ESBL-
producing K. pneumoniae (51 % ) and E. coli (23.6%) mainly the T E M and CTX-M types 
have been reported in hospital settings in China [83]. S E N T R Y 1998-2002 reported that 
the 30.7% of K. pneumoniae isolates from mainland China were positive for extended-
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spectrum P-lactamases. Also 24.5% of E. coli isolate from mainland China were ESBL 
producers [28]. A multicenter survey covering seven geographical areas (including Hong 
Kong) in the People's Republic of China reported 17% of Klebsiella and 16% of E. coli 
isolates from patients with community acquired infections were ESBL producers [2T. 
In United States, National Nosocomial Infection Surveillance (NNIS) conducted 
in 110 intensive care units from January 1998 to June 2002 found 6.1% of 6101 isolates 
of K. pneumoniae were resistant to third-generation cephalosporins or aztreonam [25, 
80]. In 2003 NNIS reported 20.6% resistance rate, a 47% increase compared to the 
1998-2002 [5]. In Australia around 5 % of K. pneumoniae are positive for ESBLs. Also, 
several outbreaks of infections due to ESBL-producing K. pneumoniae reported from 
South Africa [25:. 
1.5.5 ESBL detection 
Various laboratory methods are available for the detection of ESBLs. Screening 
for ESBLs production by using an indicator cephalosporin requires confirmation using 
specific recommended confirmatory tests [75]. 
Clinical and Laboratory Standards Institute (CLSI) [66] guidelines recommended 
the use of disk diffusion methods to screen for ESBLs production by E, coli, Klebsiella 
spp. and Proteus mirahilis using discs containing known concentrations of cefpodoxime, 
ceftazidime, aztreonam, cefotaxime or ceftriaxone. Isolates with reduced zone diameters 
of susceptibility were likely to produce ESBLs and would proceed to the confirmatory 
test for ESBL production [25, 84]. According to the CLSI, 2006 [84] if the isolate 
exhibits a cefotaxime zone size of <27mm or ceftazidime zone size of <22miTi, a 
confirmatory test will be performed. Alternatively, a microdilution method may be used 
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for screening the presence of ESBLs with bacterial growth in the presence of a 
generation cephalosporin at concentration of l|ag/ml. 
Commonly used confirmatory tests for ESBL detection such as double disk, 
combination disk and Etest methods are based on the synergy between cephalosporins 
and clavulanate. The combination disk method (CLSI, 2006) consist of two discs; a 
cephalosporin 30|j,g disc and a disc containing the same cephalosporin combined with 
clavulanic acid 10|ag. ESBL production is confirmed if the zone inhibition with 
combination disc is > 5 m m larger than the cephalosporin alone disc (Figure 1.3). 
The double disk method tests synergy between cephalosporin and clavulanate by 
placing cephalosporin (usually cefotaxime) 30|ag disc and amoxicillin/clavulanate (20|ig 
+ lOfig) disc, 30 m m apart. An expansion of the cephalosporin inhibition zone towards 
the amoxicillin/clavulanate disc (keyhole effect) indicates synergy (Figure 1.4) [25, 75'. 
Other methods available for ESBL detection included commercially available 
Etest, Vitek ESBL cards and molecular approaches (DNA�probes，PCR)�to�detect genes' 
encoding of ESBLs. 
CLSI, 2006 [84] recommends to report isolates confirmed to be positive for 
ESBL producers according to the confirmatory tests, as resistant to all penicillins, 
cephalosporins and aztreonam. 
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Figure 1.3 Combination disc test for detecting ESBLs.�The�discs�are:�left�lower�
CTX30�(cefotaxime�30|^g),�left�upper C T X + C L A (cefotaxime SOjiig + lOjug clavulanatq), 
right upper CAZ30 (ceftazidime SOiug), right lower C A Z + C L A (ceftazidime SO^ig + 
lOpg clavulanate). Zone inhibition with combination disc C T X + C L A is > 5 m m larger 
than the cefotaxime alone disc indicating the presence of ESBL production. 
Figure 1.4 Double disc synergy tests for detecting ESBLs. Discs are: left CTX30 
(cefotaxime 30 jug), centre A M C 3 0 (amoxicillin 20|ag +clavulanate 10|ag), right CAZ30 
(ceftazidime 30 |Lig). Expansion of the cephalosporin inhibition zone towards the 
amoxicillin/clavulanate disc indicates synergy. 
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1.5.6 Risk factors for acquisition of ESBL-producing organisms 
Several risk factors for colonization and infection with ESBL-producing 
organisms in hospital settings have been described. Seriously ill patients with invasive 
medical devices such as indwelling urinary or central venous catheters and endotracheal 
tubes are more prone to get colonization or infection with ESBL-producing organisms 
77]. The spread of resistance of ESBL-producing organisms from patient to patient 
especially via contaminated healthcare workers hands and contaminated surfaces or 
equipments have been reported [25]. Case control studies have recognized prolonged 
length of hospital stay and intensive care units stay as risk factors [25, 85, 86". 
Prior exposure to antimicrobials especially to third-generation cephalosporin has 
been described as an important risk factor [25, 86, 87]. Studies have suggested 
association of exposure to other antimicrobials like quinolone, aminoglycosides, 
trimethoprim-sulfamethoxazole, metronidazole, 4^ g^eneration� cephalosporin， 
carbapenems�and�subsequent�infections�with�ESBL-producing�organisms [25, 86, 88". 
One study associated the risks to exposure to piperacillin/tazobactam and vancomycin in 
an ICU [89]. Studies done to assess the risk factors for acquisition of bloodstream 
infections due to ESBL-producing organisms in hospitalized patients recognized 
exposure to antibiotic therapy especially to oxyimino-P-lactams or fluoroquinolones and 
length of hospitalization as significant risk factors [90, 91]. 




infection were found to have been associated with infections caused by ESBL-producing 
organisms in children [92，93, 94]. 
Other risk factors found in studies included, decubitus ulcers, bums, 
presence of gastrostomy or jejunostomy tubes, renal failure, hemodialysis, arterial 
catheters and receipt of total parenteral nutrition and prior isolation of ESBL-producing 
organisms [25, 88]. High frequency of colonization with ESBL-producing organisms in 
long-term care facility residents may bring resistance organisms into the acute care 
hospitals and vice versa [25, 95:. 
1.5.7 Clinical and economic impact of infections caused by ESBL-
producing organisms 
Extended-spectrum p-lactamases have been detected in gram-negative bacteria 
like Enterohacteriaceae and P. aeruginosa. K. pneumoniae is the most common species 
but it is increasingly found in other Enterohacteriaceae such as E. coli and Proteus 
inirabilis [77, 80, 96]. ESBL-producing organisms are one of the major pathogens 
responsible for nosocomial infections especially in the intensive care units but have been 
recognized in the community setting and in nursing homes as well. 
Usually ESBL-producing organisms colonize in the gastrointestinal tract of 
hospitalized patients and the upper respiratory tract and skin of seriously ill patients. 
They can cause urinary tract infections, intraabdominal infections like cholangitis, 
peritonitis and abscesses. Also they can be the causative organisms for hospital-acquired 
pneumonia, catheter-related blood stream infections and post-neurosurgical meningitis 
[75,96]. 
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Infections due to ESBL-producing organisms are associated with increased 
morbidity, mortality and high hospital costs. Numerous studies have been done to 
evaluate the impact on clinical outcomes and hospital costs. According to a recent study 
done in the United Kingdom involving patients with E. coli bacteraemia, patients 
infected with ESBL-producing E. coli had a significantly higher mortality compared to 
the non-ESBL group, with an odds ratio of 3.57 (95% CI; 1.48-8.6, P<.005) [97]. 
Another study reported that bacteremia due to ESBL-producing Enterobacteriaceae was 
associated with higher mortality [54, 93, 94], increased length of stay [54, 86, 94], 
discharge to chronic care [54] and higher costs [54]. A matched cohort study done to 
evaluate the hospital costs showed infection-related costs of non-urinary tract infections 
caused by ESBL-producing E. coli and Klebsiella species was 1.7 times the costs of 
non-urinary tract infections caused by non-ESBL producers [98:. 
1.5.8 Treatment options for infections caused by ESBL-producing 
organisms 
Limited antibiotic options are available for the treatment of infections caused by 
ESBL-producing organisms. Studies and guidelines suggest that carbapenems are the 
drug of choice for serious infections caused by ESBL-producing organisms [80，99:�
Limited�studies�have�been�done�to�see�the�therapeutic�options�against�ESBL-bacteremia.�





Carbapenems are stable against the hydrolysis by the extended-spectrum p-
lactamases due to trans configuration of its hydroxyethyl side chain at position C-6 [45:. 
Previously published observational studies and in vitro susceptibility data have 
repeatedly suggested that carbapenems are the treatment of choice for serious infections 
caused by ESBL-producers [25, 75, 96, 100, 101] and recommended as the first line 
therapy for infections such as bacteremia, nosocomial pneumonia (especially for the 
ventilator associated pneumonia) and intraabdominal infections caused by ESB-
producing pathogens. Meropenem is recommended for nosocomial meningitis caused by 
ESBL- producing pathogens due to the less neurological side effects [25, 96". 
Studies done to evaluate the treatment outcome of patients with serious 
infections due to ESBL-producers reported that treatment with carbapenem was 
associated with better clinical outcomes than the treatment with noncarbapenems [80, 99, 
100, 102]. One study showed that treatment with carbapenem during a five day period 
after the onset of bacteremia due to ESBL-producing K. pneumoniae was associated 
with a significantly lower mortality than with treatment with noncarbapenems active in 
vitro [80]. Another study reported treatment with carbapenem for nosocomial 
pneumonia caused by ESBL-producing organisms resulted in treatment success in all 
patients [102:. 
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Table 1.7 Treatment outcomes of patients with serious infections due to ESBL-
producing organisms, treated with carbapenems or noncarbapenems. 
~� of�study� i^^ggifn� I�A n二， b i� I� Qut^me�measures� Reference�
Prospective� Bacteremia� Carbapenem� 14-day�all-cause�
observational� vs.� mortality�
study� noncarbape� 4.8%�vs.�27.6% ；户=,017�






analysis� pneumonia,� Carbapenem� 4/4(100%)�
urinary�tract� piperacillin/� 6/11�(55%)� 0�
infection� tazobactam�
Retrospective� Bacteremia� Imipenem� Treatment�failure-
study� vs. 2/10(20%)�vs. 5/7 (71.4) 卯 
ciprofloxaci� P=.03�
n�
Evaluator-blind,� Nosocomial� Imipenem� Treatment�failure。�
Prospective,� pneumonia� vs.� 0/10�(0%)�vs.�4/13�
randomized�study� cefepime� (30.7%)�
诛 ciprofloxacin,cephalosporins (cefepime, ceftriaxone, cefotaxime), (3-Lactam/(3-lactamase inhibitor 
combinations (piperacillin/tazobactam, ticarcillin/clavulanate), amikacin 
• Absence of resolution or worsening of signs and symptoms 
o Absence of a response to treatment, documentation of a bacterium resistant to the allocated regimen 
resulting in the introduction of another antibiotic, death due to pneumonia or inability to complete the 
study due to severe adverse effects. 
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But the prevalence of imipenem resistance in isolates of P. aeruginosa and 
imipenem resistance Acinetobacter species are increasing and antibiotic options are 
becoming more limited for infections caused by gram-negative bacilli [22, 103]. Various 
studies have demonstrated the association of imipenem-resistant P. aeruginosa and prior 
carbapenem use [46,�50，104, 105]. Also outbreaks due to carbapenemases producing 
Klebsiella and Enterobacter species have been reported recently [75'. 
1.5.8.2 Noncarbapenems 
1.5.8.2.1 Quinolones, aminoglycosides and sulfonamides 
ESBLs are plasmid mediated p-lactamases. Frequently these plasmids also 
encode the genes that encode resistance to aminoglucosides and sulfonamides [21, 25". 
Quinolones can be used for treating the urinary tract infections due to ESBL-producing 
organisms according to the in vitro susceptibility [75，106]. Reports say that there is an 
association of plasmid-mediated cephalosporin resistance and plasm id-mediated reduced 
susceptibility to quinolones [25]. Although the mechanism is not known there is a strong 
association of ESBL-production and quinolone resistance [25]. A previously published 
study which evaluated the treatment outcome of patients with bacteremia due to TEM-
52 ESBL-producing K. pneumoniae observed treatment failure in five out of seven 
patients treated with ciprofloxacin and suspected that treatment failure may be due to the 
failure to achieve the therapeutic concentrations at the infected site [99]. These drugs are 
not suitable for treating the serious infections caused by ESBL-producing organisms [21, 
25, 75]. One study that evaluated the treatment outcome of patients suffered from 
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bacteremia due to ESBL-producing Enterobacteriaceae other than E. coli and Klebsiella 
species (included Enterohacter cloacae, Enterobacter aerogenes, Proteus mirabilis, 
Citrobacter diversus’ Serratia marcescens and Citrobacter freundii) reported overall 
survival rate of 72.7% with carbapenem and 70% with ciprofloxacin [107:. 
1.5.8.2.2 Cephalosporins 
Reports have suggested that third-generation cephalosporin should not be used to 
treat serious infections caused by ESBL-producers even though they are susceptible in 
vitro because of the inoculum effect that is the increase in the MIC for the isolate to the 
antimicrobial agent when the inoculum of infecting organism rises [96, 108'. 
Cefepime, a fourth-generation�cephalosporin，shows�the�inoculum�effect [25, 109, 
110]. Published studies and reports suggested not using cefepime to treat the serious 
infections caused by ESBL-producing organisms as a first line therapy [25, 109, 110, 
111]. It was suggested to use high dosage, when it is used [25]. However some in vitro 
and observational studies done recently suggested that cefepime may be use to treat 
nosocomial infections (eg. pneumonia, bacteremia and urinary tract infections) caused 
by ESBL-producing organisms [112, 113]. A recently published study reported a clinical 
cure in 12 episodes and improvement in one episode among 13 patients with 15 episodes, 
infected with ESBL-producing K. pneumoniae and E. coli treated with cefepime [113". 
Cephamycins are stable against the hydrolysis by the extended spectrum beta 
lactamases and active in vitro against TEM- and SHV-type ESBL-producing 
Enterobacteriaceae [21, 114], These organisms may develop resistance to cephamycin 
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due to loss of outer membrane protein or due to pi asm id-mediated expression of A m p C 
^-lactamases [25，21]. Published studies that evaluate the treatment efficacy of 
cephamycin against ESBL-producing organisms are lacking. One�study，that�compared�
the�treatment�outcome�of�bacteraemia�due�to�ESBL-producing K, pneumoniae� in�patients�
treated�with�flomoxef�and�carbapenem,�found�that�there�was�no�significant�difference�in�
mortality�between�two�groups [114: 
1.5.8.2.3 P-Lactam/P-Iactamase inhibitor combinations 
P-Lactamase inhibitors (clavulanic acid, tazobactam and sulbactam) irreversibly 
bind to the catalytic site of p-lactamases and prevent hydrolysis of the accompanying p-
lactam antimicrobials [115]. They are the same as cephalosporins, p-lactam/p-lactamase 
inhibitor combinations that also exhibit the inoculum effect. The co-existence of A m p C 
(3-lactamases, hyperproduction of other P-lactamases and porin loss can lead to the 
resistance to p-lactam/p-lactamase inhibitor combinations [21, 25]. The 
parmacokinetics - pharmacodynamics studies indicated the inability of 
piperacillin/tazobactam to achieve high probability of target attainment against ESBL-
producing organisms [116, 117:. 
P-lactam/(3-lactaiTiase inhibitor combinations may be used for treating urinary 
tract infections due to ESBL-producing organisms according to the in vitro susceptibility 
106]. Although some studies have been done to investigate the effectiveness of 
piperacillin/tazobactam in treating infections (eg. pneumonia, bacteremia and urinary 
tract infections) caused by ESBL-producing organisms, so far no clinical study has been 
done to see the effectiveness of cefoperazone/sulbactam [100, 118]. /w vitro studies have 
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indicated that addition of sulbactam to cefoperazone resulted in good in vitro activity 
against cefoperazone-resistant gram-negative bacilli and ceftazidime-resistant ESBL-
producing Klebsiella [119, 120；. 
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1.6. Objectives of the study 
Although�during�the�past�few�years�several�measures�and�studies�have�been�taken�
to�encourage�the�prudent�use�of�antimicrobials�in�the�Prince�of�Wales�Hospital,�these�



















The finding of this study will help to understand the use of these agents in these 
patient groups and impact of the ASP. 
Limited antibiotic options are available for the treatment of infections caused by 
ESBL-producing organisms and limited studies have been done to see the therapeutic 
options against ESBL-bacteremia. Although some studies have been done to investigate 
the effectiveness of noncarbapenem antimicrobials in treating infections caused by 
ESBL-producing organisms, so far no study has been done to see the effectiveness of 
cefoperazone/sulbactam. 
Objective 11 
1. To evaluate the treatment outcome of patients with bacteremia due to ESBL-
producing organisms, receiving carbapenem or p-lactam/p-lactamase inhibitor 
combinations including cefoperazone/sulbactam, piperacillin/tazobactam and 
amoxicillin/clavulanate. 
2. To identify the factors affecting treatment outcomes of patients with bacteremia due 
to ESBL-producing organisms, receiving carbapenem or p-lactam/p-lactamase inhibitor 
combinations including cefoperazone/sulbactam, piperacillin/tazobactam and 
amoxicillin/clavulanate. 
By this study we will have a better understanding of antimicrobial options for 
bacteremia due to ESBL-producing organisms. 
59 
CHAPTER 2 - METHODS 
2.1 Data collection 
Data were collected from patient medical and electronic patient records and 
included demographic characteristics, clinical and laboratory data. Type and source of 
infection was decided according to Centers for Disease Control and Prevention (CDC) 
definitions [121]. Antimicrobial consumptions were measured in Define Daily Doses per 
1000 Bed Day Occupied (DDDs/lOOOBDO) according to the W H O collaborating center 
for drug statistics methodology [122]. These data were obtained from the hospital 
computerized system (Clinical Data Analysis and Reporting System-CDARS). 
Antibiotic susceptibilities were obtained from the Microbiology laboratory and the 
hospital computerized laboratory reporting system. 
2.2 ESBL detection at PWH 
The microbiology laboratory of Prince of Wales Hospital does the screening test 
for ESBLs according to the CLSI [84]. If the isolate exhibits a cefotaxime zone size of 
or ceftazidime zone size of <22mm, a confirmatory test will be performed which 
does the combination disk method as the confirmatory test according to the CLSI 
guideline, using cefotaxime 30|ag discs and ceftazidime 30)ag discs with or without lOjiig 
clavulanate and reporting as ESBL positive if the zone diameter of either combination 
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disc is > 5 m m larger than its clavulanate free counterpart (Figure 1.3). K. pneumoniae 
A T C C 700603 is used as the test control strain for ESBL production [123；. 
The� microbiology� laboratory� of�Prince� of�Wales� Hospital� reports� ESBL�
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2006) were included. Six hundred and five patients from the same department were 
reviewed retrospectively for the preintervention period. (March to May 2005). Clinical 
ethics approval was obtained from the local institutional Ethical Board of Committee for 
the review of the patients' charts and medical records. 
3.2.3 Definitions 
Definitions were made prior to the data collection. Healthcare-associated 
infections (HAIs) were defined as infections that patients acquire during the course of 
receiving treatment for other conditions within a healthcare setting including long term 
care facility (included hospital acquired infections, recent hospitalization within one 
month, transfer from other hospitals and nursing home residents). Hospital acquired 
infection (nosocomial infection) was defined as occurrence of an infection after hospital 
admission (>48hrs) without the evidence that the infection was present or incubating on 
admission. Immunosuppression was defined as receipt of immunosuppressive agents 
such as anti-neoplastic therapy, corticosteroids and presence of neutropenia and HIV 
infection. Systemic inflammatory response syndrome (SIRS) and Severity of sepsis 
was decided according to definitions for sepsis in the CHEST publication by American 
College of Chest physicians [124]. Treatment outcome: complete response defined as 
complete resolution of fever, leucocytosis and local signs and symptoms of infection, 
partial response defined as improvement of fever, leucocytosis and local signs and 
symptoms of infection without complete resolution and treatment failure as absence of 
resolution or progression of signs and symptoms despite 48 hrs of antimicrobial therapy 
resulting in death or a change in the antibiotic regimen, target an isolated pathogen not 
susceptible to original regimen during treatment, recurrence of the infection and adverse 
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drug effect. All-cause mortality was defined as death from any cause during the 
hospital stay or death within one month after discharge. Appropriateness of antibiotic 
use was evaluated according to a set of predetermined guidelines. These guidelines were 
prepared for each targeted antimicrobial by the A M T according to the published and 
local guidelines (Appendix 11). 
3.2.4 Data collection 
Data collection included demographic characteristics, clinical and laboratory data, 
antimicrobials received appropriateness of indication, reasons for inappropriate use, 
suggestions made by A M T , acceptance of the recommendations by the in-charge doctors, 
clinical outcomes, antibiotic consumption and antibiotic susceptibility pattern. 
Comorbid conditions included underlying malignancy, hypertension, 
immunosuppression, ischaemic heart disease (IHD), diabetes mellitus (DM), chronic or 
end stage renal failure (ESRF), chronic respiratory conditions like chronic obstructive 
airway disease (COAD) or bronchiectasis, history of pulmonary tuberculosis, chronic 
liver disease, cerebrovascular accidents, surgery or a surgical procedure within one 
month before the acquisition of the infection leading to prescription of a targeted 
antimicrobials, intravenous (IV) drug addiction and any other significant underlying 




3'^ -generation cephalosporins and macrolides was collected. The antibiotic resistance 
rates for prevalent organisms and multidrug-resistant organisms were evaluated. These 
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included methicillin vQshimi-Staphylococcus aureus (MRSA), E. coli including ESBL-
producing isolates and P. aeruginosa. Data were collected for one year before and the 
year after the start of the Antimicrobial Stewardship Program, unless where specified. 
3.2.5 Data analysis 
3.2.5.1 Outcome measures 
Outcome measures included appropriateness of use of antimicrobial agents, 
length of hospital stay, all-cause mortality, antimicrobial consumption and antibiotic 
susceptibility pattern, compared between the preintervention and the intervention 
periods. 
3.2.5.2 Statistical analysis 
Categorical variables, compared using x^test or Fisher's exact test and 2-tailed 
independent sample t-test, were performed for continuous variables to see a statistically 
significant difference between two periods. To compare the outcome measures 
(appropriateness of indication, all-cause mortality) between 2 periods, odds ratio (OR) 
with their 95% confidence intervals (CI) and P values were calculated. A P value of 
<.05 was considered statistically significant. Multiple logistic regressions with backward 
stepwise method were used to control for confounding variables and to look for the 
influential factors. Two separate models were constructed for appropriateness and all-
cause mortality. Variables with P<2 in the univariate analysis were entered in to these 
models. The SPSS software (version 14, SPSS Inc) was used for data analysis. 
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3 3 Results 
3.3.1 Patient characteristics 
Patient characteristics in the pre and postintervention period are listed in Table 
3.1. There were no statistical differences to the age and sex in the two groups. Patients in 
the preintervention period had a higher mean number of comorbid conditions, of 3.4 
versus 3.2 in the intervention group. This was mainly accounted by a significantly higher 
percentage of patients in the group with >5 comorbidities. 
Patients in the preintervention period had more comorbid conditions like diabetes 
mellitus, ischaemic heart diseases, chronic obstructive airway disease and bronchiectasis. 
Statistical significant increases in underlying immunosuppression and intravenous drug 
addiction were noted in the intervention group. 
3.3.2 Clinical characteristics 
3.3.2.1 Source of infection 
The commonest source of infection was the respiratory tract (49.9-59.0%), 
followed by urinary and intraabdominal infections. A significant proportion of cases 
(7.9%) in the intervention period were treated for two or more sources of infection. 
Significant increase in cases of respiratory tract infections was noted in the 
preintervention group compared to the intervention group (59% vs. 49.9%; P=0.001) 
and significant increase in the urinary tract infections and intravenous (IV) catheter 
related infections were noted in the intervention group (Table 3.2). 
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Table 3.1 Demographic and comorbid characteristics of patients included in the 
study during preintervention and intervention periods of Antimicrobial 
Stewardship Program 
Characteristic� Preintervention� Intervention ？-value�
period� period�
(n�=�605)� (n�=635)�
Age,�mean�years ± SD 70.1 ± 14.7 68.9 ± 16.4 0.2 
median years (IQR) 73 (61-80) 73 (58-81) 
Gender 0‘5 
Male 348 (57.5) 355 (55.9) 
Female 257 (42.5) 280 (44.1) 
Comorbidities 
Hypertension 230 (38) 234 (36.9) 0.7 
Diabetes mellitus 207 (34.2) 185 (29.1) 0.05 
Ischaemic heart disease 198 (32.7) 162 (25.5) 0.005 
Chronic/End stage renal failure 136 (22.5) 161 (25.4) 0.2 
Immunosuppression^ 91 (15) 154 (24.3) 0.005 
COAD^/Bronchiectasis 175 (28.9) 134 (21.1) 0.001 
Crebrovascular accidents^ 138 (22.8) 134 (21.1) 0.4 
Malignancy 104(17.2) 119(18.7) 0.4 
History of pulmonary tuberculosis 98 (16.2) 80 (12.5) 0.08 
Surgery/ procedure within one month 53 (8.8) 59 (9.3) 0.7 
Chronic liver disease 36 (6.0) 39 (6.1) 0.8 
IV drug addiction 1 (0.2) 9(1.4) 0.01 
Mean no. of comorbidities 3.4 3.2 0.01 
No. of cases with multiple no. of comorbidities 
0 7(1.2) 11(1.7) 0.3 
1 35(5.8) 50(7.9) 0.1 
2 117(19.3) 133(20.9) 0.52 
3 189(31.2) 192(30.2) 0.7 
4 127(21) 140(22.0) 0.7 
> 5 130(21.5) 109 (17.2) 0.05 
N O T E . Data are no. (%) of patients unless otherwise indicated 
a Presence of neutropenia, HIV, receipt of steroids, cyclosporine etc. 
b Chronic obstructive airway disease 
e Old and new 
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Table 3.2 Type and source of infection during preintervention and intervention 
periods of Antimicrobial Stewardship Program 
Variable Preintervention Intervention P-value 
period period 
(n = 605) (n =635) 
Type of infection 
Healthcare-associated 342(56.5) 394 (62) 0.01 
Community acquired 229(37.9) 193 (30.4) 0.01 
Source of infection 
Respiratory 358(59) 317 (49.9) 0.001 
Urinary tract 41(6.8) 79 (12.4) 0.001 
Intraabdominar 73(12.1) 63 (9.9) 0.2 
Skin and soft tissue 21(3.5) 22 (3.5) 0.9 
IV catheter related 4 (0.7) 18 (2.8) 0.007 
Bacteremia 10(1.7) 7(1.1) 0.4 
Bone 1(0.2) 4(0.6) 
Two or more source 24(4) 50 (7.9) 0.004 
No infection^  34(5.8) 48 (7.6) 0.2 
Unknown 36(6) 26 (4.1) 0.1 
Others 3(0.5) 1 (0.2) 
N O T E . Data are no. (%) of patients unless otherwise indicated 
a 56 cases are C A P D peritonitis in preintervention period and 33 cases are C A P D 
peritonitis in intervention period 
Include 21 cases of prophylaxis & 13 cases of SIRS (Systemic Inflammatory Response 
Syndrome) in preintervention period & 35 cases of prophylaxis & 9 cases of SIRS in 
intervention period. 
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3.3.2.2 Severity of infection-Intervention period 
62.9% of patients in the intervention group had sepsis and 34.9% were culture 
proven sepsis while 28% were not. 178 patients (30.3%) had severe sepsis and in this 
group 17.5% had positive cultures and 12.8% did not. 6.8% of patients (40 patients) in 
the intervention group had septic shock and 4.8% were culture proven cases while 2 % 
were not (Table 3.3). 
3.3.2.3 Healthcare-associated infections (HAIs) 
Healthcare-associated infections accounted for 62% of the use of these targeted 
antibiotics during the intervention period versus 56.5% in the preintervention period. 
Conversely, these drugs were used less often in infections of community in origin in the 
intervention period (30.4% vs. 37.9%) (Table 3.2). During the intervention period, a 6 % 
reduction in hospital-acquired infections (35.4% vs. 29.4%; F=0.08) was noted but there 
was a statistical significant increase in the number of patients who were admitted from 
long term care facilities (7.9% vs. 14%; P=0.01). The breakdown of the healthcare-
associated infections is listed in Table 3.4. 
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Table 3.3 Severity of infection in patients who received targeted antimicrobials 
during intervention period 








N O T E . ''No infection group (48 cases) excluded "" 
Table 3.4 Healthcare-associated infections during preintervention and intervention 
periods of Antimicrobial Stewardship Program 
Variable Preintervention Intervention 户-value�
period� period�
(n�=�342)� (n�=394)�
Hospital-acquired infections' 121(35.4) 116 (29.4) 
Recent hospital admission within 2 weeks 97(28.3) 114 (28.9) 0.8 
Transfer from other hospital 54(15.8) 62 (15,7) 0.9 
Old age home residents 27(7.9) 55 (14.0) 0.01 
Nursing home + recent hospital admission 20(5.8) 29 (7.4) 0.5 
ICU related 23(6.7) 18 (4.6) 0.2 
N O T E . Data are no. (%) of patients unless otherwise indicated 
a Infections acquired 48 hrs after the hospital admission 
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3.3.3 Prescribing practices 
3-3.3.1 Prescriptions reviewed and pattern of antibiotic prescription 
After the implementation of ASP, the rate of antibiotic prescription of these 
target drugs were reduced from 83 to 63 prescription/1000 admissions (P=0.08). The 
pattern and proportion of each of the eight targeted antibiotics prescribed were similar. 
Sulbactam/cefoperazone was the most commonly-used drug, accounting for 38% and 
350/0 of use in the preintervention and intervention period respectively, followed by 
cefepime (20.3% and 18.7% respectively) and piperacillin/tazobactam (13.9% and 
16.2% respectively) (Figure 3.1). 
B Preintervention period ( n = 6 0 5 ) • Intervention period (n=635 ) 
40� —�
3 5 — 」 ‘ 3 4 
30 ^ — — — _ _ _ _ _ _ _ _ _ 
f�25 一� f� :�
§ [ 20.3 
0 2 0——‘ 
2 16.2 
15 .— ？ i ‘ ^ ••站�H i�
— ^� W� M� 12.1�
0-1�1」:通� I�Li、d 丨� _ L i� L� L J� L�j 」� t-�L i� 。.5 二 
Sulbactam + Cefepime Piperacillin + Ceftazidime Vancomycin Carbapenem Linezolid 
Cefoperazone Tazobactam 
Drug 
Figure 3.1 Percentage of targeted antimicrobial prescriptions evaluated during 
preintervention and the intervention period of Antimicrobial Stewardship Program 
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These antimicrobials were started as empirical treatment for almost 75% of the 
cases, and targeted for known pathogen treatment in only 20% of cases in both periods. 
These agents were prescribed as prophylaxis in 21 (3.5%) patients and 35 (5.5%) 
patients during preintervention and intervention periods respectively (Figure 3.2). There 
was no significant difference in pattern of antibiotic prescription. 
80.0% - Intervention 
• preintervention 
^ ^ ^ H • intervention I 
M735%M 
o.oo/O —^hHI一 
Empirical therapy known pathogen Rx Prophylaxis 
Pattern of antibiotic prescription 
Preintervention Intervention P-value 
period (n=605) period (n=635) 
Empirical therapy 451 (74.5) 467 (73.5) 0.7 
Known pathogen treatment 133(22) 133 (20.9) 0 7 
Prophylaxis 21(3.5) 35 (5.5) 0.08 
Figure 3.2 Pattern of targeted antimicrobial prescription during preintervention 
and intervention periods of Antimicrobial Stewardship Program 
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3.3.3.2 Indication 
3.3.3.2.1 Appropriateness of indication 
Appropriateness was evaluated according to the predetermined guidelines for 
antimicrobial indications. These guidelines are shown in Appendix 11. Appropriate 
antimicrobial use increased significantly from 77.9% in the preintervention to 90.1% 
intervention phase. Inappropriate antimicrobial use was significantly reduced from 124 
(20.5%) prescriptions to 53 (8.3%) prescriptions after the ASP implementation (PO.OOl) 
(Figure 3.3). Indications of use were uncertain in 10 occasions from each group. The 
appropriateness of indication of individual targeted antimicrobials is shown (Appendix 
III). 
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Figure 3.3 Appropriateness of indication during preintervention and intervention 
periods of Antimicrobial Stewardship Program 
74 
3.3.3.2.2 Appropriate indications of use-Individual targeted antimicrobials 
Appropriate�indications�of�use�of�individual�targeted�antimicrobials�during�
preintervention�and�intervention�periods�are�shown�(Appendix�IV).�





















84% and 93.5% episodes during preintervention and intervention periods respectively; 
an almost 10% improvement in appropriateness. As anticipated, the majority of the 
appropriate ceftazidime prescriptions were for the empirical treatment of continuous 
ambulatory peritoneal dialysis (CAPD) peritonitis (57.1%, 45.8%) and for the definitive 
treatment for P. aeruginosa infection (11.1%, 13.9%) in both periods. 
Carbapenems which included both meropenem and imipenem have been 
prescribed appropriately in 73.5% and 89.4% prescriptions during preintervention and 
intervention periods respectively; a 15% increase in appropriate use. In contrast to the 
previously described targeted antimicrobials, carbapenems were prescribed as a definite 
therapy for the majority of cases; 52% (13/25) in the preintervention period and 40.5% 
(17/42) in the intervention period for the serious infections due to ESBL-producing 
organisms and other organisms resistant to other available antimicrobials. Other 
frequently-used appropriate indications were empirical therapy for serious infections in 
patients treated with other broad-spectrum antimicrobials and for high risk patients with 
neutropenic fever. 
The percentage of appropriate vancomycin use increased from 75.9% (41/54 
prescriptions) to 86.4% (57/66 prescriptions). Around 50% of appropriate vancomycin 
prescriptions were for the definite treatment for infections caused by P-lactam resistant-
gram-positive organisms, predominantly for M R S A ; 53.6% (22/41) and 50.9% (29/57) 
prescriptions before and after ASP implementation respectively. 
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Considering� the� individual� antimicrobials,�vancomycin� prescriptions� were�
inappropriate�in�24%�and�13.6%�of�cases�during�preintervention�and�intervention�periods�
respectively�and�the�majority�of�them�were�inappropriate�surgical�prophylaxis�used�for�






Table 3.5 Inappropriate antimicrobial use and reasons for inappropriateness 
during preintervention and intervention periods of Antimicrobial Stewardship 
Program 
Variable� Preintervention� Intervention 户-value�
period� period�
(n�=�605)� (n�=635)�
Inappropriate' 124(20.5) 53 (8.3) < 0.001 
Reason for inappropriateness 
Narrow spectrum available 84(13.9) 22 (3.5) 
Bacterial resistance 8(1.3) 11 (1.7) 
Inappropriate prophylaxis 15(2.5) 9 (1.4) 
Antimicrobial agent not indicated 15(2.5) 7 (1.1) 
Spectrum too narrow 2(0.3) 3 (0.5) 
Side effects 0 1 (0.1) 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a inappropriate dose regimen not included 
Table 3.6 Breakdown of individual antibiotics with inappropriate indications 
Preintervention period Intervention period 
No. with No. with 
Antibiotic Total no. of inappropriate Total no. inappropriate 
cases indications of cases indications 
Cefepime 一� 123� —� 28�(22.5)� 119� 6�(5.1)�
Ceftazidime� 75� “� 11�(14.7)� 77� 5�(6.5)�
Vancomycin� 54� —� 13�(24.1)*—� 66 9�(13.6)*�
Carbapenem� 34 一� 8�(23.5)� “� 47� 4�(8.5)�
Linezolid� 3� 0� 7� 3�
Cefoperazone/sulbactam� 232� 54�(23.3)� 21�(9.7)�
Piperacillin/tazobactam� 84� 10(11.9)� f  ^ 5 (4.8) 




3,3.4 Recommendations made and acceptance 
Recommendations were made in 19.1% (121) of the cases by the A M I during 
the intervention period. These included changing of targeted antimicrobials (10.1%), 
stopping of unnecessary concurrent antimicrobials (4.7%), dose adjustments, and 
addition of antimicrobials and request for more specimens for specific diagnostic testing. 
During the first six months of intervention, the percentage of inappropriate antimicrobial 
use dropped from 15.5% to 5.5% and the number of recommendations fell from 27.6% 
to 9.2% (Figure 3.4). 
Complete acceptance of the recommendation occurred in 73.6% (89/121) of the 
cases and partial acceptance occurred in 4.1% (5/121) of the cases. 15.7% (19/121) did 
not follow the recommendations. Acceptance could not be recorded in eight patients 
because of transfer, discharge or death before the follow-up. 
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Figure 3.4 Percentage inappropriate indications and recommendations made 
during intervention period of Antimicrobial Stewardship Program 
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pre�and�postintervention.�A� reduction� in�all-cause�mortality�was�observed� in�the�
intervention�group.�







A� multivariate�model� constructed� for�appropriateness�demonstrated� strong�























Table 3.7 Clinical outcome measures during preintervention and intervention 
periods of Antimicrobial Stewardship Program 
Outcome Preintervention Intervention O R P-value 
period period (95% CI) 
Appropriate 471(77.9) 572 (90.1) 3.152(2.07-4.79)<0.001 
Length of hospital sta/ 
Mean days 士�SD� 16.47士�19.8� 16.42 士�18.8� 0.9�
Median�days�(IQR)� 10(6-19)� 11�(6-19)�
All-cause mortality'''' 115 (20.8) 96 (17.2) 0.68(0.49-0.95) 0.025 
N O T E , a prophylaxis group was excluded 
b Include patients died during the hospital stay or died within one month 
after discharge from the hospital 
* Multiple antibiotics use in the same episode were considered as one case for 
analysis of length of hospital stay and all-cause mortality 
Table 3.8 Multivariate analysis on factors associated with appropriate use of 
targeted antimicrobials 
Variable O R (95 % CI) P- value 
ASpa 3.15 (2.07 -4.79) <0.001 
Intraabdominal sepsis 16.17 (3.84 - 67.94) <0.001 
Bronchiactasis/COAD^ 1.75 (1.09-2.81) 0.02 
Immunosuppression 2.48 0.32 - 4.6) 0.005 
Prophylactic use 0.014 (0.002 - 0.078) <0.001 
Urinary tract infections 0.399 (0.231 -0.689) 0.001 
Skin and soft tissue infections 0.29 (0.132 -0.638) 0.002 
Community-acquired infections 0.219 (0.146 -0.328) <0.001 
a Antimicrobial Stewardship Program 
b Chronic obstructive airway disease 
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Table 3.9 Multivariate analysis on factors associated with all-cause mortality 
among patients on targeted antimicrobials 
ble “ O R (95 % CI) P- value 
ASP^b 0.68 (0.49-0.95) 0.025 
HAIs 4.77 (3.04 — 7.4) <0.001 
Respiratory tract infections 2.65 (1.69 -4.1) <0.001 
> 2 source of infections 3.12 (1.59 -6.12) 0.001 
Oncological comorbidity 2.34 (1.6-3.42) <0.001 
No of comorbidities 1.18 (1.05 -1.34) 0.006 




3.3.5.3 Treatment outcome-intervention period 
To further assess the impact of the ASP, detailed treatment outcome of patients 
in the intervention group was analyzed. Five hundred and eighty six patients were 
included in this analysis and those with final diagnosis other than infection excluded. 
63.30/0 (371/586) of patients experienced a complete response. Forty cases (6.8%) had a 
partial response while 29.9% (175) of cases failed treatment. 16.7% was due to 
insufficient clinical response leading to change of antimicrobial agent or death. The 
second most common reason for treatment failure in 61 (10.4%) of the patients was the 
isolation of a pathogen in subsequent cultures which was not susceptible to the original 
regimen. Recurrence of the infection occurred in 10 patients (1.7%) and in six cases 
adverse drug effect resulted in a switch to another agent. 
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3.3.6 Antimicrobial consumption 
3.3.6.1 Targeted antimicrobials 
The�consumption�of�the�targeted�antimicrobials�one�year�before�and�the�year�
after�the�start�of�the�Antimicrobial�Stewardship�Program�is�listed�in�Table�3.10.�Overall,�
a�4.5%� reduction� of�targeted� antimicrobial�consumption� in�DDD/IOOOBDO� was�
obtained.�The�use�of�cefepime�and�cefoperazone/sulbactam�was�significantly�reduced,�as�
was� almost� 10%� reduction� in� ceftazidime� use.� The� consumption� of�
piperacillin/tazobactam�was�increased�significantly.�














Table 3.10 Consumption of targeted antimicrobials one year before and the year 
after start of the Antimicrobial Stewardship Program. 
Preintervention Intervention Percentage P-value 
period period change 
DDD/1OOOBDO DDD/IOOOBDO 
Cefepime 
Ceftazidime 6.16 5.55 - 9.9 0.355 
Sulbactam/cefoperazone 23.02 18.92 -17.8 0.002 
Piperacillin/tazobactam 14.57 18.25 +25.2 0:02 
Carbapenem^ 10.12 11.38 +12.4 0.601 
Vancomycin 4.88 4.96 +1.6 0.915 
Linezolid 0.47 1.58 
Total 93.55 89.43 -4.5 0.714 
NOTE. 
b Meropenem and imipenem 
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Figure 3.5 Consumption of targeted antimicrobials one year before and the year 
after start of the Antimicrobial Stewardship Program 
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Table 3.11 Consumption of some non-targeted antimicrobials one year before and 
the year after start of the Antimicrobial Stewardship Program. 
Preintervention Intervention Percentage P-value 
period period change 
ODD/1OOOBDO DDD/1OOOBDO 
Fluoroquinolones' ^ 
p-lactam/p-lactamase inhibitors''478.42 472.86 _ 1.5 0.8 
3' -generation cephalosporins'" 29.19 30.06 +2.9 0.7 
Macrolides^ 125.52 104.96 -16.4 0.09 
NOTE, A ciprofloxacin, levofloxacin and moxifloxacin 
amoxicillin/clavulanate, ampicillin/sulbactam and ticarcillin/clavulanate 
c cefotaxime and ceftriaxone 
azithromycin and clarithromycin 
500.00 一� ^^^^^^ ^^ —� Interevention�
TO'^L • preintervention 
• Intervention 
400.00 - 「.； 
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Figure 3.6 Comparison of consumption of some non-targeted antimicrobials during 
one year before and the year after start of the Antimicrobial Stewardship Program 
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3.3.7 Bacterial susceptibility 
The�impact�on�ASP�on�antibiotic�resistance�rates�for�some�multidrug-resistant�
organisms�and�some�prevalent�organisms�such�as�methicillin xQs\s,i?ir\i-Staphylococcus 




3.3.7.1 Escherichia coli 
3.3.7.1.1 Resistance rates to amoxicillin/clavulanate 
There� was� a� significant�reduction� in�the�resistance� rates�of E. coli�to�
amoxicillin/clavulanate�for�all�specimens�(35%� vs.�30%; ？=0.02)�and�even� more�
significant�reduction�for�the�blood�culture�specimens�(47%�vs.�29%;�P=0,006)�observed�
after�the�ASP�implementation�(Figure�3.7).�
3.3.7.1.2 ESBL-producing Escherichia coli 
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Figure 3.7 Trend in antimicrobial resistance rates oiEscherichia coli to 
amoxycillin/clavulanate during preintervention and intervention periods of 
Antimicrobial Stewardship Program 
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Figure 3.8 Trend in ESBL-producing Escherichia coli in blood culture specimens 
during preintervention and intervention periods of Antimicrobial Stewardship 
Program. 
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3.3.7.2 Methici l l in resist议nt-Staphylococcus aureus ( M R S A ) 
丁he�percentage�of�methicillin YQ^hXdini-Staphylococcus aureus�(MRSA)�in�all�
specimens�with S. aureus�was�reduced�by�2 %�(41%�vs.�39%;�P=0.5),�in�2005�vs.�2006.�
There�is�an�increase�in�percentage�of� M R S A�bacteremia,�but�the�number�of�isolates�is�
small�and�it�was�not�statistically�significant�(18/59�vs.�25/57;�P=0.1)�(Figure.3.9).�
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Figure 3.9 Trend in MRSA during the preintervention and the intervention periods 
of Antimicrobial Stewardship Program 
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3.3.7.3 Pseudomonas aeruginosa 
3.3.7.3.1 Susceptibility rates to targeted antimicrobials 
The�percentage�of�susceptibility�of P. aeruginosa� to�cefepime�increased�from�
950/0�to�99%.�Overall�significant�increase�in�resistance�rates�of P. aeruginosa� to�
sulbactam/cefoperazone� was� noted� during� intervention� period� (5.27%� vs.�9.57%;�
/M).01).�Susceptibility�rate�to�sulbactam/cefoperazone�was�reduced�to�85%�during�the�
third� quarter� of�the� intervention� period.�The� percentage� susceptibility� to�other�
antipseudomonal�agents�remained�at�>95�%�(Figure�3.10).�
3.3.7.3.2 Susceptibility rates to other antimicrobials 
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Figure 3.10 Antibiotic susceptibility rates of Pseudomonas aeruginosa (for 
allspecimens) to targeted antimicrobials during the preintervention and 
the intervention periods of Antimicrobial Stewardship Program 
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Figure 3.11 Antibiotic susceptibility rates of Pseudomonas aeruginosa (for all 
specimens) to other antimicrobials during preintervention and intervention periods 
of Antimicrobial Stewardship Program 
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Figure 3.12 Antimicrobial consumption and susceptibility rates of Pseudomonas 
aeruginosa to cefoperazone/sulbactam�and piperacillin/tazobactam during 
preintervention and intervention periods. 
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3.4 Discussion 
3.4.1 Background characteristics of patients who were prescribed 
targeted antimicrobials 
In the 21 St century, authorities over the world are concerned with the provision of 
adequate healthcare services for a growing aging population. These elderly people often 
have multiple comorbidities, need frequent hospitalizations, and are prone to difficult-to-
treat infections caused by resistant organisms. 
In Hong Kong, according to the Census and Statistics Department 
(www.censtatd.gov.hk/products—and—services/products/publications/index.jsp), the life 
expectancy for males and females was 79.4 and 85.5 years respectively in 2006 and 
expected to rise to 82.5 and 88 years by 2033 (Council for Sustainable Development-
www.susdev.gov.hlc/html/en/council/). In 1961 the proportion of elderly > 65 years of 
age was only 3.2%, increased to 12.1% in 2005 and is expected to account for 26.8% of 
the total population in 2033. About 0.85 million elderly people (12.4% of the whole 
population) lived in Hong Kong in 2006. 
Most of the patients in our study are aged and had many comorbidities. The 
mean and median age was 70 and 73 years respectively, compared to the mean age of 45 
years in the study population of Taiwanese medical center [65] and 65 years in the study 
population of the antibiotic control program in a tertiary care hospital in Thailand [54:. 
Approximately 70% of patients had > 3 major comorbid factors and 21% of the patients 
had > 5 comorbid factors in the preintervention group. Most of these patients had to be 
given broad-spectrum antimicrobials on admissions on suspicion of healthcare-
associated infections because of their frequent hospital admissions and residency in 
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long-term care facilities. Chronic illnesses such as C O P D and bronchiactasis were 
present in >28% of patients from the preintervention group and >20% of patients from 
the intervention group. Generally physicians tend to prescribe broad-spectrum 
antimicrobials on admission for those with underlying structural lung damage. 
With the rapid emergence of antimicrobial resistance and the concomitant slow 
progress in development of new antimicrobial agents, rational use of currently available 
antimicrobials is essential to maintaining their effectiveness in combating infections. 
The development of more specific criteria for diagnosis, more specific guidelines for 
antimicrobial use, educating the front line staff about the importance of sending 
appropriate cultures and adjustment of the antimicrobials according to the culture results 
will facilitate improved management outcomes and cost savings. 
3.4.2 Healthcare-associated infections (HAIs) 
A significant proportion of the infections treated were HAIs. As illustrated, 
HAIs resulted in increased morbidity and mortality and were attributed to antimicrobial 
resistant organisms. In the intervention group, the length of hospital stay in HAIs 
compared to the community-acquired infections was 17.8 days vs. 13.5 days; P=0.005, 
whilst all-cause mortality was 23.3% vs. 7.2%; P< 0.001). The multivariate model of all-
cause mortality showed a strong association with HAIs (Table 3.9). HAIs included those 
acquired from the hospitals and those from long-term nursing facilities, and are 
potentially modifiable factors. Healthcare professionals should focus on minimizing 







[47]. This reduction may have been accounted for by the increased resources allocated, 
the application of rigorous infection control measures, educational activities and 
awareness at P W H after the outbreak of severe acute respiratory syndrome (SARS) in 
2003, the intensification of infection control measures due to the emergence of H5N1 
bird flu, and an outbreak of the norovirus in medical wards in 2006. In the medical 
literature, the occurrence of antimicrobial resistance in long-term care facilities (LTCFs) 





3.4.3 Impact of ASP on appropriateness of antimicrobial prescription 
Over�the�past�three�decades,�numerous�active�and�passive�antimicrobial�control�
programs�have�been�attempted�to�combat�the�rising�incidence�of�antimicrobial�resistance�
1,�61, 63]. The multidisciplinary Antimicrobial Stewardship Program is increasingly 
recognized worldwide. To encourage the rational use of antimicrobials several measures 
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have been taken in P W H in recent years with varying degree of success. These were 
however, limited to educational programs and the implementation of institution-specific 
guidelines [125]. Previously published studies that have demonstrated combined 
individual strategies via a multidisciplinary antimicrobial management team were 
effective in doing Antimicrobial Stewardship Programs [1，55]. Our data also 
demonstrate the effectiveness of multidisciplinary Antimicrobial Stewardship Program 
resulting in more rational use of antimicrobials. The rate of antibiotic prescription was 
reduced in the intervention period (83 vs. 63/1000 admissions). A real-time audit 
performed in two local hospitals before the implementation of ASP in Hong Kong has 
revealed that 20% to 25% of broad-spectrum antimicrobials use was not appropriate [62". 








care�hospital�in�Thailand�reported�a�decreased�incidence�of�inappropriate�use [55]. In 
another study, the use of an Antimicrobial management team demonstrated better 
outcome in appropriate antimicrobial prescribing than by Infectious Disease Fellows 
alone [66:. 
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3.4.4 Compliance to recommendations 
The overall compliance to recommendations done by A M T was almost 78%. 
This high acceptance rate may have been because of the multidisciplinary nature of the 
decision-making process, involving the collaboration of ID physicians, microbiologists 
and pharmacists. Also it involved significant participation from physicians working in 
the Department of Medicine and Therapeutics. Any feedback was made by discussions 
with the in charge doctors explaining the reasons for the change together with the 
written recommendations in a feedback form. The acceptance rate was higher (89%) in 
the cases where recommendations were made after the availability of susceptibility 
results in 21.5% of all cases. 
3.4.5 Clinical impact of ASP 
Some clinicians are worried that switching to a narrow spectrum of 
antimicrobials will adversely affect the clinical outcomes like mortality, ICU admissions, 
length of hospital stay and readmission rates. Several recently published ASPs reported 
reduction of inappropriate antimicrobial prescriptions and antimicrobial consumptions 
without compromising the clinical outcomes of the patients [61]. An intensive 
antimicrobial program done in a Taiwanese medical centre achieved positive results 
without any effect on mortality and length of hospital stay [65]. Similarly, in our study, 
no significant differences were observed in the length of hospital stay. 
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A multivariate model of all-cause mortality demonstrated a significant inverse 
association of ASP with all-cause mortality. Recent studies have also reported a 
reduction in infection-related mortality after the ASP implementations [61]. In one study, 
a significant decrease in infection-related mortality (8.28% vs. 6.61%; F=0.007) was 
observed after the ASP implementation. Another study reported reduction in infection-
related mortality from 4% to 2.4% [61]. In these studies there were no differences in 
patient demographics and also the severity of illness scoring was not determined. Most 
of the other studies reported no differences in mortality. 
Most of the patients in our study had advanced age as well as multiple 
numbers of comorbidities. 21% of the patients who were in the preintervention group 
had > 5 comorbid factors. Advanced age and underlying comorbid conditions may be 
the reasons for high mortality in both groups. There were differences in case-mix 
between two periods, revealing the non-randomized nature of the patient sample. The 
preintervention group had more comorbid conditions like D M , IHD, C O A D and 
bronchiectasis. In the multivariate model of all-cause mortality, some of these 
confounding factors including comorbidities, source of infection and age were controlled, 
but were unable to control for some confounding variables like the severity of sepsis and 
MedisGroup score (severity of illness scoring). Also there was a lack of information on 
the mortality attributable to the infections and there may be some unmeasured 
confounding variables like infection control measures during the two periods. 
Although we cannot definitively determine the contribution of the ASP that 
may have caused a reduction in all-cause mortality, as the latter can be affected by many 
potential confounders including those mentioned before, an increased awareness of the 
rational use of antimicrobials due to the educational programs and concurrent feedbacks 
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by the multidisciplinary A M I which helped the management of the patients, may have 
contributed to the improvement of clinical outcomes. 
3.4.6 Impact of ASP on antimicrobial consumptions 
Previously published studies demonstrated that the implementation of ASP have 
had a favorable impact on both antimicrobial prescription habits and consumptions. 
The ASP led to a reduction in consumption in several targeted antimicrobials. 
The consumption of cefepime and sulbactam/cefoperazone was decreased significantly 
and ceftazidime use reduced by almost 10%. However a significant increase in the 
consumption of piperacillin/tazobactam was seen. A gradual reduction of susceptibility 
rates of P. aeruginosa to su 1 bactam/cefoperazone over the period was observed and may 
partly explain the increased consumption of piperacillin/ tazobactam. 
The overall reduction in consumption of antimicrobials was only 4.5% for the 
targeted antimicrobials. However, a significant reduction of the rate of prescriptions of 
targeted antimicrobials was observed, while the number of admissions had not risen. A 
multidisciplinary antimicrobial management program done in a university-affiliated 
hospital achieved 22% decrease in the parenteral broad-spectrum antimicrobials during a 
seven-year study period, and this was mainly due to the reduction in consumption of 
third-generation cephalosporions and aztreonam. The consumption of imipenem 
remained stable [58]. In our study although there was a slight increase in consumption of 
carbapenems, it was not significant. A pilot study [70] actually showed more appropriate 
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use of carbapenems as a result of the implementation of ASP. An ASP in the Taiwanese 
medical center led to a 4.2% reduction in parenteral antibiotic-prescribed cases and 
13.2% reduction in consumption of parenteral antimicrobials. They observed the 
increased usage of meropenem by 50% and piperacillin/tazobactam by 17% [65；. 
Another antimicrobial control program done at a university hospital in USA resulted in 
15% reduction in vancomycin use but revealed a 29% increase in carbapenem use [59". 
It was observed that some patients in the intervention group needed a longer 
duration of treatment or a higher dosage and thus may not be reflected by DDDs. One 
limitation observed was that the computerized prescription ordering system is currently 
not available in our hospital and the pharmacy kept on refilling the drugs until the ward 
staff asked it to stop. So the accumulation of unused ward stock may also partly 
contribute to this. By the last quarter of the year 2007, an automatic stop order for all 
intravenous antimicrobials, after 3 days+ldose was implemented as a result of the AMT, 
unless the duration of treatment is specified on the prescription. Continuous monitoring 
of the antimicrobial usage will reveal its long-term effect and impact. 
Restrictions of selected agents promote the increase in the use of other 
antimicrobials in the formulary, the phenomenon called the 'squeezing the balloon' 
effect [56, 59]. An antimicrobial control program done at a university hospital in USA 
observed the increased use of piperacillin/tazobactam in response to the restriction of 
ceftazidime and cefotaxime [59]. In our hospital we observed the significant increase in 
fluoroquinolones use after the ASP implementation. This increase in consumption of 
fluoroquinolones may be partly due to its ability to replace most of the targeted 
antimicrobials because of its broad-spectrum activity and pharmacokinetic profile with 
the oral formula. This limitation in the program emphasized the importance of 
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monitoring other broad-spectrum agents such as fluoroquinolones. As a part of an 
ongoing ASP, another intervention, an intravenous-to-oral switch of fluoroquinolones 
was latterly added to the program in late 2007, so this might reduce its consumption and 
promote more rational use of fluoroquinolones. 
Although we experienced a significant increase in consumption of 
fluoroquinolones; 16% reduction in macrolides (azithromycin and clarithromycin) use 
noted after the ASP implementation. This favorable impact may be due to the 
educational programs conducted by the AMT，including the appropriate use of 
antimicrobials in respiratory tract infections and relevant site-specific infections. 
3.4.7 Impact of ASP on antimicrobial resistance 
An association between antimicrobial use and resistance was described soon 
after the discovery of penicillin. Most recently published studies demonstrated a 
significant correlation of (3-lactam use and S. pneumoniae resistance to penicillin, 
erythromycin, tetracycline and trimethoprim-sulfamethoxazole in Europe [48]. Although 
some published studies supported the concept that the decrease in antimicrobial 
consumption leads to the decrease in antimicrobial resistance，some studies did not. An 
antimicrobial program done at a tertiary-care teaching hospital in USA resulted in 
reductions in both broad-spectrum and total antimicrobials without improvement in the 
hospital antibiogram [56]. Another study in the USA reported that a decrease in 
consumption of third-generation cephalosporins resulted in a significant reduction of 
ceftazidime resistant K. pneumoniae [59]. Another study done in a university-affiliated 
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teaching hospital reported a decrease in the parenteral broad-spectrum antimicrobials, 
leading to decrease in nosocomial infections caused by resistant Enterohacteriaceae [58.. 
Also, we achieved a significant reduction of resistance rates of E. coli to 
amoxicillin/clavulanate after the ASP implementation. Reduction in use of broad-
spectrum antimicrobials may reduce the overall selective pressure for the resistance in E. 
CO"，but other factors including infection control measures may play a role. 
Although there was no overall worsening of the incidence of infections caused 
by MRSA, there was an increase in the incidence of MRSA bacteremia. But the overall 
numbers of strains remain low in both periods. During the period of one year before 
ASP implementation only 18 of 59 aureus bacteremic episodes (30.1%) were due to 
MRSA, whereas in the year after the ASP implementation, 25 of the 57 S. aureus 
bacteraemic episodes were due to MRSA (43.85%). This increase may have been due to 
the difference in case-mix of the patients during these two periods. Further detailed 
evaluation including demographics of these MRSA bacteraemic patients will be 
necessary. 
The susceptibility rates of P. aeruginosa to cefoperazone/sulbactam decreased 
despite decreased consumption. A reduction in susceptibility of P. aeruginosa to 
fluoroquinolones along with cefoperazone/sulbactam and piperacillin/tazobactam was 
observed in the 3�d quarter of the intervention. Further investigation revealed that both P. 
aeruginosa strains which were resistant only to cefoperazone/sulbactam and a clone with 
resistance to cefoperazone/sulbactam and fluoroquinolones were present. Although 
resistance to fluoroquinolones and piperacillin/tazobactam might be explained by an 
increased consumption of these antimicrobials, resistance to cefoperazone/sulbactam 
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without an increased use illustrated the complexity of the antimicrobial resistance and 
their association with antimicrobial consumption. 
Figure 3.12 illustrates the relationship of antimicrobial consumption and 
susceptibility of P. aeruginosa to cefoperazone/sulbactam and piperacillin/tazobactam 
during the study periods. 
The reduction in susceptibility of P. aeruginosa to cefoperazone/sulbactam 
may have led to the clinicians prescribing more piperacillin/tazobactam, thus resulting in 
significant increase in its consumption during the intervention period. In the third quarter 
of the intervention period, there was a slight drop in susceptibility rates to 
piperacillin/tazobactam, with the marked drop of susceptibility to 
cefoperazone/sulbactam. This may be the reason for an increased consumption of 
cefepime in this quarter. 
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3.4.8 Influential factors associated with appropriate antimicrobial use 
A multivariate model of an appropriate antimicrobial model identified 
intraabdominal sepsis, underlying immunosuppression, bronchiectasis and COAD as 
influential factors associated with broad-spectrum antimicrobial use apart from ASP. 
More than half of the cases of intraabdominal sources of sepsis included patients 
with CAPD peritonitis. According to the hospital CAPD peritonitis management 
protocol, the empirical treatment is intraperitoneal ceftazidime and cefazoline. 
The use of antimicrobials appropriately for the patients with underlying 
immuosuppresion is not surprising. Many of these patients presented with neutropenic 
fever. According to our guidelines, empirical therapy for neutropenic fever is a criterion 
for use of most of the targeted antimicrobials including cefepime, ceftazidime, 
piperacillin/tazobactam, cefoperazone/sulbactam and carbapenems for neutropenic fever 
in high-risk patients. 
Appropriate antimicrobial use in patients with comorbidities such as 
bronchiectasis and COAD may have been due to frequent exacerbations requiring 
frequent hospitalizations, recent isolation of P. aeruginosa or treatment for suspected 
infections with P. aeruginosa in these elderly patients. 
Identifying the factors inversely associated with appropriate antimicrobial 
prescribing is important if antimicrobial stewardship programs are to take the necessary 
actions to minimize its inappropriate use. Previous studies have demonstrated that 
around 20%- 25% of inappropriate prescribings were due to inappropriate surgical 
prophylaxis [55] and some ASP especially focus on this area [65]. Our study further 
confirmed the significant association of prophylactic use and inappropriateness. 
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As expected, community-acquired infections, skin and soft tissue infections and 
urinary tract infections were associated with inappropriate antimicrobial use. Most of 
these cases only require narrow-spectrum antimicrobials and highlight the need for more 
educational programs targeting these areas. 
3.4.9 Limitations 
There are some limitations in our study. This was not a randomized study and 
we were unable to control for some confounding variables. There were significant 
differences in the baseline characteristics of the two groups. Patients were reviewed 
prospectively (from February to August 2006) for the intervention group and, while a 
retrospective review of all cases was done (from March to May 2005) for the 
preintervention group, a comparable sample size was obtained. To see if any seasonal 
changes may have affected the clinical outcomes, a subgroup analysis was performed 
including the patients only from March to May 2006 (n=284) as the intervention group 
and all cases from March to May 2005 as the preintervention group. These results were 
similar and demonstrated a reduction in all-cause mortality during the intervention 
period and no difference in the length of hospital stay. These analysis tables are shown 
in Appendix VI. 
There was a lack of information on the severity of illness，mortality 
attributable to the infections and readmission rates. In the correlation analysis of all-
cause mortality we were unable to include a severity of illness score together with other 
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bias from unmeasured confounding factors that cannot be eliminated. Also, only the 
documented mortalities were counted. 
The length of hospital stay was calculated according to the date of admission 
and date of discharge from PWH. Around 40% of the patients included in the study 
transferred to a rehabilitation hospital for convalescence, there was no significant 
difference observed in the transfer rate between the two groups. 
Only the prescriptions from the Department of Medicine and Therapeutics 
were included in this analysis. The A M I was extended to the Department of 
Orthopedics, the Department of Surgery and ICU over different periods subsequently. 
The medical department accounts for major consumptions of these targeted 
antimicrobials in the hospital and thus was chosen for analysis. If other departments 
were also included, a more significant impact would be likely to be seen, especially 
regarding the appropriate antimicrobial prescribing. 
Prescriptions at weekends and public holidays were not reviewed and comprised 
about a quarter of total prescriptions because of reduced effectiveness, because on-call 
doctors would be less likely to wish to switch antibiotics without their own team 
physician's decisions. They were also not reviewed subsequently on the next working 
day because of a lack of manpower and because the delay in review would not be cost 
effective since patients would have chosen to discharge already. Although the AMI 
follow up the patients until the availability of the initial culture results, AMI did not 
follow up the patient until the discharge from the hospital. 
Although the focus of ASP is the patient and public health, economic impact is 
important to the healthcare institutes. Most of the antimicrobials control programs also 
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focus on economic outcomes [54, 59, 66]. Another limitation of our study is that to date 
we have yet to analyze the economic impact. 
3.4.10 Areas for further evaluation 
Respiratory tract infections are the commonest source of infection in our study 
group. 59% in the preintervention group and almost 50% of the patients in the 
intervention group were admitted because of respiratory tract infections. According to 
our guidelines >86% of the prescriptions for respiratory tract infections were justified. 
A targeted broad spectrum antimicrobial was started as empirical treatment for 90% of 
the cases. Subsequent positive cultures were available only for 47% of cases and others 
were culture negative (53%). Further detailed study is needed to identify the risk 
categories among patients in this group and implementation of more specific guidelines 
for such groups. 
In the intervention group, 20 (6.3%) of respiratory cases were finally diagnosed 
with pulmonary tuberculosis. These included cases of smear negative but culture 
positive cases or radiologically diagnosed cases. These cases were given multiple 
courses of broad-spectrum antimicrobials before the start of anti-tuberculosis treatment. 
Future study is needed to identify specific predictive factors of this group of patients to 
ensure early treatment with empirical anti-tuberculosis drugs. 
The use of vancomycin as prophylaxis for the creation of arteriovenous (AV) 
fistulae or AV graft and declotting of thrombosed AV graft is the commonest 
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inappropriate surgical prophylaxis found in our study group. According to the CDC 
(HICPAC) guidelines [16]; routine surgical prophylaxis other than in a patient who has a 
life-threatening allergy to beta-lactam antibiotics or routine prophylaxis for patients on 
continuous ambulatory peritoneal dialysis or hemodialysis use of vancomycin should be 
discouraged. According to the previously published studies surgical prophylactic 
antimicrobials are unnecessary for creation of native AV fistulae [126] and single-dose 
intravenous vancomycin has reduced the postoperative vascular access infection in 
haemodialysis vascular graft procedures [127]. Hong Kong has one of the highest 
prevalence rates of MRSA among hospitals within the Asia -Pacific region [6，128，129". 
Hemodialysis patients are more prone to get catheter-related bacteremia and are at an 
increased risk of getting MRSA. A single-dose vancomycin may be justified and further 
evaluation is necessary. 
As mentioned in section 3.4.9, an economic model is needed to evaluate the 
cost-effectiveness of ASP. 
This study included only the analysis of the first six months and first year of 
implementation of ASP; a longer term study will be needed to evaluate the long-term 
impact of ASP including the effectiveness of the newly-added strategies; the 
intravenous-to-oral switch of fluoroquinolones and the automatic stop orders of the 
intravenous antimicrobials. 
It has been suggested that combining a multifaceted approach with a full-time 
dedicated multidisciplinary team appears to be effective for sustainability of ASP [1]. In 
our institution, the major barrier for sustainability of the ASP will be the lack of 
manpower to run the ASP. One solution might be the implementation of the AMT for 
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monitoring appropriate use on a rotational basis in different specialties, together with 
monitoring total antimicrobial consumption within different departments. 
The incorporation of guidance into a computer-based physician order entry and 
computer-assisted decision support programs based on guidelines and patient-specific 
data have been implemented with success in some institutions as an antimicrobial 
stewardship strategy [61]. Taiwanese Medical Center is also planning to incorporate its 
intensive antimicrobial control program into a computerized prescription order system 
65]. This may be a solution for maintaining the sustainability of our ASP. 
113 
CHAPTER 4 - OBJECTIVE II 
4.1 Title:-Treatment outcome and factors affecting treatment 
outcome of patients with bacteremia due to extended-
spectrum P-lactamases-producing organisms receiving 
carbapenems or p-lactam/p-lactamase inhibitor combinations 
4.2 Method 
4.2.1 Study setting 
Prince of Wales Hospital (PWH) is a 1350-bed regional hospital and the medical 
teaching centre associated with The Chinese University of Hong Kong (CUHK), and 
The North District Hospital (NDH) is a 540-bed district hospital with an ICU facility but 
lacking a microbiology laboratory. All the specimens for microbiological analysis from 
NDH hospital are processed at the microbiology laboratory at PWH. Both hospitals 
provide acute care services for a population of 1.2 million people in the New Territories 
in Hong Kong. 
4.2.2 Study design and sample 
A retrospective observational study was conducted from January 2002 to 
December 2004 in-patients of Prince of Wales Hospital and The North District 
Hospital with positive blood culture results for ESBL-producing bacteria. These patients 
were identified from the microbiology records in the PWH. We identified patients with 
bloodstream infections due to ESBL-producing E. coli, K. pneumoniae or Klebsiella spp., 
and who had been treated with carbapenem or cefoperazone/sulbactam or 
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piperacillin/tazobactam or amoxicillin/clavulanate (which were active in vitro against 
the blood culture isolates) for at least 48hrs during the five day period after the onset of 
bacteremia, and these patients were included in the study. Exclusion criteria included 
patients who died <48hrs after the onset of bacteremia, presence of polymicrobial 
bacteremia, pediatric patients，patients treated with antimicrobials other than 
carbapenems, piperacillin/tazobactam, cefoperazone/sulbactam and 
amoxicillin/clavulanate, patients who developed adverse drug effect resulting change in 
the antimicrobial agent, cases of switching of antimicrobials after the availability of 
culture results and patients with insufficient data in the medical records. If multiple 
blood cultures were taken within 7 days from the same patient and were positive for 
ESBL, the patient was included once only. Finally, 53 episodes for carbapenem group 
and 58 episodes for p-1 actam/p-1 actamase inhibitor group were reviewed and compared. 
To further assess the treatment outcome and factors affecting the outcome, comparison 
between the bacteremic episodes treated with individual p-lactam/p-lactamases inhibitor 
combinations and those with carbapenems were done. The study was approved by The 
Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research 
Ethics Committee. 
4.2.3 Definitions 
Definitions were made prior to the data collection. Pitt bacteremia score is used 
to assess the severity of septicemia. The calculation of the Pitt bacteremia score was 
done using the following criteria [80, 130]: Oral temperature: 2 points for < 35 or > 
40 OC, 1 point for 35.1- 36°C or 39- 39.9 and 0 point for 36.1-38.9�C, hypotension: 2 
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points for acute drop in systolic BP >30 mmHg and diastolic >20 mmHg; or use of 
intravenous vasopressor; or systolic BP <90 mmHg, 2 points for mechanical ventilation, 
4 points for cardiac arrest, mental status: alert 0 point, disoriented 1 point, stuporous 2 
points and comatose 4 points. Healthcare-associated infections (HAIs) were defined as 
infections that patients acquire during the course of receiving treatment for other 
conditions within a healthcare setting, including a long-term care facility (including 
hospital-acquired infections, recent hospitalization within one month, transfer from other 
hospitals and nursing home residents). Hospital-acquired infection (nosocomial 
infection) was defined as occurrence of an infection after hospital admission (>48hrs) 
without evidence that the infection was present or incubating on admission. 
Immunosuppression was defined as receipt of immunosuppressive agents such as anti-
neoplastic therapy, coticosteroids and the presence of neutropenia and HIV infection. 
Therapeutic success was defined as resolution of fever, leucocytosis and local signs and 
symptoms of infection and microbiological eradication. Therapeutic failure included 
absence of resolution or progression of signs and symptoms despite 48 hrs of 
antimicrobial therapy resulting in death or a change in antibiotic regimen, persistent 
bacteremia despite 48 hrs of therapy and relapse. Relapse was defined as recurrence of 
infection with the same organism (sepsis with ESBL-producing organism) <1 month at 
any body site after completing the antimicrobial cause (exclude colonization). All-cause 
mortality was defined as death from any cause within one month after the onset of 
blood stream infection (BSI). 
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4.2.4 Data collection 
Data collected included demographic characteristics, clinical and laboratory data. 
The source of infection included urinary tract infection, intraabdominal infection, skin 
and soft tissue infection，respiratory tract infection and primary blood stream infection. 
The comorbid conditions and predisposing factors for acquisition of bacteremia were 
investigated. Comorbidities included underlying obstructive uropathy malignancy， 
hypertension, immunosuppresion, IHD, DM, chronic or end stage renal failure, chronic 
respiratory conditions like COAD or bronchiectasis, chronic liver disease, solid organ 
transplantation and any other significant underlying diseases like cerebrovascular 
accidents, Parkinsons disease, endocrine diseases, autoimmune diseases and 
rheumatological diseases. Predisposing factors included history of intubation, thoracic 
and abdominal drainage, insertion of intravascular and bladder catheters, receipt of 
immunosuppressive agents such as corticosteroids and anti-neoplastic therapy, surgery 
or procedures performed, recent hospital admissions, previous use of antimicrobials 
which had been taken at least for two days within one month before the onset of blood 
stream infection, and previous isolation of ESBL-producing organisms within one year. 
Values needed to calculate Pitt bacteremia score, admission to intensive care unit, 
antimicrobials received, length of hospital stay and duration of hospital stay before BSI 
onset were collected. 
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4.2.5 Data analysis 
4.2.5.1 Outcome measures: 
Outcome measures included therapeutic success, therapeutic failure and all-cause 
mortality. Analysis included comparison between the two major groups; i.e. 
carbapenems group and the P lactam/p lactamase inhibitor combinations group and 
subgroup analysis included comparison of the carbapenems group and each individual 
antimicrobial in the p lactam/p lactamase inhibitor combinations group. 
4.2.5.2 Statistical analysis: 
Categorical variables were compared using x�test or Fisher's exact test, and a 2 
tailed independent sample t-test was performed for continuous variables to see a 
statistically significant difference between carbapenems group and p lactam/p lactamase 
inhibitor combinations group. A 2-tailed P-value of <0.05 was considered as statistically 
significant. Two separate models were constructed for outcome measures (for treatment 
failure and for all-cause mortality). Variables with P<0.2 in the univariate analysis were 
entered into these models. This value was chosen for analysis because it was used in the 
main reference paper of this project [80]. Each model was clustered on the patient to 
adjust for multiple episodes (weight cases). Multiple logistic regressions with a 
backward stepwise method were used to control for confounding variables and to look 
for the influential factors associated with treatment failure and all-cause mortality. For 
subgroup analysis, categorical variables were compared using x^test, Continuity 
correction or Fisher's exact test, where appropriate and the Mann-Whitney U test was 
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used to compare the continuous variables. The SPSS software (version 14, SPSS inc) 
was used for data analysis. 
4.3 Results 
A total of 1806 episodes of bacteremia due to E. coli, K. pneumoniae or 
Klebsiella spp. occurred during the study period; 225 episodes (12.5%) were due to 
ESBL-producing organisms. A hundred and eleven episodes in 109 patients with 
bacteremia due to ESBL-producing organisms treated with carbapenem or p-lactam/p-
lactamase inhibitor combinations were studied; 53 episodes were in carbapenem group 
(30 episodes were treated with imipenem whilst 23 episodes with meropenem) and 58 
episodes were treated with one of three [3-lactam/p-lactamase inhibitor combinations. In 
the carbapenem group, 49 episodes were treated with carbapenem monotherapy. 
Combination therapy with aminoglycoside was used in four episodes (2 with amikacin 
and gentamicin were used in 2 episodes). Within the p-lactam/p-lactamase inhibitor 
group, seven episodes were treated in combination with aminoglycoside (amikacin was 
used in 2 episodes and gentamicin was used in 5 episodes). 
Most of the patients were from the Department of Medicine and Therapeutics; 
54.7% (29/53) for carbapenem group and 55.9% (33/58) for P-lactam/(3-lactamase 
inhibitor group, 11 and 16 episodes respectively from the Department of Surgery. 
Eleven patients (20.8%) for carbapenem group and 7 (12.1%) for p-lactam/p-lactamase 
inhibitor group were from Department of Oncology. One patient each from Department 
of Orthopedics and Gynecology was in the carbapenem group whilst two patients from 
Department of Orthopedics were in the (3-lactam/f3-lactamase inhibitor group. 
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4.3.1 Patient characteristics 
There was no significant difference in gender distribution among patients treated 
with carbapenem or p-lactam/p-lactamase inhibitor antimicrobials. Patients in the 
carbapenem group were slightly younger but it was not statistically significant (Table 
4.1). Two groups were similar with respect to comorbidities. In each group, around 60% 
of patients had > 3 comorbid factors. 34 percent (18/53) of patients in the carbapenem 
group and 44.8% (26/58) of patients in the p-lactam/p-lactamase inhibitor group were 
old-age-home residents. 
4.3.2 Predisposing factors 
Previous exposure to antimicrobials within one month was the most frequent 
risk factor found in both study groups, with 60.4% patients in the carbapenem group and 
51.7% patients in the p-lactam/p-lactamase inhibitor group. A history of intravascular 
catheterization and urinary catheterization was found in more than 35% of patients in the 
carbapenem group. Around 20% of patients in both groups had a history of exposure to 
surgery or other invasive procedures. Prior isolation of ESBL-producing organisms 
within one year was found in >20% of the patients. There were no significant differences 
in predisposing factors among the study groups, but a higher proportion of patients in the 
carbapenem group had a history of intubation compared to p-lactam/p-lactamases 
inhibitor group; 11.3% vs. 1.7%;户=0.053 (Table 4.2). 
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Table 4.1 Demographic and comorbid characteristics of patients with bacteremia 
due to extended-spectrum P-lactamases-producing organisms treated with 
carbapenems or p-lactam/p-lactamase inhibitor combinations 
Characteristic Carbapenem P-lactam /p-lactamase ？-value 
group inhibitor group 
(n = 53) (n-58) 
Age, mean years 土 SD 69.4 士 16.5 72.8 ± 16.8 
median years (IQR) 73 (57-82) 77.5 (64-85) 
Gender 0.42 
Male 25 (47.2) 23 (39.7) 
Female 28 (52.8) 35 (60.3) 
Mean no. of comorbidities 2.75士 1.2 2.88 士 1.2 0.58 
> 3 no. of comorbidities 33(62.3) 37(63.8) 0.86 
Comorbidities 
Malignancy 20(37.7) 22(37.9) 0.98 
Hypertension 21(39.6) 24 (41.4) 0.85 
Obstructive uropathy 13 (24.5) 16(27.6) 0.71 
Immunosuppresion' 9(17) 10(]7.2) 1.00 
Ischaemic heart disease 7(13.2) 7(12.1) 1.00 
Diabetes mellitus 5(9.4) 10(17.2) 0.35 
Chronic/Endstage renal failure 5(9.4) 1 (1.7) 0.1 
COADV Bronchiectasis 5 (9.4)) 8 (13.8) 0.67 
Chronic liver disease 1 (1.9) 2 (3.4) 0.1 
Solid organ transplantation 1 (1.9) 1 (1.7) 1.00 
Others 35 (66) 38(65.5) 0.95 
OAHRC 18(34.0) 26(44.8) 0.33 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a Presence of neutropenia, HIV, receipt of steroids, cyclosporine etc. 
b Chronic obstructive airway disease 
e Old-age-home residents 
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4.3.3 Clinical characteristics 
In the carbapenem group 77.3% (4�/53) episodes were due to ESBL-producing 
E. coli, 16.4% episodes were due to ESBL-producing K. pneumoniae and the remainders 
were due to ESBL-producing Klebsiella species. In the p-lactam/p-lactamases inhibitor 
group 89.6% episodes were due to ESBL-producing E. coli, and the remainder were due 
to ESBL-producing K. pneumoniae and ESBL-producing Klebsiella species (Figure 4.1). 
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Figure 4.1: No of strains of ESBL-producing Enterobacteriaceae found in two 
patients groups treated with carbapenems or p-lactam/p-lactamase inhibitor 
combinations 
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4.3.3.1 Type and source of infection 
In both groups more than 80% of the blood stream infections were healthcare-
associated; 88.7% and 82.8% for carbapenems and p-lactam/p-lactamase inhibitor-
combinations group respectively. The commonest source of infection was the urinary 
tract followed by an intraabdominal source. Few episodes were related to indwelling 
intravascular catheters and the respiratory tract. There were no significant differences 
found relating to the source of infection (Table 4.2). 
4.3.3.2 Severity of illness markers 
Patients in the carbapenem group had an increased severity of illness as 
determined by the Pitt bacteremia score and the accommodation in the ICU at the time 
of bacteremia. Patients who were treated with carbapenems had a significantly high 
mean Pitt bacteremia score (2,3土2.1 vs. 1.17士 1.7;尸=0.002) and a higher proportion of 
admission to ICU (28.3% vs. 5.2%;尸=0.002). 
Also, the length of the hospital stay was significantly higher in the carbapenem 
group compared to the (3-lactam/p-lactamases inhibitor combinations group. There was 
no significant difference in the duration of the previous hospitalization, although it was 
slightly higher in the carbapenem group (Table 4.2). 
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Table 4.2 Predisposing factors and clinical characteristics of patients with 
bacteremia due to extended-spectrum p-lactamases-producing organisms treated 
with carbapenems or p-lactam/p-lactamase inhibitor combinations 
Variable Carbapenem p-lactam/p-lactamase P-value 
group inhibitor group 
( n - 5 3 ) (n-58) 
Predisposing factors 
Previous use of antibiotics 32 (60.4) 30(51.7) 0.35 
Intravascular catheter 20(37.7) 14(24.1) 0.12 
Bladder catheter 19(35.8) 17(29.3) 0,46 
Previous surgery 14(26.4) 12(20.7) 0.47 
Corticosteroid/anti-neoplastic Rx 11(20.8) 11(19) 0.81 
Previous isolation of ESBL ‘ 12(22.6) 16(27.6) 0.54 
Drainages (thoracic/abdominal) 6(11.3) 4(6.9) 0.51 
Intubation 6(11.3) 1(1.7) 0.053 
Type of infection 
Healthcare-associated 47(88.7) 48 (82.8) 0.53 
Community-acquired 6(11.3) 10(17.2) 0.53 
Source of infection 
Urinary tract 29(54.7) 39 (67.2) 0.176 
Intraabdominal 11(20.8) 11 (19) 0.81 
Intravascular catheter related 5(9.4) 1 (1.7) 0.102 
P B S ” 4(7,5) 5(8.6) 1.00 
Respiratory 3(5.7) 2(3.4) 0.66 
Skin and soft tissue 1(1.9) 0(0) 0.46 
Pitt bacteremia score (mean) 2.3 士 2.1 1.17 士 1.7 0 . 0 0 2 
ICU admission 15(28.3) 3(5.2) 0.002 
LOHS'(mean) 27.9 士 28.9 11.2 土 7.8 <0.001 
Previous LOHS e (mean) before BSI d 5.9 土 10.8 3.19 士 5.7 0.1 
Length of therapy 10.7 士 4.8 7.5 士 3.6 < 0 . 0 0 1 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a Extended-spectrum p Lactamase- producing organisms 
b Primary blood stream infection 
e Length of hospital stay 
d Bloodstream infection 
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4.3.4 Outcome measures 
4.3.4.1 Treatment outcome and reasons for therapeutic failure 
Bacteremic episodes due to ESBL-producing organisms which were treated with 
carbapenems antimicrobials achieved better clinical outcomes than episodes treated with 
3-lactam/p-lactamases inhibitor combinations. Table 4.3 shows the treatment outcome 
and the reasons for the therapeutic failure in each group. Episodes treated with 
carbapenems had a lower therapeutic failure rate than the p-lactam/p-lactamase inhibitor 
combinations group (17% vs. 48.3%; P <0.001). Relapse was the commonest reason for 
treatment failure in the P-1 actam/p-lactamase inhibitor combination group, with relapse 
rates of 18.9% and 5.6% in the p-lactam/p-lactamase inhibitor combinations group and 
in the carbapenem group respectively. A switch to another antimicrobial and death 
despite antimicrobial treatment for >48 hrs were common. 
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Table 4.3 Treatment outcome and therapeutic failure reasons of patients with 
bacteremia due to extended-spectrum P-lactamases-producing organisms treated 
with carbapenems or p-lactam/p-lactamase inhibitor combinations 
Variable Carbapenem P-lactam /p-lactamase P-value 
group inhibitor group 
(n 二 53) (n=58) 
Treatment outcome 
Therapeutic success 44(83) 30 (51.7) < 0.001 
Therapeutic failure 9(17) 28 (48.3) < 0.001 
Therapeutic failure reasons 
Relapse 3 (5.6) 11(18.9) 
Death 4(7.5) 7(12.1) 
Persistent bacteremia 1 (1.9) 3 (5.2) 
Switch to another antibiotic 0 (0) 7(12.1) 
Surgery needed 1(1.9) 0(0) 
NOTE. Data are no. (%) of patients unless otherwise indicated 
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4.3.4.2 Factors associated with therapeutic failure 
4.3.4.2.1 Univariate analysis of variables to be associated with therapeutic 
failure 
Treatment failure occurred in 33.3% (37/111) of bacteremic episodes due to 
ESBL-producing orgamisms which were treated with either carbapenems or P-lactam/(3-
lactamase inhibitor combinations. 
Univariate analysis of all the variables to be associated with therapeutic 
failure is shown Table 4.4. Patients who had >3 numbers of comorbidities and 
underlying IHD, intubation within one month before the onset of bacteremia and 
treatment with p-lactam/p-lactamase inhibitor combinations antimicrobials were 
significantly associated with treatment failure. 
The Pitt bacteremia score, ICU admission and the length of hospital stay were 
higher in the therapeutic failure group, but were not statistically significant. 
Age, previous length of hospital stay, presence of underlying malignancy, 
hypertension, obstructive uropathy, immunosuppression, DM, chronic or end-stage renal 
failure, COAD, bronchiactasis, type and source of infection, strain type, admission from a 
nursing home, presence of predisposing factors such as previous use of antibiotics, 
intravascular, bladder catheters, previous surgery, receipt of corticosteroid or anti-
neoplastic therapy, thoracic or abdominal drainages and previous isolation of ESBL-
producing organisms were not associated with significantly increased therapeutic failure. 
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Table 4.4 Univariate analysis of variables to be associated with treatment failure for patients with 
bacteremia due to extended-spectrum (3-Iactamases-producing organisms treated with carbapenems 
or p-lactam/p-lactamase inhibitor combinations 
Variable Therapeutic failure Therapeutic success 
group group 戶-value 
(n = 37) (n=74) 
Age, mean years 士 SD 72 土 16.2 71.6 士 15.9 0.907 
>65years of age 25(67.6) 54(73) 0.553 
Mean no. of comorbidities 3.4 土 1.3 2.5 士 1.1 < 0.001 
> 3 no. of comorbidities 29(78.4) 41(55.4) 0.018 
Comorbidities 
Malignancy 17(45.9) 25(33.8) 0.213 
Hypertension 18(48.6) 27(36.5) 0.219 
Obstructive uropathy 10(27) 19(25.7) 1.000 
Immunosuppression' 7(18.9) 12(16.2) 0.929 
Ischaemic heart disease 10(27) 4 (5.4) 0.002 
Diabetes mellitus 6(16.2) 9(12.2) 0.556 
Chronic/Endstage renal failure 1(2.7) 5(6.8) 0.662 
COADV Bronchiectasis 4(10.8) 9(12.2) 1.000 
Chronic liver disease 1(2.7) 2(2.7) 1.000 
Solid organ transplantation 0(0) 2(2.7) 0.552 
Others 23(62.2) 50(67.6) 0.572 
OAHRe �5(40 .5) 29(39.2) 0.891 
Predisposing factors 
Previous use of antibiotics 23 (62.2) 39(52.7) 0.419 
Intravascular catheter 12(32.4)) 22(29.7) 0.771 
Bladder catheter 14(37.8) 22(29.7) 0.390 
Previous surgery 9(24.3) 17(23) 1.000 
Corticosteroid/anti-neoplastic Kx 9(24.3) 13(17.6) 0.556 
Previous isolation of ESBL d 10(27) 18(24.3) 0.938 
Drainages (thoracic/abdominal) 5(13.5) 5(6.8) 0.297 
Intubation 5(13.5) 2(2.7) 0.04 
Healthcare-associated infection 33(89.2) 62(83.8) 0.633 
Source of infection 
Urinary tract 23(62.2) 45 (60.8) 0.89 
Intraabdominal 8(21.6) 14(18.9) 0.993 
P B S ” 3(8.1) 6(8.1) 1.000 
Intravascular catheter related 1 (2.7) 5(6.8) 0.662 
Respiratory 2(5.4) 3(4.1) 1.000 
Pitt bacteremia score (mean) 2.0 土 2.3 1.6 士 1.7 0.37 
ICU admission 7(18.9) 11(14.9) 0.785 
Carbapenem treatment 9(24.3) 44(59.5) < 0.001 
Mean LOHS ^ 20.8 ± 26.9 17.9 土 19.5 0.512 
Previous LOHS ^ (mean) before BSI ® 4.4 土 5.8 4.1 士 9.3 0.829 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a Presence of neutropenia, HIV, receipt of steroids,cyclosporine etc 
b Chronic Obstructive Airway Disease 
e Old age home residents 
d Extended-spectrum (3 lactamase- producing organisms 
e Primary blood stream infection 
f Length of hospital stay 
g Blood stream infection 
^Variables with P-value < 0.2 (bold) entered in to the multivariate model 
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4.3.4.2.2 Multivariate model of treatment failure 
Multivariate analysis was performed using the variables with 户-value <0.2 which 
were revealed by the univariate analysis. These included the number of comorbidities, 
>3 number of comorbidities and underlying IHD, intubation within one month before the 
onset of bacteremia and treatment with carbapenem during the five day period after the 
onset of bacteremia. 
Carbapenem use, significantly, was inversely associated with therapeutic failure 
(OR, 0.093; 95% CI, 0.028-0.316; P <0.001). 
Also the multivariate analysis demonstrated the significant association of 
treatment failure with the underlying number of comorbidities and intubation (Table 4,5). 
Table 4.5 Multivariate model of treatment failure for patients with bacteremia due 
to extended-spectrum p-lactamases-producing organisms treated with 
carbapenem or p-Iactam/p-lactamase inhibitor combinations 
Variable OR (95 % CI) P-value 
Carbapenem treatment 0.093 (0.028-0.316) <0.001 
No of comorbidities 2.706 (1.606-4.561) <0.001 
Intubation a 50.116 (4.878-514.86) 0.001 
a Predisposing factor for ESBL bacteremia 
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4.3.4.3 Factors associated with all-cause mortality 
43.4.3.1 Univariate analysis of variables to be associated with all-cause 
mortality 
All-cause mortality occurred in 15.3% patients with bacteremia due to ESBL-
producing organisms, treated with either carbapenems (5/53, 9.4%) or (3-lactam/p-
lactamase inhibitor combinations (12/58, 20.7%). The Kaplan-Meier plot for survival is 
shown in Figure 4.2. 
Factors significantly associated with all-cause mortality revealed by the 
univariate analysis included the patient's underlying number of comorbidities, >3 
number of comorbidities, underlying IHD and malignancy, presence of predisposing 
factor of intravascular catheters. 
The Pitt bacteremia score (户=0.051), prior intubation (户=0.071) were higher in 
the mortality group, but were not statistically significant (Table 4.6). 
Patients who were treated with carbapenem antimicrobials at least two days 
during the five-day period after the onset of bacteremia had a lower all-cause mortality 
rate than the patients who received p-lactam/p-lactamase inhibitor combination 
antimicrobials (9.4% [5/53]) vs. 20.7% [12/58]; P=0.1). 
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Figure 4.2: Kaplan-Meier plot for survival for patients with bacteremia due to 
extended-spectrum P-lactamases-producing organisms treated with carbapenems 
or P-lactam/p-lactamase inhibitor combinations 
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Table 4.6 Univariate analysis of variables to be associated with all-cause mortality for patients with 
bacteremia due to extended-spectrum P-lactamases-producing organisms treated with carbapenems 
or (3-Iactam/p-Iactamase inhibitor combinations 
Variable Mortality group Survival group P-value 
(n = 17) (n=94) 
Age，mean years 士 SD 73 士 13.6 71.5 士 16.4 0.72 
> 6 5 y e a r s of age 13(76.5) 66(70.2) 0,774 
Mean no. of comorbidities 3.9 士 1.3 2.6 士 1.1 < 0 . 0 0 1 
> 3 no. of comorbidities 15(88.2) 54(57.4) 0 . 0 3 3 
Comorbidities 
Malignancy 12(70.6) 30(31.9) 0 . 0 0 6 
Hypertension 7(41.2) 38(40.4) 0.954 
Obstructive uropathy 4(23.5) 25(26.6) 1.00 
Immunosuppression' 4(23.5) 15(16) 0.486 
Ischaemic heart disease 5(29.4) 9 (9.6) 0 . 0 3 9 
Diabetes mellitus 3(17.6) 12(12.8) 0.69 
Chronic/Endstage renal failure 1(5.9) 5(5.3) 1.00 
C O A D V Bronchiectasis 1(5.9) 12(12.8) 0.687 
Chronic liver disease 1(5.9) 2(2.1) 0.396 
Solid organ transplantation 0(0) 2(2.1) � . 0 0 
Others 12(70.6) 61(64.9) 0.649 
OAHRC 5(29.4) 39(41.5) 0.504 
Predisposing factors 
Previous use of antibiotics 10 (58.8) 52(55.3) 0.998 
Intravascular catheter 10(58.8)) 24(25.5)) 0 . 0 0 6 
Bladder catheter 8(47.1) 28(29.8) 0.263 
Previous surgery 5(29.4) 21(22.3) 0.541 
Corticosteroid/anti-neoplastic Rx 5(29.4) 17(18.1) 0.323 
Previous isolation of ESBL ^ 3(17.6) 25(26.6) 0.554 
Drainages (thoracic/abdominal) 3(17.6) 7(7.4) 0.18 
Intubation 3(17.6) 4(4.3) 0.071 
Healthcare-associated infection 16(94.1) 79(84) 0.458 
Source of infection 
Urinary tract 11(64.7) 57 (60.6) 0.96 
Intraabdominal 3(17.6) 19(20.2) 1.00 
P B S P 3(17.6) 6(6.4) 0.14 
Intravascular catheter related 0 (0) 6(6.4) 0.588 
Respiratory 0(0) 5(5.3) 1.00 
Pitt bacteremia score (mean) 2.6 士 2.7 1.6 土 1 ’8 0.051 
ICU admission 5(29.4) 13(13.8) 0.148 
Carbapenem treatment 5(29.4) 48(51.1) 0.167 
Mean LOHS f 15.5 士 11.4 19.5 土 23.6 0.499 
Previous LOHS ^ (mean) before BSI ® 6.1 ± 6 . 2 3.8 ± 8.6 0.308 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a Presence of neutropenia,HIV, receipt of steroids,cyclosporine etc 
b Chronic obstructive airway disease 
e Old-age-home residents 
d Extended-spectrum f3-lactamase- producing organisms 
e Primary blood stream infection 
^ Length of hospital stay 
® Blood stream infection 
*Vanables with P-value < 0.2 (in bold) entered in to the multivariate model 
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4.3.4.3.2 Multivariate model of all-cause mortality 
Variables with 户-value <0.2 were revealed by univariate analysis entered into 
the multivariate model (Table 4.6, P values are highlighted in bold). 
Multivariate analysis showed that carbapenem treatment was independently 
associated with a lower all-cause mortality (OR, 0.096; 95% CI, 0.016-0.589; P= 0.011). 
Number of comorbidities, underlying oncological comorbidity and prior 
intubation within one month before the onset of bacteremia were associated with a 
significantly higher all-cause mortality rate (Table 4.7). 
Table 4.7 Multivariate model of all-cause mortality for patients with bacteremia 
due to extended-spectrum p-lactamases-producing organisms treated with 
carbapenems or p-lactam/p-lactamase inhibitor combinations 
Variable OR (95 % CI) P- value 
Carbapenem treatment 0.096 (0.016-0.589) 0.011 
No.ofcomorbidities 3.659 (1.717-7.797) 0.001 
Oncological comorbidity 6.004 (1.292-27.902) 0.022 
Intubation a 18.36 (1.392-242.28) 0.027 
a Predisposing factor for ESBL bacteremia 
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4.3.5 Subgroup analysis 
Carbapenems were prescribed for 53 bacteremic episodes of which 30 were 
treated with imipenem and 14 with meropenem. There was no significant difference in 
treatment outcome between these two groups. 
3-lactam/p-lactamases inhibitor combinations were prescribed for 58 bacteremic 
episodes of which 21 were treated with cefoperazone/sulbactam, 14 with 
piperacillin/tazobactam and 23 with amoxicillin/clavulanate. 
4.3.5.1 Carbapenem versus Cefoperazone/sulbactam 
There were no significant differences found between patients in the carbapenem 
and cefoperazone/sulbactam group with respect to age, gender and comorbid conditions 
(Table 4.8). 
Patients in the carbapenem group had increased severity of illness compared to 
the cefoperazone/su 1 bactam group as determined by the Pitt bacteremia score and 
requiring ICU admission at the time of bacteremia. Patients who were treated with 
carbapenem had a higher proportion of admission to ICU (28.3% vs. 0%; P=0.004) and 
also a trend towards a higher median Pitt bacteremia score, although this was not 
statistically significant (2[l-4] vs. 1 [0-2.5]; ？=0.06). The length of hospital stay was 
significantly higher in the carbapenem group compared to cefoperazone/sulbactam 
group (Table 4.9). 
The episodes treated with cefoperazone/sulbactam group had a lower therapeutic 
success rate than the carbapenem group (57.1% vs. 83%; P= 0.04), but the mortality 
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between patients treated with cefoperazone/sulbactam and those with a carbapenem 
were not significantly different (1/21 [4.8%] vs. 5/53[9.4%]; 二0.67) (Table 4.9). 
Nine out of 21 (42.85%) episodes of bacteremia treated with cefoperazone/ 
sulbactam failed. Reasons for therapeutic failure included a switch to another class of 
antimicrobial because of insufficient clinical response despite antimicrobial treatment 
for > 48 hrs (4/21; 19.04%), relapse of infection (4/21; 19.04%) and death (1/21). 
The univariate analysis of all the variables to be associated with therapeutic 
failure in patients with bacteremia due to ESBL-producing organisms treated with 
carbapenems or cefoperazone/sulbactam are shown in Table 4.10. Influential factors 
significantly associated with therapeutic failure included patients' underlying number of 
comorbidities, IHD, intubation, presence of thoracic or abdominal drainages within one 
month before the onset of bacteremia and treatment with cefoperazone/sulbactam. The 
length of hospital stay and duration of previous hospitalization before bloodstream 
infection were significantly higher in the treatment failure group. 
Multivariate analysis which used variables with P-value <0.2 found on univariate 
analysis showed that cefoperazone/sulbactam use was associated with increased failure 
(OR, 23.68; 95% CI, 3.19-175.67; P=0.002). Also, intubation within one month before 
the onset of bacteremia, an intraabdominal source of infection and number of 
comorbidities were associated with a significantly higher treatment failure rate (Table 
4.11). 
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Table 4.8 Demographic and comorbid characteristics of patients with bacteremia 
due to extended-spectrum p-lactamases-producing organisms treated with 
carbapenems or cefoperazone/sulbactam 
Characteristic Carbapenem Cefoperazone/sulbactam 户-value 
group group 
(n = 53) (n-21) 
Age, [median (IQR)] 77 (58-82) 74 (66.5-86) ^ 
Gender 1.00 
Male 25 (47.2) 10 (47.6) 
Female 28 (52.8) 11 (52.4) 
no.of comorbidities [median (IQR)] 3(2-3) 3(2-3.5) 0.99 
> 3 no. of comorbidities 33(62.3) 12(57.1) 0.88 
Comorbidities 
Malignancy 20(37.7) 7(33.3) 0.93 
Hypertension 21(39.6) 1 1 (52.4) 0.46 
Obstructive uropathy 13 (24.5) 6(28.6) 0.94 
Immunosuppression^ 9(17) 2(9.5) 0.78 
Ischaemic heart disease 7(13.2) 1(4.8) 0.43 
Diabetes mellitus 5(9.4) 3(14.3) 0.68 
Chronic/Endstage renal failure 5(9.4) 0(0) 0.31 
COADV Bronchiectasis 5 (9.4)) 4(19) 0.26 
Chronic liver disease 1 (1.9) 1 (4.8) 0.49 
Solid organ transplantation 1 (1.9) 0(0) 1.00 
Others 35 (66) 12(57.1) 0.88 
OAHR' 18 (34) 9(42.9) 0.65 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a Presence of neutropenia, HIV, receipt of steroids,cyclosporine etc 
b Chronic obstructive airway disease 
e Old-age-home residents 
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Table 4.9 Clinical characteristics of patients with bacteremia due to extended-
spectrum P-lactamases-producing organisms treated with carbapenems or 
cefoperazone/sulbactam 
Variable Carbapenem Cefoperazone/sulbactam 户-value 
group group 
(n = 53) (n=21) 
Predisposing factors 
Previous use of antibiotics 32 (60.4) 13(61.9) 1.00 
Intravascular catheter 20(37.7) 4(19) 0.2 
Bladder catheter 19(35.8) 8(38.1) 1.00 
Previous surgery 14(26.4) 5(23.8) 1.00 
Corticosteroid/anti-neoplastic Rx 11(20.8) 2(9.5) 0.33 
Previous isolation of ESBL ‘ 12(22.6) 5(23.8) 1.00 
Drainages (thoracic/abdominal) 6(11.3) 0(0) 0.17 
Intubation 6(11.3) 0(0) 0.17 
Type of infection 
Healthcare-associated 47(88.7) 17 (81) 0.45 
Community-acquired 6(11.3) 4 (19) 0.45 
Source of infection 
Urinary tract 29(54.7) 16 (76.2) 0.15 
Intraabdominal 11(20.8) 5 (23.8) 0.76 
Intravascular catheter related 5(9.4) 0(0) 0.31 
PBSI b 4(7.5) 0(0) 0.57 
Respiratory 3(5.7) 0(0) 0.55 
Skin and soft tissue 1(1.9) 0(0) 1.00 
Pitt bacteremia score [median (IQR)] 20-4) 1(0-2.5) 0.06 
ICU admission 15(28.3) 0(0) 0.004 
LOHS ‘ [median (IQR)] 13(10-38.5) 10(6-16) 0.024 
PreviousLOHSC[median(iQR)]beforeBSld 0(0-6) 0(0-3.5) 0.516 
Length of therapy 10(7-14) 7 (6-8.5) 0.001 
Treatment outcome 
Therapeutic success 44 (83) 12(57.1) 0.04 
All-cause mortality 5(9.4) 1(4.8) 0.67 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a Extended-spectrum p-lactamase- producing organisms 
b Primary blood stream infection 
e Length of hospital stay 
d Blood stream infection 
137 
Table 4.10 Univariate analysis of variables to be associated with treatment failure for patients with 
bacteremia due to extended-spectrum p-Lactamases producing organisms treated with 
carbapenems or cefoperazone/Sulbactam 
Variable Therapeutic failure Therapeutic success 
group group P-value 
( n = 18) (n=56) 
Age [median (IQR)] 75.5(58.2-80.2) 75.5(61.5-83) 0.504 
>65years of age 1 1(61.1) 41(73.2) 0.496 
no.of comorbidities[inedian(IQR)] 3(2.75-4.2) 3(2-3) < 0.017 
> 3 no. of comorbidities 13(72.2) 32(57.1) 0.388 
Comorbidities 
Malignancy 9(50) 18(32.1) 0.277 
Hypertension 8(44.4) 24(42.9) 1.000 
Obstructive uropathy 5(27.8) 14(25) 1.000 
Immunosuppression' 3(16.7) 8(14.3) 1.000 
Ischaemic heart disease 5(27.8) 3(5.4) 0.018 
Diabetes mellitus 3(16.7) 5(8.9) 0.393 
Chronic/Endstage renal failure 1(5.6) 4(7.1) 1.000 
COADV Bronchiectasis 1(5.6) 8(14.3) 0.439 
Chronic liver disease 0(0) 2(3.6) 1.000 
Solid organ transplantation 0(0) 1(1.8) 1.000 
Others 10(55.6) 37(66.1) 0.600 
O A H R � 5(27.8) 22(39.3) 0.548 
Predisposing factors 
Previous use of antibiotics 13 (72.2) 32(57.1) 0.388 
Intravascular catheter 8(44.4)) 16(28.6) 0.336 
Bladder catheter 10(55.6) 17(30.4) 0.099 
Previous surgery 7(38.9) 12(21.4) 0.213 
Corticosteroid/anti-neoplastic Kx 3(16.7) 10(17.9) 1.000 
Previous isolation of ESBL d 1(5.6) 16(28.6) 0.055 
Drainages (thoracic/abdominal) 4(22.2) 2(3.6) 0.028 
Intubation 4(22.2) 2(3.6) 0.028 
Healthcare associated infection 16(88.9) 48(85.7) 1.000 
Source of infection 
Urinary tract 10(55.6) 35 (62.5) 0.805 
Intraabdominal 7(38.9) 9(16.1) 0.053 
P B S r 0(0) 4(7.1) 0.566 
Intravascular catheter related 1(5.6) 4(7.1) 1.000 
Respiratory 0(0) 3(5.4) 1.000 
Pitt bacteremia score [median(IQR)] 2.00(1-4) 1 (.25-3) 0.298 
ICU admission 5(27.8) 10(17.9) 0.500 
Cefoperazone/sulbactam treatment 9(50) 12(21.4) 0.041 
LOHS f [median (IQR)] 16(11.7- 43.5) 11.5(7.2-22.7) 0 . 0 3 4 
Previous LOHS [before BSI ^[median(IQR)] 4.5(0-8.2) 0(0-1.7) 0.015 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a Presence of neutropenia,HIV, receipt of steroids,cyclosporine etc 
b Chronic obstructive airway disease 
c Old-age-home residents 
d Extended-spectrum (3-lactamase- producing organisms 
e Primary blood stream infection 
f Length of hospital stay 
g Blood stream infection 
^Variables with p-value < 0.2 (bold) entered in to the multivariate model 
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Table 4.11 Multivariate model of treatment failure for patients with bacteremia 
due to extended-spectrum p-lactamases-producing organisms treated with 
carbapenems or cefoperazone/sulbactam 
Variable OR (95 % CI) P-value 
Cefoperazone/sulbactam treatment 23.68 (3.19-.175.67) 0.002 
No. of comorbidities 2.5 (1.15-5.44) 0.021 
Intraabdominal source of infection 9.07 (1.42-57.77) 0.019 
Intubation a 36.52 (1.96-679.84) 0.016 
a Predisposing factor for ESBL bacteremia 
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Table 4.12 Univariate analysis of variables to be associated with all-cause mortality for patients with 
bacteremia due to extended-spectrum p-lactamases producing organisms treated with carbapenems 
or cefoperazone/sulbactam 
Variable Mortality group Survival group P-value 
(n = 6) (n=68) 
Age, [median (IQR)] 81(76.75-83.5) 73.5(59.25-82) 0.137 
> 65years of age 6 (100) 46(67.6) 0.017 
Comorbidities [median (IQR)] 5(4.5-5) 3(2-3) < 0.001 
> 3 no. of comorbidities 6(100) 39(57.4)) 0.075 
Comorbidities 
Malignancy 3(50) 24(35.3) 0.662 
Hypertension 3(50) 29(42.6) 1.000 
Ischaemic heart disease 3(50) 5 (1) 0.015 
Diabetes mellitus 2(33.3) 6(8.8) 0.124 
Chronic/Endstage renal failure 1(16.7) 4(5.9) 0.353 
Obstructive uropathy 1(16.7) 18(26.5) 1.000 
COAD''/Bronchiectasis 1(16.7) 8(11.8) 0.554 
Immunosuppression' 0(0) 11(16.2) 0.583 
Chronic liver disease 0(0) 2(2.9) 1.000 
Solid organ transplantation 0(0) 1(1.5) 1.000 
Others 5(83.3) 42(61.8) 0.406 
OAHRC 1(16.7) 26(38.2) 0.406 
Predisposing factors 
Previous use of antibiotics 4 (66.7) 41(60.3) 1.000 
Intravascular catheter 5(83.3) 19(27.9)) 0.012 
Bladder catheter 5(83.3) 22(32.4) 0.022 
Previous surgery 3(50) 16(23.5) 0.172 
Drainages (thoracic/abdominal) 2(33.3) 4(5.9) 0.072 
Intubation 2(33.3) 4(5.9) 0.072 
Corticosteroid/anti-neoplastic Rx 0(0) 13(19.1) 0.583 
Previous isolation of ESBL ^ 0(0) �7(25) 0.326 
Healthcare-associated infection 6(100) 58(85.3) 0.588 
Source of infection 
Urinary tract 4(66.7) 4] (60.3) 1.00 
Intraabdominal 2(33.3) 14(20.6) 0.604 
P B S r 0(0) 4(5.9) 1.000 
Intravascular catheter related 0(0) 5(7.4) 1.000 
Respiratory 0(0) 3(4.4) 1.000 
Pitt bacteremia score [median (IQR)] 3.5(2.5- 4.5) 1 (0.25-3) 0 . 0 3 4 
ICU admission 3(50) 12(17.6) 0.093 
Carbapenem treatment 5(83.3) 48(70.6) 0.668 
Cefoperazone/sulbactam treatment 1(16.7) 20(29.4) 0.668 
LOHS Viedian(IQR)] 14.5(12.5-32.2) 12(8-23.7) 0.280 
Previous LOHS ^ before BSI ^[median(IQR)] 5(4.7-9.5) 0(0- 4.2) 0.009 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a Presence of neutropenia,HIV, receipt of steroids,cyclosporine etc 
b Chronic obstructive airway disease 
c old-age- home residents 
d Extended-spectrum (3-lactamase- producing organisms 
e Primary blood stream infection 
�Length of hospital stay 
g Blood stream infection 
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Altogether, six (8.1%) among 74 patients with ESBL bacteremia died. Factors 
significantly associated with all-cause mortality revealed by the univariate analysis 
included: > 65 years of age, patient's underlying number of comorbidities, underlying 
IHD , presence of predisposing factors such as intravascular catheters and bladder 
catheters, a high Pitt bacteremia score and longer duration of hospital stay before blood 
stream infection occurred (Table 4.12). Treatment with cefoperazone/sulbactam was not 
significantly associated with increased all-cause mortality. 
4.3.5.2 Carbapenem versus Piperacillin/tazobactam 
Demographics, comorbid status, predisposing factors, type and source of 
infection and severity of illness markers between patients treated with 
piperaci 11 in/tazobactam and those with carbapenem were not statistically different (Table 
4.13 and Table 4.14). Patients who were treated with piperacillin/tazobactam had 
significantly higher all-cause mortality rate (35.7% vs. 9.4%; P=0.027) and also a trend 
towards higher therapeutic failure rate (35.7% vs. 17%; P=0.149) although this was not 
statistically significant. Treatment failed in five out of 14 (35.7%) episodes which were 
treated with piperacillin/tazobactam. Reasons for therapeutic failure included death 
(3/14; 21.4%) switch to other antimicrobials because of insufficient clinical response 
despite antimicrobial treatment for >48 hrs (1/14; 7.1%) and relapse (1/14; 7.1%). 
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Table 4.13 Demographic and comorbid characteristics of patients with bacteremia 
due to extended-spectrum p-lactamases-producing organisms treated with 
carbapenems or piperacillin/tazobactam 
Characteristic Carbapenem Piperacillin/tazobactam ？-value 
group group 
(n = 53) (n=14) 
Age, [median (IQR)] 77 (58-82) 75 (55.2-83.2) ^ 
Age>65 35(66) 10(71.4) 1.00 
Gender 1.00 
Male 25 (47.2) 6 (42.9) 
Female 28 (52.8) 8 (57.1) 
no.of comorbidities [median (IQR)] 3(2-3) 2.5(2-3.5) 0.67 
> 3 no. of comorbidities 33(62.3) 7(50) 0.6 
Comorbidities 
Malignancy 20(37.7) 7(50) 0.6 
Hypertension 21(39.6) 3(21.4) 0.34 
Obstructive uropathy 13 (24.5) 4(28.6) 0.74 
Immunosuppression^ 9(17) 4(28.6) 0.45 
Ischaemic heart disease 7(13.2) 3(21.4) 0.42 
Diabetes mellitus 5(9.4) 2(14.3) 0.63 
Chronic/Endstage renal failure 5(9.4) 1(7.1) 1.00 
COADb/ Bronchiectasis 5 (9.4) 1(7.1) 1.00 
Chronic liver disease 1 (1.9) 1(7.1) 0.34 
Solid organ transplantation 1 (1.9) 0(0) 1.00 
Others 35 (66) 9(64.3) 1.00 
OAHRC 18(34) 4(28.6) 1.00 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a Presence of neutropenia,HIV, receipt of steroids,cyclosporine etc. 
b Chronic obstructive airway disease 
e Old-age-home residents 
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Table 4.14 Clinical characteristics of patients with bacteremia due to extended-
spectrum P-lactamases-producing organisms treated with carbapenems or 
piperacillin/tazobactam 
Variable Carbapenem Piperacillin/tazobactam P-value 
group group 
(n = 53) (n=14) 
Predisposing factors 
Previous use of antibiotics 32 (60.4) 9(64.3) 1.00 
Intravascular catheter 20(37.7) 6(42.9) 0.97 
Bladder catheter 19(35.8) 3(21.4) 0.36 
Previous surgery 14(26.4) 2(14.3) 0.49 
Corticosteroid/anti-neoplastic Rx 11(20.8) 4(28.6) 0.49 
Previous isolation of ESBL a 12(22.6) 4(28.6) 0.72 
Drainages (thoracic/abdominal) 6(11.3) 2(14.3) 0.67 
Intubation 6(11.3) 1(7.1) 1.00 
Type of infection 
Healthcare-associated 47(88.7) 12 (85.7) 0.66 
Community acquired 6(11.3) 2(14,3) 0.66 
Source of infection 
Urinary tract 29(54.7) 6 (42.9) 0.62 
Intraabdominal 11(20.8) 3 (21.4) 1.00 
Intravascular catheter related 5(9.4) 1 (7.1) 1.00 
PBSI b 4(7.5) 4(28.6) 0.053 
Respiratory 3(5.7) 0(0) 1.00 
Skin and soft tissue 1(1.9) 0(0) 1.00 
Pitt bacteremia score (median) 2(1-4) 1(0-2.7) 0.35 
ICU admission 15(28.3) 3(21.4) 0.74 
LOHS c [median (IQR)] 13(10-38.5) 10(8.7-18.2) 0.26 
Previous LOHS ‘ (median) before BSI ^ 0(0-6) 2(0-12) 0.39 
Length of therapy 10(7-14) 7(4-10.5) 0.007 
Treatment outcome 
Therapeutic success 44 (83) 9(64.3) 0.149 
Therapeutic failure 9(17) 5(35.7) 
All-cause mortality 5(9.4) 5(35.7) 0.027 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a Extended-spectrum P-lactamase- producing organisms 
b Primary blood stream infection 
e Length of hospital stay 
d Blood stream infection 
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4.3.5.3 Carbapenem versus Amoxicillin/clavulanate 
There were no significant differences found between patients in the carbapenem 
group and in the amoxicillin/clavulanate group regarding age，gender, comorbid 
conditions and admissions from nursing homes. Patients who were treated with 
carbapenem had a significantly higher proportion of previous use of antibiotics (60.4% 
vs. 34.8%;户=0.04), increased severity of illness (admission to ICU 28.3% vs. 0%; 
P=0.004 and Pitt bacteremia score) and longer length of hospital stay (Table 4.15 and 
Table 4.16). 
Episodes treated with amoxicillin/clavulanate had a higher therapeutic failure 
rate than the episodes treated with carbapenem group (60.9% vs. 17%; PO.OOl), and 
also a trend toward higher all-cause mortality, although this was not statistically 
significant (5/53[9.4%] vs. 6/23[26.1%];尸=0.079). 
Treatment failed in 14 out of 23 (60.9%) episodes which were treated with 
amoxicillin/clavulanate. The commonest reason for therapeutic failure was a relapse 
"6/23 (26.1%)] followed by persistent bacteremia and death [3/23 (13.1%) for each；. 
The other reason was the switch to other antimicrobials because of insufficient clinical 
response despite antimicrobial treatment for >48 hrs [2/23 (8.7%)]. 
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Table 4.15 Demographic and comorbid characteristics of patients with bacteremia 
dye to extended-spectrum P-lactamases- producing organisms treated with 
carbapenems or amoxicillin/clavulanate 
Characteristic Carbapenem Amoxicillin/clavulanate P -value 
group group 
(n = 53) (n-23) 
Age, [median (IQR)] 77 (58-82) 79 (63-88) 
Age>65 35(66) 17(73.9) 0.68 
Gender 0.27 
Male 25 (47.2) 7 (30.4) 
Female 28 (52.8) 16(69.6) 
no.of comorbidities [median (IQR)] 3(2-3) 3(3-4) 0.17 
> 3 no. of comorbidities 33(62.3) 18(78.3) 0.27 
Comorbidities 
Malignancy 20(37.7) 8(34.8) 1.00 
Hypertension 21(39.6) 10(43.5) 0.95 
Obstructive uropathy 13 (24.5) 6(26.1) 1.00 
Immunosuppression' 9(17) 4(17.4) 1.00 
Ischaemic heart disease 7(13.2) 3(13) 1.00 
Diabetes mellitus 5(9.4) 5(21.7) 0.16 
Chronic/Endstage renal failure 5(9.4) 0(0) 0.31 
COADV Bronchiectasis 5 (9.4) 3(13) 0.69 
Chronic liver disease 1(1.9) 0(0) 1.00 
Solid organ transplantation 1 (1.9) 1(4.3) 0.51 
Others 35 (66) 17(73.9) 0,68 
OAHRC 18(34) 13(56.5) 0.11 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a Presence of neutropenia, HIV, receipt of steroids,cyclosporine etc. 
b Chronic obstructive airway disease 
e Old-age-home residents 
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Table 4.16 Clinical characteristics of patients with bacteremia due to extended-
spectrum P-Lactamases-producing organisms treated with carbapenems or 
amoxicillin/clavulanate 
Variable Carbapenem Amoxicillin/clavulanate P-value 
group group 
(n 二 53) (n二23) 
Predisposing factors 
Previous use of antibiotics 32 (60.4) 8(34.8) 0,04 
Intravascular catheter 20(37.7) 407.4) 0.14 
Bladder catheter 19(35.8) 6(26.1) 0.57 
Previous surgery 14(26.4) 5(21.7) 0.88 
Corticosteroid/anti-neoplastic Rx 11(20.8) 5(21.7) 1.00 
Previous isolation of ESBL ‘ 12(22.6) 7(30.4) 0.66 
Drainages (thoracic/abdominal) 6(11.3) 2(8.7) 1.00 
Intubation 6(11.3) 0(0) 0.17 
Type of infection 
Healthcare-associated 47(88.7) 19 (82.6) 0.48 
Community-acquired 6(11.3) 4(17.4) 0.48 
Source of infection 
Urinary tract 29(54.7) 17 (73.9) 0.18 
Intraabdominal 11(20.8) 3(13) 0.53 
Intravascular catheter related 5(9.4) 0 (0) 0.31 
PBSib 4(7.5) 1(4.3) 1.00 
Respiratory 3(5.7) 2(8.7) 0.63 
Skin and soft tissue 1(1.9) 0(0) 1.00 
Pitt bacteremia score (median) 2(1- 4) 0(0-1) < 0.001 
ICU admission 15(28.3) 0(0) 0.004 
LOHS ‘ [median (IQR)] 13(10-38.5) 7(4-10) < 0.001 
Previous LOHS�(median) before BSI ^ 0(0-6) 0(0-3) 0.19 
Length of therapy 10(7-14) 7(5-10) 0.001 
Treatment outcome 
Therapeutic success 44 (83) 9(39.1) < 0.001 
Therapeutic failure 9(17) 14(60.9) <0.001 
All-cause mortality 5(9.4) 6(26.1) 0.079 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a Extended-spectrum P-lactamase- producing organisms 
b Primary blood stream infection 
e Length of hospital stay 
d Blood stream infection 
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4.3.5.4 Comparison of treatment outcome 
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Figure 4.3 Treatment Outcome of patients with bacteremia due to ESBL-producing 
organisms treated with cabapenems or p-lactam/p-Iactamase inhibitor 
combinations 
Among the four antimicrobial(s)/combinations used to treat patients with 
bacteremia due to ESBL-producing E. coli, K. pneumoniae or Klebsiella species, 
carbapenem had the highest therapeutic success rate, followed by 
piperacillin/tazobactam at 83% and 64.3% respectively. Although the all-cause mortality 
was lowest in the cefoperazone/sulbactam group, it had a 42.9% failure rate. 
Amoxicillin/clavulanate showed the worst outcome compared to the other three 
antimicrobial(s) combinations (Figure 4.3). 
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4.4 Discussion 
4.4.1 Predisposing factors 
Prior exposure to antimicrobials [88, 90, 91], recent surgery [25, 94], 
exposure to invasive medical devices such as mechanical ventilation, central venous 
catheters [25, 86], urinary catheterization [91], prior isolation of ESBL-producing 
organisms [88] have been described as important risk factors for infections due to 
ESBL-producing organisms. 
In our study, previous exposure to antimicrobials within one month was the most 
frequent risk factor found in both study groups, with 60.4% patients in the carbapenem 
group and 51.7% patients in p-lactam/p-lactamase inhibitor group. A history of 
intravascular catheterization and urinary catheterization was found in 24-37% of patients. 
Around 20% of patients in both group had a history of exposure to surgery or other 
invasive procedures. Prior isolation of ESBL-producing organisms within one year was 
present in >20% of the patients. 11 percent of patients in the carbapenem group had a 
history of intubation within one month. 
However, the project did not aim to identify the risk factors for bacteremia 
with ESBL-producing organisms. Patients who were treated with noncarbapenems 
(other than the previously-mentioned three groups of p-lactam/p-lactamase inhibitor 
combinations) were excluded, and a control group of patients with bacteremia due to 
non-ESBL-producing organisms was not included in the study. 
However, predisposing factors were included in our analysis as they have a 
potential to be confounders for treatment outcome and all-cause mortality. Multivariate 
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models of treatment failure and all-cause mortality demonstrated the significant 
association of prior intubation with treatment failure and all-cause mortality. 
4.4.2 Treatment outcome 
An increasing prevalence of ESBL-producing organisms has become a 
global concern. Treatment of serious infections caused by ESBL-producing organisms is 
becoming more difficult because of the availability of very limited antibiotic options. 
Paterson recommended carbapenems as the first-line therapy for treatment of serious 
infections such as bacteremia, nosocomial pneumonia, intraabdominal infections and 
meropenem for meningitis caused by ESBL-producing organisms [96:. 
Limited studies have been done to evaluate the therapeutic options against 
bacteremia by ESBL-producing organisms. Treating the bacteremia due to ESBL-
producing organisms with noncarbapenem antimicrobials even reported as susceptible 
has shown poor clinical outcomes and higher mortality [80, 99'. 
By definition, ESBL can generally be inhibited in vitro by p-lactamases 
inhibitors such as clavulanate, sulbactam or tazobactam. These are irreversibly bound to 
the catalytic site of P-lactamases and prevent hydrolysis of the accompanying p-lactam 
antimicrobials [115]. Very limited studies involving only small number of patients have 
been done to investigate the effectiveness of p-lactam/p-lactamase inhibitor combination 
in treating serious infections caused by ESBL-producing organisms. 
Previously published studies reported that treatment with carbapenem was 
associated with better clinical outcomes than treatment with noncarbapenems. A 
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prospective observational multicenter study done by Paterson et.al [80] demonstrated 
that treatment with carbapenem during the five-day period after the onset of 
bacteraemia due to ESBL-producing K. pneumoniae was associated with a significantly 
lower mortality than treatment with noncarbapenems active in vitro [80]. In this study 
group, only four patients were treated with p-lactam/(3- lactamase inhibitor combinations 
(two patients on piperacillin/tazobactam and the other two on ticarcillin/clavulanate) and 
50% 14-day mortality was reported within this group. Another retrospective study 
performed by Burgess et.al [100], involving patients infected with ESBL-producing 
organisms, reported 100% cure rate with carbapenems but only 55% cure rate (6/11) 
with piperacillin/tazobactam either alone or in combination with a fluoroquinolone, and 
56% cure rate (5/9) for isolates susceptible to piperacillin/tazobactam. 
The main objective of our study was to compare the treatment outcome of 
patients with bacteremia caused by ESBL-producing organisms that were treated with 
carbapenems or p-lactam/p-lactamase inhibitor combinations including 
piperacillin/tazobactam, cefoperazone/sulbactam and amoxycillin/clavulanate. The 
initiation of appropriate antimicrobials soon after the onset of infection is an important 
factor in determining outcome [112]. Thus we included patients treated with these agents 
(which were active in vitro against the blood culture isolates) for at least 48 hrs during 
the 5-day period after the onset of bacteremia regardless of the availability of the culture 
results at the time of initiating the treatment. Cases that switched antimicrobials after the 
availability of culture results, not because of insufficient clinical response, but simply 
due to the clinicians' decisions, were excluded to avoid bias. 
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Our data supports the superiority of carbapenems in treating serious 
infections with ESBL-producing organisms. The data demonstrated significantly better 
clinical outcomes in patients who received carbapenem in the five-day period after the 
onset of bacteremia compared to those treated with p-lactam/p-lactamase inhibitor 
combinations, despite the patients in the carbapenem group having increased severity of 
illness as determined by the Pitt bacteremia score and the necessity of an ICU admission 
at the time of bacteremia. 
In this study 48.3% of patients in the (3-lactam/p-lactamase inhibitor 
combinations group experienced treatment failure and accounted for 20.7% (12/58) of 
all-cause mortality rate. This high failure rate may be explained by the inoculum effect 
and co-existence of other possible resistance mechanisms such as hyperproduction of 
other (3-lactamases and porin loss, as described in the literature [25, 96]. Laboratory 
studies detected most consistent inoculum effect with cephalosporins and least 
frequently with carbapemems and intermediate with piperacillin/tazobactam [109, 110 . 
The pharmacokinetics-pharmacodynamics study indicated an inability for 
piperacillin/tazobactam to achieve a high probability of target attainment [116，117]. In 
the study, relapse was the commonest reason (18.9%) for treatment failure in the (3-
lactam/p-lactamase inhibitor combinations group, and three patients had a persistent 
bacteremia. 
Among the three P-lactam/(3-lactamase inhibitor combinations, 
amoxycillin/clavulanate showed the worst outcome. The therapeutic success rate among 
patients treated with piperacillin/tazobactam was slightly higher (64.3%; 9/14) than for 
the patients in the study of Burgess et.al's group [100], but showed 35.7% (5/14) 
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mortality rate. Statistical analysis demonstrated an inferior treatment outcome among 
patients treated with piperacillin/tazobactam compared with those treated with 
carbapenems. 
Paterson, in his recommendations article [96] for treatment of severe infections 
due to ESBL-producing Enterobacteriaceae, mentioned a combination of 
cephalosporins and (3-lactamase inhibitors as a theoretically attractive option, but there 
was the possibility of limitations similar to that with penicillin/p-lactamase inhibitors. 
According to our knowledge so far no clinical study has been done to examine the 
effectiveness of the cephalosporins with p-lactamase inhibitor combinations in treatment 
of severe infections due to ESBL-producing Enterobacteriaceae. In vitro studies have 
reported that the addition of sulbactam to cefoperazone resulted in good in vitro activity 
against cefoperazone resistant gram-negative bacilli and ceftazidime resistant ESBL-
producing Klebsiella [119, 120]. Cefoperazone/sulbactam is a commonly-used 
formulation in hospital-acquired infections in Hong Kong and many Asian countries. In 
our study, we were able to include 21 ESBL-bacteremic episodes that were treated with 
cefoperazone/sulbactam. Statistical analysis demonstrated inferior treatment outcome 
among patients treated with cefoperazone/sulbactam compared with those treated with 
carbapenems, as predicted by Paterson. Cefoperazone/sulbactam treatment was 
significantly associated with treatment failure. Although the all-cause mortality rate was 
low (4.8%; 1/21), 89% (8/9) of patient in the treatment failure group subsequently had to 
be treated with other antimicrobials due to breakthrough fever (after 5-7 days treatment 
with cefoperazone/sulbactam) or relapse, and the majority of them (6/9) were 
subsequently treated with carbapenems. 
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4.4.3 Limitations and areas for further study. 
This was a retrospective study. To eliminate the possible bias resulting from 
poor documentation, medical records with incomplete data were excluded. Although we 
were able to include important confounding variables such as age, severity score, 
comorbid conditions, and source of infection in our multivariate models, the possibility 
of bias that was introduced by unmeasured confounding factors cannot be eliminated. 
Although infection-related mortality is the perfect indicator to analyze the 
treatment outcome, to eliminate the potential bias arising from the patient's physicians in 
this assessment, a 30-day all-cause mortality was assessed. Only the documented 
mortalities were counted. 
Ideally a large, multicenter, randomized, controlled trial should be done to 
compare the efficacy of carbapenems with that of other antimicrobial classes [80: • 
Further prospective studies are needed to evaluate the correlation between MIC values, 
p-lactam/p-lactamase inhibitor combinations and treatment outcome. 
In 1990s SHV and TEM types ESBLs were found in isolates of 
Enrerobacterieaceae in Hong Kong [35]. Now CTX-M types are emerging in health-
care setting [131], in community [132] and in food animals [133]. A variety of CTX-M 
enzymes have been detected in isolates of Enrerobacterieaceae including CTX-M-2,-9, 
-13,-14 and -24; CTX-M-14 being dominant. Since the types can show significant 
differences in susceptibilities to various combinations [134] and the prevalent types of 
ESBL can shift with time, a study is needed to examine for the molecular characteristics 
of the ESBL involved in our patient group. 
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CHAPTER 5 - CONCLUSIONS 
This study demonstrates that a systematic Antimicrobial Stewardship Program 
executed by a multidisciplinary antimicrobial management team within a teaching 
hospital in Hong Kong had a beneficial impact on antimicrobial prescription. 
The implementation of multidisciplinary ASP resulted in more rational use of 
antimicrobials, reduction in both prescriptions and consumptions of selected 
antimicrobials and better clinical outcomes. 
Although it did not show a significant impact on common multidrug-resistant 
microorganisms, it shows a positive impact on susceptibilities of E. coli to 
amoxicillin/clavulanate. Since the antimicrobial resistance is multifactorial, sustainable 
infection control measures within healthcare settings including long-term care facilities 
and generalization of ASP to the community settings are needed to combat antimicrobial 
resistance. 
Future investigations are needed to evaluate the sustainability and long-term 
impact of the program, effectiveness of new strategies and cost effectiveness of the 
Antimicrobial Stewardship Program. 
Multivariate models of both treatment failure and all-cause mortality showed 
treatment with carbapenem during the five-day period after onset of bacteremia due to 
ESBL-producing organisms was independently associated with lower treatment failure 
and mortality. Conversely, treatment with p-lactam/p-lactamase inhibitor combinations 
active in vitro was associated with inferior treatment outcome. The presence of multiple 
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comorbidities and prior intubation at ICU were identified factors influencing the 
outcome of patients with bacteremia due to ESBL-producing organisms. 
This study supports the superiority of carbapenems in treating serious infections 
with ESBL-producing organisms. The prevalence of imipenem resistance in isolates of P. 
aeruginosa and in Acinetobacter barmanii is increasing in many ICUs worldwide. 
Antibiotic options are becoming more limited for infections caused by these gram-
negative bacilli. A large-scale, multicenter, randomized clinical study is needed to 
investigate treatment options for serious infections caused by ESBL-producing 
organisms. The prudent use of carbapenems is also warranted. 
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Antibiotic Ordering Form (AOF) 
N T E C A n t i b i o t i c O r d e r F o r m 
Please send/fax completed form together with new drug order to pharmacy 
ID No; Dr. Signature; 
，ex: Age: pr. Name/Rank: 
Patient Name: 
Ward: (Please affix gum label) Dr. Code: 
SpeciaTt^ Z I Date: 
Organ/System involved: iTreatment; Previous Ant ib iot ic: Organism isolated: 
•Lung • Intra-abdominal • Prophylaxis • Not on antibiotic currently (if known) 
•Urinary • IVcatheter-related • Empirical • Switch from 
•Bacteremia • Peritoneal dialysis- • Known pathogen 
related treatment Concurrent Ant ib iot ic: 
•Others (please specify) Culture Site: 
Ant ib iot ic Al lergy History: 
Please ^ the appropriate boxes 
!• Tieiiani • Meropenem | 
• Empirical therapy of hospital acquired infections with history of broad spectrum antibiotics exposure 
• Empirical therapy of neutropenic fever in high risk patients 
• Treatment of documented infections attributed to ESBL-producing bacteria 
• Treatment of documented infections due to pathogens those are resistant to other antibiotics 
• Empirical therapy of LIFE-THREATENING infections (e.g septic shock) 
• [Tienam Only] Treatment of severe necrotizing pancreatitis 
• [Meropemem Only] Treatment of meningitis which failed the previous treatment with first-line agents 
• Others (please specify). 
I ~ 
jn Ceftazidime 
• Empirical therapy (monotherapy or in combination with an aminoglycoside) of neutropenic fever 
• Treatment of documented Pseudomonas aeruginosa infection sensitive to ceftazidime 
• Empirical therapy of peritonitis (intra-peritonea! only) 
• Empirical therapy of LIFE-THREATENING infections (e.g. septic shock) 
• Others (please specify): 
— — — — — 1 
！口 Tazocin • Sulperazon • Cefepime | 
• Empirical therapy of suspected hospital acquired infections with history of broad spectrum antibiotics exposure 
• [Tazocin and Cefepime Only] Empirical therapy (in combination with an aminoglycoside) of neutropenic fever 
• [Tazocin and Cefepime Only] Empirical therapy of LIFE-THREATENING infections (e.g. Septic shock) 
• Treatment of documented gram-negative infections attributed to organisms that are resistant to line antimicrobial agents 
(e. g: Unas/n, Augmentin, Cefurox丨me) 
• Others (please specify): 
P VancoiiiycLii • Teicoplanin 
• Treatment for serious infections caused by p-lactam resistant gram positive bacteria (e, g: MRSA, MRSE) 
• Treatment for infections due to gratThpositive organisms in patients with SERIOUS beta-taatam allergy 
• Prophylaxis for endocarditis in high risk cardiac patients with beta-lactam allergy 
• Prophylaxis in the implantation of prosthetic devices in known carriers of MRSA 
• [Oral vancomycin only] For treatment of antibiotic-associated colitis in patient that has failed/is intolerant to metronidazole 
therapy 
• Others fp/ease specify): 
Note; Vancomycm is NOT recommended for: 1) eradication of MRSA earner or colonization, 2) use in response to single positive coagulase-
neg-dtive Staph, blood culture. 3) use in rena] patient just for dosing convenience 
!• Linezolid 
• Treatment of vancomycin-resistant Enterococcus faecium, including cases with concurrent bacteremia 
• Treatment of vancomycin-resistant gram positive organisms, if susceptible in vitro, to linezolid, incl. vancomycin-resistant 
Staphylococcus aureus (VRSA) 
• Treatment of senous infections caused by B-lactam resistant gram positive microorganisms where vancomycin is severely 
contra-indicated In patient eg. hypersensitivity 




Guidelines used to determine the appropriateness of indication of antimicrobials in 
ASP 
INDICATIONS OF USE — Carbapenem (Imipenem/Meropenem/Ertapenem) 
Situations in which the use of carbapenams is appropriate or acceptable: 
(A) (Definite therapy) Serious infections caused by ESBL-producing organisms. 
(B) (Definite therapy) Serious infections caused by organisms with inducible AmpC 
beta-lactam ses. 
(C) (Definite therapy) Serious infections caused by organisms resistant to other available 
antibiotics. 
(D) Empirical therapy for life-threatening infections (e.g septic shock) [de-escalation in 
72 hours when culture results available]. 
(E) Empirical therapy for serious infections, where patients had received prior broad 
spectrum antibiotics (Tazocin / Sulperazone / Cefepime). 
(F) Empirical therapy for serious infections, where patients had prior documented 
infection with multidrug-resistant organisms. 
(G) Neutropenic fever in high risk patients. 
(H) Empirical therapy for severe necrotizing pancreatitis (as per impact guide) 
(I) (Meropenem) Treatment of meningitis, failed first line agent / documented 
multidrug resistant organisms. 
Situations in which the use of carbapenems should be discouraged: 
(1) (Definite therapy) When other antibiotics (narrower spectrum) available and not 
contra indicated 
(2) (Emipirical therapy) In community acquired infections and in the absence of risk 
factors 
(3) Surgical prophylaxis 
(4) Treatment of proven or suspected Stenotrophomonas maltophila infection 
(5) (Ertapenem) Treatment of suspected / proven Pseudomonas aeruginosa / 
Acinetobacter infections 
(6) Treatment of colonizer 
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INDICATIONS OF USE - Ceftazidime 
Situations in which the use of Ceftazidime is appropriate or acceptable: 
(A) Empirical therapy for neutropenic fever 
(B) Empirical therapy for life-threatening infections 
(C) Definite therapy for Pseudomonas aeruginosa infection 
(D) Therapy for probable i definite melioidosis 
(E) CAPD peritonitis (empirical therapy) 
(F) Clinical failure to respond to line treatment 
(G) Prophylaxis for Tenchkoff catheter cap off 
Situations in which the use of Ceftazidime should be discouraged: 
(1) Treatment of organisms known to be resistant to ceftazidime 
(2) (Definite therapy) When other antibiotics (narrower spectrum) available and not 
contraindicated 
(3) Surgical prophylaxis 
(4) Treatment of colonizers 
(5) (Emipirical therapy) In community acquired infections and in the absence of risk 
factors e.g. CAP / meningitis 
(6) Therapy for Streptococcus pneumoniae / Staphylococcus aureus / Enterococcus spp. 
(7) Monotherapy in mixed infection involving probable anaerobes 
INDICATIONS OF USE - Cefoperazone/sulbactam, Piperacillin/tazobactam 
Situations in which the use of Cefoperazone/sulbactam, Piperacillin/tazobactam is 
appropriate or acceptable: 
(A) Empirical therapy for neutropenic fever (in combination with aminoglycosides) 
(B) Empirical therapy for suspected hospital acquired infections with history of broad 
spectrum antibiotics exposure 
(C) Treatment of documented gram-negative infections attributed to organisms that are 
resistant to line antimicrobial agents (e.g. augmentin, cefuroxime, unasyn) 
(D) Definite therapy and to cover Pseudomonas aeruginosa infection 
(F) Clinical failure to respond to line treatment 
Situations in which the use of Cefoperazone/sulbactam, Piperacillin/tazobactam 
should be discouraged: 
(1) Treatment of organism known to be resistant to Cefoperazone/sulbactam, 
P iperaci 11 i n/tazobactam 
(2) (Definite therapy) When other antibiotics (narrower spectrum) available and not 
contraindicated 
(3) Treatment of colonizers 
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INDICATIONS OF USE - Cefepime 
Situations in which the use of Cefepime is appropriate or acceptable: 
(A) Empirical therapy for neutropenic fever (in combination with aminoglycosides) 
(B) Empirical therapy for suspected hospital acquired infections with history of broad 
spectrum antibiotics exposure 
(C) Treatment of documented gram-negative infections attributed to organisms that are 
resistant to line antimicrobial agents (e.g. augmentin, cefuroxime, unasyn) 
(D) Treatment of organism known to produce inducible AmpC beta-lactamases 
(E) Clinical failure to respond to line treatment 
Situations in which the use of Cefepime should be discouraged: 
(1) Treatment of organism known to be resistant to Cefepime 
(2) (Definite therapy) When other antibiotics (narrower spectrum) available and not 
contraindicated. 
(3) Treatment of colonizers 
INDICATIONS OF USE - Linezolid 
Situations in which the use of Linezolid is appropriate or acceptable 
A). Treatment of vancomycin-resisitant Enterococcus faecium, including cases with 
concurrent bacteremia 
(B).Treatment of vancomycin-resisitant gram-positive organisms, if susceptible in vitro, 
to linezolid, including VRSA. 
(C). Rx of serious infections caused by (3-lactam-resistant gram-positive 
microorganisms where vancomycic is severely contraindicated 
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INDICATIONS OF USE -Vancomycin 
Situations in which the use of Vancomycin is appropriate or acceptable: 
(A) (Definite therapy) infections caused by (3-lactam-resistant gram-positive 
microorganisms 
(B) Empirical therapy for presumed infections in patients with subsequent positive 
culture of p-lactam-resistant gram-positive microorganisms. 
(C) Discontinued empiric use for presumed infections in patients with subsequent 
negative cultures. 
(D) Discontinued empiric use for presumed infections in patients with subsequent 
positive culture of p-lactam-sensitive gram-positive microorganisms. 
(E) Infections caused by gram-positives in patients who have serious allergies to beta 
lactam antimicrobials. 
(F) When antibiotic induced colitis fails to respond to metranidazole therapy or is severe 
and potentially life-threatening. 
(G) Prophylaxis for endocarditis following certain procedures in patients at high risk for 
endocarditis (as recommended by the AHA and BSAC Working Party) 
(H) Prophylaxis for major surgical procedures involving implantation of prosthetic 
materials or devices 
(I) Routine surgical prophylaxis in patients who have life threatening allergy to beta 
lactam antibiotics. 
Situations in which the use of Vancomycin should be discouraged 
(1) Routine surgical prophylaxis other than in a patient who has life-threatening allergy 
to beta-lactam antibiotics. 
(2) Empiric antibiotic therapy for a febrile neutropenic patient, unless initial evidence 
indicates that the patient has an infection caused by gram-positive microorganisms. 
(3) Treatment in response to a single blood culture positive for coagulase-negative 
staphylococcus, if other blood cultures taken during the same time frame are negative. 
(4) Continued empiric use of presumed infections in patients whose cultures are 
negative for beta-lactam resistant gram-positive microorganisms. 
(5) Treatment of infections caused by P-lactam-sensitive gram-positive microorganisms 
without serious allergies to P-lactam antimicrobials. 
(6) Systemic or local prophylaxis for infection or colonization of indwelling central or 
peripheral intravascular catheters. 
(7) Selective decontamination of the digestive tract. 
(8) Eradication of MRSA colonization. 
(9) Primary treatment of antibiotic-associated colitis. 
(10) Routine prophylaxis for very low-birth infants. 
(11) Treatment (for dosing convenience) of infections caused by P-lactam-sensitive 
gram-positive microorganisms in patients who have renal failure. 


































































































































































































































































































































































































































































Appropriate indications of use-Individual targeted antimicrobials in ASP 
INDICATIONS OF USE - Cefepime 
Situations in which the use of Cefepime is appropriate or acceptable: 
Preintervention Intervention 
period (n=90) period (n二 109) 
(A). Empirical therapy for neutropenic fever 5 (5.6) 9 (8.3) 
(In combination with aminoglycosides) 
(B). Empirical therapy for suspected hospital-acquired 
infections with history of broad spectrum antibiotics 
exposure 56 (62.2) 40(36.6) 
(C). Treatment of documented gram-negative 
infections attributed to organisms that are 
resistant to 1st line antimicrobial agents 
(e.g. augmentin, cefuroxime, unasyn) 1 (1.1) 4(3.7) 
(D). Treatment of organism known to produce 
inducible AmpC P-lactamases 1 (1.1) 4(3.7) 
(E). Clinical failure to respond to 1st line treatment 27(30) 52(47.7) 
Data are no. (%) of patients unless otherwise indicated 
INDICATIONS OF USE — Ceftazidime 
Situations in which the use of Ceftazidime is appropriate or acceptable: 
Preintervention Intervention 
period (n=63) period (n=72) 
A). Empirical therapy for neutropenic fever 5 (7.9) 3 (4.2) 
(B). Empirical therapy for life-threatening infections 2 (3.2) 2(2.8) 
(C).Definite therapy for Pseudomonas aeruginosa 
infection 7(11.1) 10(13.9) 
(D).Therapy for probable / definite melioidosis 0 (0) 0(0) 
(E). CAPD peritonitis (empirical therapy) 36(57.1) 33(45.8) 
(F). Clinical failure to respond to 1st line treatment 9 (14.3) 7(9.7) 
(G) Prophylaxis for Tenchkoff catheter cap off 4 (6.33) 17(23.6) 
Data are no. (%) of patients unless otherwise indicated 
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INDICATIONS OF USE — Carbapenem (Imipenem/Meropenem) 
Situations in which the use of Carbapenem is appropriate or acceptable: 
Preintervention Intervention 
period (n=25) period ( n=42) 
(A). (Definite therapy) Serious infections caused by ESBL. 7 (28) 14(33.3) 
producing organisms 
(B). (Definite therapy) Serious infections caused by 
organisms with inducible AmpC p-lactamases 0(0) 1(2.4) 
(C). (Definite therapy) Serious infections caused by 
organisms resistant to other available antibiotics 6 (24) 3(7.14) 
(D). Empirical therapy for life-threatening infections 
(e.g septic shock) [de-escalation in 72 hours when 
culture results available]. 2(8) 2(4.8) 
(E). Empirical therapy for serious infections, where patients 
had received prior broad spectrum antibiotics 
(Tazocin / Sulperazone / Cefepime). 6(24) 13(31) 
(F). Empirical therapy for serious infections, where patients 
had prior documented infection with multidrug-resistant 
organisms. 1(4) 2(4.8) 
(G). Neutropenic fever in high risk patients. 2(8) 7(16.6) 
(H^ Empirical therapy for severe necrotizing pancreatitis 
(as per Impact guide) 0(0) 0(0) 
(I). (Meropenem) Treatment of meningitis, failed first line 
agent / documented multidrug-resistant organisms 1 (4) 0(0) 
Data are no. (%) of patients unless otherwise indicated 
INDICATIONS OF USE - Linezolid 
Situations in which the use of Linezolid is appropriate or acceptable: 
Preintervention Intervention 
period (n=3) period (n= 4) 
(A). Treatment of vancomycin-resisitant Enterococcus 
faecium, including cases with concurrent bacteremia 0(0) (0) 
(B). Treatment of vancomycin-resistant gram-positive organisms, 
if susceptible in vitro,to linezolid, including VRSA 0(0) (0) 
(C). Rx of serious infections caused by P-lactam 
resistant gram-positive microorganisms where 
vancomycin is severely contraindicated 0(0) 2(50) 
(D) Others ‘ 3 (100) 2(50) 
Data are no. (%) of patients unless otherwise indicated 
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INDICATIONS OF USE -Vancomycin 
Situations in which the use of Vancomycin is appropriate or acceptable: 
Preintervention Intervention 
period (rp=41) period (n二57) 
A). (Definite therapy) infections caused by 22(53.65) 29(50.9) 
(3-lactam resistant gram-positive microorganisms 
(B). Empirical therapy for presumed infections in 4 (9.76) 7(12.3) 
patients with subsequent positive culture of P-lactam 
resistant gram-positive microorganisms 
(C).Discontinued empiric use for presumed infections in 3 (7.35) 1(1.75) 
patients with subsequent negative cultures 
(D) Discontinued empiric use for presumed infections 
in patients with subsequent positive culture of (3 
lactam-sensitive gram-positive microorganisms. 0(0) 0(0) 
(E). Infections caused by gram-positives in patients 
who have serious allergies to beta lactam antimicrobials 0(0) 2(3.5) 
(F). antibiotic induced colitis fails to respond to 
metranidazole therapy or is severe and Potentially 
life-threatening 0(0) 2(3.5) 
(G). Prophylaxis for endocarditis following certain 
procedures in patients at high risk for endocarditis 
(as recommended by the AHA and BSAC 
Working Party) 0(0) 2(3.5) 
(H). Prophylaxis for major surgical procedures involving 
implantation of prosthetic materials or devices (0) 1(1.75) 
(I). Routine surgical prophylaxis in patients who 
has life threatening allergy to beta lactam antibiotics 1 (2.44) 4(7.0) 
(J). Others 11 (26.8) 9(15.8) 
Data are no. (%) of patients unless otherwise indicated 
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INDICATIONS OF USE — Piperacillin/tazobactam 
Situations in which the use of Piperacillin/tazobactam is appropriate or acceptable: 
Preintervention Intervention 
period (n=73) period (n=96) 
A). Empirical therapy for neutropenic fever 10 (13.7) 9(9.4) 
(in combination with aminoglycosides) 
(B). Empirical therapy for suspected hospital-acquired 23(31.5) 39(40.6) 
infections with history of broad spectrum antibiotics exposure 
(C). Treatment of documented gram-negative infections 6(8.2) 7(7.3) 
attributed to organisms that are resistant to 1st line antimicrobial 
agents (e.g. augmentin, cefuroxime, unasyn) 
(D). Definite therapy and to cover Pseudomonas aeruginosa 
infection 24(32.9) 18(18.7) 
(E). Clinical failure to respond to 1st line treatment 10(13.7) 23(23.9) 
Data are no. (%) of patients unless otherwise indicated 
INDICATIONS OF USE — Cefoperazone/sulbactam 
Situations in which the use of Cefoperazone/sulbactam is appropriate or acceptable: 
Preintervention Intervention 
period (n=177) period (n=192) 
A). Empirical therapy for neutropenic fever 3(1.7) 1(0.5) 
(in combination with aminoglycosides) 
(B), Empirical therapy for suspected hospital-acquired 77(43.5) 54(28.1) 
infections with history of broad spectrum antibiotics exposure 
(C). Treatment of documented gram-negative infections 8(4.5) 16(8.3) 
attributed to organisms that are resistant to 1st line 
antimicrobial agents (e.g. Augmentin，cefuroxime, unasyn) 
(D). Definite therapy and to cover Pseudomonas aeruginosa 
infection 59(33.3) 75(39.1) 
(E). Clinical failure to respond to 1st line treatment 30(16.9) 46(23.9) 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Analysis tables of ASP-Comparison of preintervention period (March-May 
2005) and intervention period (March-May 2006) 
Table VI-l.Baseline characteristics of patients included in the study during 
preintervention and intervention periods. 
Characteristic Preintervention Intervention 尸-value 
period period 
(n = 605) (n=284) 
Age,mean years 士 SD 70.04 士 14.7 68.62士 16.6 ^ 
median years (IQR) 73 (61-80) 73(57-80) • 
Gender 
Male 348 (57.5) 160(56,3) 
Female 257 (42.5) 124(43.7) 
Comorbidities 
Hypertension 230 (38) 95(33.5) 0.15 
Diabetes mellitus 207 (34.2) 76(26.8) 0.02 
Ischaemic heart disease 198 (32.7) 72(25.4) 0.02 
Chronic/Endstage renal failure 136 (22.5) 81(28.5) 0.05 
Immunosuppresion^ 91 (15) 68(23.9) 0.001 
COAD^/Bronchiectasis 175 (28.9) 60(21.1) 0.01 
Crebrovascular accidents' 138 (22.8) 59(20.8) 0.4 
Malignancy 104 (17.2) 52(18.3) 0.6 
History of pulmonary tuberculosis 98 (16.2) 35(12.4) 0.1 
Surgery/ procedure within one month 53 (8.8) 23 (8.1) 0.7 
Chronic liver disease 36 (6.0) 18 (6.4) 0.8 
IV drug addiction 1(0.2) 2(0.7) 0.1 
Mean no. of comorbidities 3.4 3.1 0.03 
No. of cases with multiple no. of comorbidities 
0 7(1.2) 4(1.4) 0.7 
1 35(5.8) 29(10.2) 0.01 
2 117(19.3) 62(21.8) 0.3 
3 189(31.2) 78(27.5) 0.2 
4 127(21) 61(21.5) 0.8 
> 5 130(21.5) 50(17.7) 0.1 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a Presence of neutropenia,HIV,receipt of steroids,cyclosporine etc 
b Chronic Obstructive Airway Disease 
e Old and new 
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TableVl- 2. No of prescriptions reviewed, pattern of antibiotic prescription, type 
and sources of infection during preintervention and intervention periods. 
Variable Preintervention Intervention 
period period 尸-value 
(n= 605) (n=284) 
No. of prescriptions reviewed 
Sulbactam/cefoperazone 232(38.3) 94(33.1) 0.1 
Piperacillin/tazobactam 84(13.9) 50(17.6) 0.1 
Cefepime 123(20.3) 54(19) 0.6 
Ceftazidime 75(12.4) 32(11.3) 0.7 
Vancomycin 54(8.9) 31(10.9) 0.4 
Carbapenem^ 34(5.6) 21 (7.4) 0.3 
Linezolid 3 (0.5) 2 (1 .1) 
Pattern of antibiotic prescription 
Empirical therapy 451(74.5) 223(78.5) 0.2 
Known pathogen treatment 133(22) 45(15.8) 0.04 
Prophylaxis 21(3.5) 16(5,6) 0.1 
Type of infection 
Healthcare-associated 342(56.5) 180(69.5) 0.05 
Community acquired 229(37.9) 79 (30.5) 0.004 
Source of infection 
Respiratory 358(59) 145(51.1) 0.02 
Urinary tract 41(6.8) 30(10.6) 0.05 
Intraabdominal 73(12.1) 30 (10.6) 0.5 
Skin and soft tissue 21(3.5) 8(2.8) 0.7 
IV catheter related 4 (0.7) 12(4.2) <0.001 
Bacteraemia 10(1.7) 4(1.4) 0.9 
Bone 1(0.2) 0(0) 
Two or more source 24(4) 20(7) 0.048 
No infection 34(5.8) 25(8.8) 0.1 
Unknown 36(6) 9(3.2) 0.1 
Others 3(0.5) 1(0.4) 
NOTE. Data are no. (%) of patients unless otherwise indicated 
a Meropenem and Imipenem 
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TableVl-3.0utcome measures during preintervention and intervention periods 
Outcome Preintervention Intervention OR P-value 
period period (95% CI) 
Appropriate 471(77.9) 250 ( 8 8 % ) 3 . 3 6 ( 1 . 8 - 6 . 1 ) <0.001 
Length of hospital stay^ 
Mean days 士 SD 16.4±19.7 16 ± 53 0.7 
Median days (IQR) 10(6-19) 10(6-17) 
All-cause mortality^'' 115 (20.8) 40 (15.7) 0.54(0.34-0.83) 0.006 
NOTE, a prophylaxis group were excluded 
b Include patients died during the hospital stay or if transfer to other hospital 
or readmitted and died within one month after discharge. 
^Multiple antibiotics for same episode were considered as one case for 
analysis of length of hospital stay and all-cause mortality. 
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TableVl-4. Multivariate model of appropriate use of targeted antimicrobials 
‘ OR (95 % CI) P- value 
X ^ ‘ “ 3.36(1.8-6.1) <0.001 
Intraabdominal sepsis 12.03(2.86 - 50.5) ^.001 
Im 讓 nosuppresion 3.22(1.45 -7 .15) 0 M 4 
Prophylactic use 0.01(0.002 - 0.06) <0.001 
Urinary tract infections 0.35(0.18 -0.67) ^.002 
Skin and soft tissue infections 0.22(0.9 -0.55) O.OOl 
Community acquired infections 0.19(0.12 -0.3) <0.001 
a Antimicrobial Stewardship program 
TableVl-5. Multivariate model of all-cause mortality for patients who received 
targeted antimicrobials 
OR (95 % CI) P-value 
0.54(0.34-0.83) ~~~ 
HCAlb 4.96(2.9-8.4) <0.001 
Respiratory tract infections 2.08(1.3 -3.2) 0 M 2 
> 2 s o u r c e of infections 4.16(1.9-8.9) <^.00 
Oncological comorbidity 2.29 (1.4 - 3.6) <0^001 
No of comorbidities 1.15(1 -1.3) ：二 
Age 1.02 (1.01-1.04) 0.001 
a Antimicrobial Stewardship program 
b Healthcare-associated infections 
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